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Abstract 
Phorbol esters belong to the family of tigliane diterpenes isolated from Croton tiglium, a member of 
the Euphorbiaceae and Thymelaeaceae plants. Since its isolation in 1935 phorbol has had a rapid 
rise to fame as a tumor promoter via protein kinase C activation and is now a common tool for 
cancer biologists worldwide. The issue with investigating and evaluating phorbol and its 
derivatives, in a biological sense, is that these complex molecules are limited only to natural sources 
(i.e. isolation from plant material). Furthermore, in addition to the supply issue these compounds are 
only available in one enantiomeric series (i.e. the natural (+)-phorbol), which in combination with 
that mentioned above places extensive limits on any meaningful biological investigation. The non-
natural isomer (-)-phorbol is not known, has never been synthesised and as such never been 
biologically evaluated. Considering the importance of phorbol to current cancer biologists, 
investigating the synthesis of the non-natural isomer and its derivatives is of great importance. 
 
This thesis describes fundamental studies towards the total synthesis of (-)-phorbol. The key step in 
the approach towards the total synthesis is a rhodium catalysed [4+3] cycloaddition reaction 
between a furan (right hand fragment) and a diazo compound (left hand fragment). The diazo 
compound was successfully synthesised from commercially available cyclopentenone over four 
steps via a palladium mediated direct diazo coupling protocol. In addition, the assembly of the CD-
ring system en route to the right hand fragment is presented. Difficulties were encountered in the 
introduction of the D-ring system via cyclopropanation. To circumvent this problem it was 
discovered that a change of protecting group was essential for the success of this reaction. 
Moreover, a model study of the proposed [4+3] cycloaddition reaction between the left hand 
fragment and a number of furans of various substitution patterns is described. 
 
Furthermore, 1,2,3-sulfonyl triazoles are presented as suitable diazo substitutes as they undergo a 
“ring to chain isomerism’ to diazoimines. This equilibrium is being used in a novel approach to 
substituted cycloheptadiene systems with furans. In a rare case a [3+2] cycloaddition reaction was 
observed and a discussion of mechanistic insight is presented.  
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1 Phorbol: Structure and Activity 
1.1 Introduction 
Nature provides us with an extraordinary variety of biologically active compounds and researchers 
more often let nature inspire them to find cures for a vast amount of diseases. Not only can we learn 
from nature to better understand disease mechanisms, but we can gain unparalleled information on 
how nature designs these complex molecules. 
A significant drawback to natural product drug discovery is that extraction and isolation from plant 
material solely is neither feasible nor economical. This is due to many biologically active 
compounds being isolated in small quantities as well as plants being restricted to certain 
geographical areas.  
The syntheses of these natural products are often arduous journeys over long period of times, 
normally over years. As a consequence, the popularity of natural products as lead therapeutics and 
the synthesis for drug discovery purposes decreased significantly.
1
 
With the increased popularity of combinatorial chemistry in the early 1980’s it was envisaged that 
with its application massive numbers of novel skeletons could be produced and thus, a large number 
of lead therapeutics could be accessed rather quickly. As a consequence, the focus of 
pharmaceutical companies was diverted towards identification of fully synthetic small molecules 
via screening of combinatorial libraries. 
It is evident today that the rapid production of large libraries is associated with a “lack of 
complexity”, such as chiral centres and polycyclic structures etc., in contrast to that found in natural 
products. As a consequence, issues such as for example selectivity are not adequately addressed.
2
  
Figure 1.1 shows a pie chart
3
 depicting the percentages of small molecule drugs derived from totally 
synthetic molecules, molecules having a natural product pharmacophore, molecules derived from 
natural products and pure natural products over nearly three decades. Clearly, nearly 50% of drugs 
produced are totally synthetic drugs.  
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Figure 1.1 Influence of natural products as lead therapeutics between 1981–2006.3  
In this view natural product chemistry (isolation and synthesis) in regards to drug discovery is an 
approach that has proven to be an effective and valuable source of inspiration from nature. One 
natural product, (+)-phorbol (1.1),
4
 isolated in 1935 found significant attention by biologists and 
chemists alike due to its potent nature as a protein kinase C activator. Boehm successfully isolated 
phorbol from Croton tiglium, a member of the spurge family also called the Eurphorbiaceae family. 
Investigations by Berenblum
5
 showed that the molecules isolated from this species were the first 
pure tumor promoting compounds in mice skin and as such he introduced the term “co-
carcinogenic”. This defines tumor promoters being neither mutagenic nor carcinogenic themselves, 
but once the initiation process by a carcinogen has occurred, these compounds encourage tumor 
growth. Tumor growth in contrast to the tumor initiation process is reversible, thus a repeated 
exposure to this compound is necessary for tumor growth. 
Synthesis of Small Molecule Drugs 
between 1981 - 2006 
Totally Synthetic Drugs
Derived from Natural
Products (semisynthetic
modification)
Natural Products
Total Synthesis with Natural
Products Pharmacophore
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Figure 1.2 Structure of (+)-phorbol and TPA. 
A significant feature of phorbol esters is their extraordinary high potency, which both Hecker
6
 and 
Berenblum
7
 confirmed to be at a nanomolar range. One derivative of the parent polyol phorbol is 
12-O-Tetradecanoylphorbol-13-acetate (1.2) (TPA, figure 1.2), which is the most potent tumor 
promoter to date.
8
 Phorbol esters were initially studied for their tumor promoting activity, but it was 
quickly found that they also have profound biological properties such as anti-leukemic,
9
 anti-HIV
10
 
and anti-cancer.
11
 Table 1.1 shows four examples of biologically active phorbol derivatives 
possessing anti-leukemic activity in the P-388 and L-1210 cell lines with phorbol 12-tiglate 13 
decanoate showing activity as low as 0.06-0.25mg/kg in vivo. 
 
Compound Botanical Source Anti-leukemic activity 
Phorbol 12-tiglate 13-decanoate Croton tiglium (Eu) P-388 in vivo (0.06-0.25mg/kg) 
12-Deoxy-5-hydroxyphorbol 13-
myristate 
B.montanum (Eu) P-388 in vitro 
12-O-Deca-2,4,6-trienoylphorbol 
13-acetate 
Aquilaria malaccensis 
(Th) 
P-388 in vitro (ED50 = 0.24 ng/mL) 
Mezerein Daphne mezereum (Th) P-388 in vivo 
L-1210 in vivo 
Table 1.1 Antileukemic activity of some phorbol derivatives with Eu=Euphorbiaceae, 
Th=Thymelaeaceae, P-388=mouse leukaemia cells, L-1210=mouse lymphocytic leukaemia 
cells. 
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Phorbol esters such as 12-O-tetradecanoyl-phorbol-13-acetate (TPA, 1.2) are PKC activators 
mimicking diacylglycerol, but unlike DAG, phorbol esters do bind directly to the enzyme.
12
 
Furthermore, DAG is a short lived species and appears in the membrane cell only transiently, 
whereas phorbol esters are metabolised at a decreased rate in the cell leading to increased long term 
activation, thus resulting in unregulated protein phosphorylation. This unregulated phosphorylation 
leads to proliferation.  
 
It was shown that DAG increases the affinity of the enzyme to Ca
2+ 
without increasing the
 
Ca
2+ 
concentration. A highly specific “lipid-protein” interaction is necessary for activating the kinase. 
Active DAG is specific to 1,2-sn-conformation, whereas other isomers have not shown to induce a 
biological response. Once protein kinase C is activated it phosphorylates other cellular proteins such 
as receptor proteins of some growth factors such as the epidermal growth factor (EGF). Another 
major feature of the PKC is the down-regulation or “negative feedback control”.  
 
The natural activator for PKC is diacylglycerol 1.3 (DAG, figure 1.3),
13
 a lipophilic second 
messenger produced in the plasma membrane via hydrolysis of inositol phospholipids. Chemically, 
diacylglycerol is a glyceride with two alcohols being attached to fatty acid chains.  
 
 
Figure 1.3 Structure of diacylglycerol (DAG). 
Figure 1.4 shows the structural analogy of phorbol and its endogenous counterpart DAG. While 
Nishizuka suggested an analogy of the C-12 and C-13 oxygens to DAG,
13c,14
 Wender found that 
according to rms deviation calculations a much closer analogy can be drawn to the C-4, C-9 and the 
C-20 oxygens with the centre of mass of the (S)-DAG having a more favourable overlay.
15
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Figure 1.4 Heteroatom overlay between phorbol and DAG.
1
 
It has been shown that certain ingenane diterpenes isolated from Thymelaceae plants are also able 
to substitute for DAG. Amongst them ingenol mebutate 1.7 (scheme 1.5) which is an approved drug 
from the Food and Drug Association (FDA) for the treatment of actinic keratosis. Other promising 
DAG analogues are bryostatin (1.4),
16
 teleocidins (1.6),
17
 and aplyslatoxin (1.5)
17c
 as shown in 
figure 1.5. 
 
                                                 
1
 Figure taken from Wender, P.A.; Koehler, K.F.; Sharkey, N.A.; Dell’Aquila, M.L.; Blumberg, P.M. PNAS, 1986, 83, 
4214-4218 
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Figure 1.5 Diacylglycerol analogues. 
 
In 1982, Nishizuka and co-workers
13c
 reported for the first time that derivatives of phorbol could act 
as substitutes for the unsaturated diacylglycerol, which is responsible for protein kinase C 
activation. Some evidence suggested that esters of phorbol directly bind to the cell surface 
membrane of the serine/threonine dependent protein kinase C (PKC). In order to better understand 
the influence that phorbol and derivatives have on PKC a brief explanation of the pathway as well 
as the function of protein kinase C is necessary and will be discussed. 
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1.2 Protein Kinases in Drug Discovery 
1.2.1 Introduction 
The search for new chemotherapeutic agents has been greatly aided in recent years by a better 
understanding of the structure of enzymes and their biological function associated with diseases. 
One important class of enzymes are protein kinases.
18
 These kinases represent a large and diverse 
family of important biological catalysts transferring the terminal phosphate of adenosine 
triphosphate (ATP) to a hydroxyl group of target proteins; a mechanism responsible for cellular and 
enzymatic functions. There are two main classes of protein kinases in eukaryotic organisms, 
namely, serine/threonine kinases and tyrosine kinases. To date, 538 human protein kinases of the 
human genome sequence have been identified and encoded, of which 478 can be attributed to one 
single superfamily (figure 1.6).
19
 
Seven subgroups are allocated to the superfamily and can be divided into an array of families which 
only marginally differ in their catalytic sequence. (i) TK – tyrosine kinases (ii) TKL – Tyrosine 
kinase-like group of kinases (iii) STE – containing homologs of yeast Sterile 7, Sterile 11 and 
Sterile 20 kinases (iv) CK1 – containing casein kinas 1 (v) AGC containing protein kinase A, G and 
C (vi) CAMK containing calcium/calmodulin-dependent protein kinases (vii) CMGC containing 
cyclin-dependent kinase (CDK), mitogen-activated protein kinases (MAPK), glycogen synthase 
kinases (GSK3) and CDC-like kinases (CLK). 
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Figure 1.6 Human protein kinase dendrogram.
2
 
Within this superfamily of protein kinases AGC protein kinase family found special interest. This 
family is comprised of 21 subfamilies and is named after protein kinase A (PKA), protein kinase G 
(PKG) and protein kinase C (PKC).  
1.3 Protein Kinase C 
Since its discovery in 1977,
20
 protein kinase C (PKC) has become the focus of biological 
investigations. This kinase plays a crucial role in the signalling pathways and in cell growth 
regulation and proliferation. PKC is crucial for the transfer of extracellular information signals to 
the cell interior.
21
 It is evenly distributed in tissues and organs and is most abundant in the brain. 
Protein Kinase C is a calcium ion and phospholipid dependent kinase, in particular phosphatidyl 
serine is essential for its activation. 
22
 
                                                 
2
 Figure taken from http://www.cellsignal.com/reference/kinase/overview.html 
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1.3.1 Protein Kinase Isozymes 
Ten mammalian protein Kinase C isozymes are known to date,
21
 which can be categorised into 3 
classes; (i) conventional PKCs (cPKC) consist of four isozymes that are Ca
2+
 dependent due to the 
C2 domain containing a Ca
2+
 binding site. cPKCs contain PKCα, PKCβI, PKCβII (two alternatively 
spliced variants) and PKCγ. These conventional PKCs can be activated by phorbol esters or DAG 
and calcium. (ii) Novel protein kinase C (nPKC), which have shown to have structural similarity to 
cPKCs, but are not Ca
2+
 dependent comprising PKCδ, PKCε, PKCη and PKCθ can be activated by 
phorbol esters or DAG, but do not respond to calcium. (iii) Atypical protein kinase Cs (aPKC) 
isozymes, which as the name suggests do not provide strong structural similarities to conventional 
and novel protein kinases. They consist of PKCζ and PKCλ and have shown not to respond to either 
calcium or DAG and thus, not to phorbol esters.
19
  
Figure 1.7 shows the general structure of conventional and novel protein kinases. All members of 
the protein kinase C family consist of a cysteine rich N-terminal lobe and a C-terminal lobe 
connected via a single polypeptide strand, which acts as a “catalytic cleft”.18a,23 Typically PKC 
isozymes contain four conserved regions (C1-C4) with C1 being the diacylglycerol and C2 being 
the Ca
2+ 
sensor. It can be clearly seen that isozymes of PKC only differ in the regulatory domain, 
but show homology in the catalytic domain.
23-24
 
 
 
Figure 1.7 Stick-figure of cPKC and nPKC. 
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1.3.2 Protein Kinase C activation 
The lifecycle of a protein kinase C involves three steps: maturation, activation and inactivation.
24-25
 
Maturation of protein kinase C is a prerequisite. Work by Newton et al.
24
 has shown that PKCs are 
only able to become activated once they are “matured”, a process that involves a series of 
phosphorylation steps. Protein Kinase C in its inactive form shows an “open” conformation, which 
is pivotal as the unphosphorylated C-terminus is exposed and provides a docking site for PDK-1 
(phosphoinositide-dependent kinase 1). Following this, the turn motif and hydrophobic motif are 
phosphorylated leading to exposure of the C-terminal domain, which, after autophosphorylation 
stabilizes the enzyme after key conformational rearrangements. Following this maturation process 
specific substrate binding such as the binding of DAG and calcium can occur to the C1 domain 
leading to a high affinity interaction between the PKC and the membrane. As a result the pseudo 
substrate is released, allowing for substrate binding, phosphorylation and the activation of 
downstream signaling effectors. The interactions with DAG facilitate the dissociation of the pseudo 
substrate activating the kinase.  
 
 
Figure 1.8 Protein kinase C activation process.
3
 
                                                 
3
 Figure taken from  http://www.ruf.rice.edu/~rur/issue1_files/barron.html 
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With phorbol being identified as a DAG substitute for the PKC activation in 1982 by Nishizuka,
12
 
kinases quickly became desired “targets” for pharmaceutical industries.26 Without full 
understanding of the structure of enzymes investigations were focused on designing inhibitors 
targeting the catalytic region, which was believed to be the favoured binding site. Having now a 
better understanding of the structure of enzymes, we know that the C-terminal domain does not 
differ significantly between PKCs. As such a lot of selectivity problems have been encountered 
throughout the years yielding at times health threatening side effects of marketed drugs. A good 
example is Gleevec® (1.8) by Novartis.
27
 Gleevec® (Imatinib mesylate, figure 1.9) is an anti-
cancer drug with a relatively broad activity profile. Even though Gleevec® was a huge therapeutic 
success in treating chronic myelogenous leukaemia (CML), studies have shown that some patients 
developed congestive heart failure after being exposed to it.
28
 In addition, these studies have shown 
that Imatinib mesyalte triggered contractile dysfunction in treated mice. 
 
 
Figure 1.9 Gleevec®. 
These side effects could be attributed to the non-specifity of imatinib mesylate – an important 
reminder of the need for highly selective inhibitors. 
  
 12 | P a g e  
 
1.4 The Euphorbiaceae and Thymelaeaceae Plant Families 
The Eurphorbiaceae plant family, also called the spurge family contains about 300 genera and more 
than 8000 species with the largest genera being Euphorbia, Croton, Jatropha and Sapium. 
Compounds isolated from this plant family exhibit a large chemical diversity and are hence of great 
interest to synthetic organic chemists.
29
 
The Thymelaeaceae family, also known as the daphnane family consists of 90 genera and more than 
500 species with Gridia, Pimelea and Daphne the largest amongst them. The Thymelaeaceae family 
not only consist of tumor promoting members, but also antitumor daphnane derivatives have been 
isolated and identified. 
29
 
Euphorbiaceae and Thymelaeaceae have long been known for their versatile properties and thus 
have been applied in both, herbal and traditional Chinese medicine, respectively to treat common 
discomforts such as diarrhoea and migraine. Furthermore, the extracts and plants itself were used as 
anti-histaminic, anti-asthmatic and anti-leukemic agents among other. Aside from this, these plant 
families have been used as a major food source. To date cassava or Manihot esculenta, a toxic plant 
isolated from Euphorbia still remains one of the top three food sources in developing countries. 
Extreme care must be taken in the preparation of the cassava root as it contains cyanogenic 
glycosides (figure 1.10) that, if not properly removed can lead to an increased cyanide concentration 
in the body. As a consequence, cyanide intoxication and potential partial paralysis could occur. 
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Figure 1.10 Examples of cyanogenic β-glycosides. 
The Eurphorbiaceae and Thymelaeaceae families have been of great interest for chemists and 
biologist since the 1940’s after the isolation and characterisation of 12-O-tetradecanoylphorbol-13-
acetate (TPA, 1.2, scheme 1.2). TPA 1.2 was the first pure tumor promoting compound isolated 
from natural sources (Croton tiglium) and has held this position since its discovery. So far, more 
than 100 tumor promoting and pro-inflammatory phorbol derivatives have been characterised and 
are being used to further understand the biological pathway of cancer and pro-inflammatory 
diseases.  
These two plant families comprise a vast amount of toxic diterpenes known as tigliane, daphnane 
and ingenane diterpenes with their parent polyol being phorbol (1.1), resiniferonol (1.9) (figure 
1.12). 
A third family, the ingenane diterpenes have been isolated from the Euphorbia lathyris L. species, 
with (+)-ingenol (1.10) as the parent polyol.  
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Figure 1.11 Three classes of diterpenes. 
1.5 Phorbol: A Tigliane Diterpene 
Since its isolation in 1935 phorbol (1.1)
4
 has had a meteoric rise to fame as a tumor promoter via 
protein kinase C activation and is now a “house hold” tool for cancer biologists worldwide.8a The 
issue with investigating and evaluating phorbol (1.1) and its derivatives, in a biological sense, is 
that these complex molecules are limited only to natural sources (i.e. isolation from plant material), 
of which only some are commercially available. Furthermore, in addition to the supply issue these 
compounds are only available in one enantiomeric series (i.e. the natural (+)-phorbol), which in 
combination with that mentioned above places extensive limits on structure-activity relationship 
studies. 
 
The highly potent biological activity of phorbol derives from their selective ability to activate 
isozymes of the protein kinase C family as they mimic the behaviour of 1,2-diacylglycerol (DAG), 
a lipophilic secondary messenger (discussed in detail in section 1.1, page 4), responsible for 
regulating cellular growth. 
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Figure 1.12 Tigliane diterpenes and their numbering system. 
The tigliane scaffold of phorbol as shown in figure 1.13 is a fused tetracyclic system with a five-
membered A ring, a seven-membered B ring, six-membered C-ring and the cyclopropane moiety 
designated as ring D. It is a highly oxygenated tetracyclic system with the C-ring system hosting six 
consecutive stereocentres. Trans-annelation between the A and B ring is crucial for phorbol activity 
as its cis- counterpart (4α) was shown to be entirely biologically inactive. Furthermore, the C-4 
hydroxyl group has shown to be pivotal for hydrogen bonding. It has been shown that replacement 
of the latter for a methyl group leads to a complete loss of activity.
30
 
According to Blumberg et al.
31
 the main oxygens that perform hydrogen bonding with the enzyme 
are located at C-3, C-4 and C-20, with the latter acting as a donor and acceptor respectively. 
Furthermore, it was suggested that C-9 and C-13 are not hydrogen bonding to the kinase itself but 
rather form intramolecular hydrogen bonding. 
 
Another representative of the tigliane diterpene family is prostratin 1.12 (figure 1.14).
32
 Initially 
used to treat hepatitis by a Samoan healer, prostratin is now in phase 1 human clinical trials for the 
fight against AIDS. Mostly, these derivatives and analogues are prepared synthetically from the 
isolated parent polyol phorbol (1.1). Of course if a feasible synthesis was available to these systems 
more drugs could potentially be identified.  
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Figure 1.13 Prostratin 
1.6 Biosynthesis 
The biosynthesis of the tigliane, ingenane and daphnane diterpenes is still reserved.
33
 A large 
number of diterpenes are known from the Euphorbiacaeae plant family including mono-, di-, tri- 
and tetracyclic compounds. While many di- and triterpenoids as well as steroids are biosynthetically 
derived from a concertina-like cyclisation of geranylgeranyl pyrophosphate (GGPP) as shown by 
Banthorpe and Charlwood, it was initially believed that tiglianes, daphnanes and ingenanes could be 
derived via a similar route. However, with the existence of the monocyclic compounds such as 
casbane 1.14 (scheme 1.1), a head to tail cyclisation of GGPP was likely. Although casbane or other 
monocyclic compounds have not been isolated from the Euphorbiacaeae plant family, they are 
known from other plant sources. Robinson and West isolated casbene 1.15 in 1977 from the castor 
oil plant riccinus communis,
34
 a species of the spurge family and rationalised its origin to the head-
to-tail cyclisation of GGPP initiated by a single enzyme. They suggested that a head to tail 
cyclisation is preferred as this leads to monocyclic compound 1.14 in only one step compared to a 
concertina-like cyclisation with the monocycle being accessed in many steps. 
 
Head to tail cyclisation initiated by the enzyme casbene synthase provides carbonium intermediate 
1.14 followed by the cyclopropane ring closure and stereospecific hydrogen loss at C-1 of GGPP to 
provide casbene 1.15. Different enzyme classes then rearrange 1.15 into the various skeletons with 
elegant atom economy. 
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Scheme 1.1 Biosynthetic pathway to tigliane, daphnane and ingenane diterpenes. 
1.7 Previous Synthetic Strategies 
Considering the attention received by phorbol and related diterpenes, due to their broad range of 
biological activities and structural complexity, their chemical syntheses still remain a challenge 
today. To date, 76 years after initial isolation
4
 and 49 years after characterisation,
35
 a concise and 
atom economical synthesis of phorbol or derivatives has yet to be achieved. Numerous efforts 
towards the synthesis of phorbol have been made to date. Amongst these, various ingenious 
strategies have been employed in the construction of the tigliane core. However, the difficulty in 
achieving absolute stereocontrol and the introduction of functionalities to further elaborate the 
natural product have been major challenges. The majority of synthetic approaches have focussed 
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their attention on the synthesis of the ABC ring system 1.19 (scheme 1.2) in anticipation that this 
tricycle may serve as an advanced intermediate precursor in the synthesis of phorbol and related 
family members. The D-ring system is incorporated at a later stage in synthesis. It is worth noting 
here that this gem-dimethylcyclopropane moiety bears its own challenge in both its construction and 
stability throughout the following synthetic sequences.  
 
Scheme 1.2 Proposed precursor for three classes of diterpenes (tiglianes, daphnanes and 
ingenanes). 
To date there are only two known total synthesis of phorbol both of which have been achieved by 
Wender et al.
36
In addition, a formal asymmetric synthesis has also been reported by Wender
37
 and 
Cha,
38
 respectively. Wender’s first total synthesis, a pinnacle achievement in the field of organic 
synthesis at the time required 52 synthetic steps. His second generation synthesis required 47 steps, 
and the third, which investigated aspects of asymmetric incorporation, required 34 steps in a total 
synthesis of phorbol. This was a great achievement in that nearly 20 synthetic steps were removed 
in the final synthesis, however, 34 steps remains unattractive, especially considering an asymmetric 
total synthesis has yet to be achieved. 
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1.7.1 Wender’s Efforts to Phorbol 
Wender’s first generation approach towards the synthesis of phorbol involved the intramolecular 
Diels-Alder reaction of readily available 1.22 in the construction of the BC ring system 1.23 
(scheme 1.3).
39
 He proposed key intermediate 1.23 could serve as a precursor to the tigliane and 
daphnane diterpenes respectively. In addition, through chemical rearrangement the third class of 
diterpenes – the ingenanes – could potentially be accessed.  
Wender’s studies began with a hetero Diels-Alder reaction of readily available starting materials 
ethyl glyoxalate 1.19 and 2-methoxybutadiene 1.20 and subsequent instalment of the diene side 
chain at C-6 was achieved by intermediate 1.21 with LDA and 1-bromo-2,4-pentadiene. Subsequent 
reduction of the ester at C-6 utilising LiAlH4 followed by protection of the resulting alcohol as a 
benzyl ether afforded 1.21. Selective oxidation with m-chloroperbenzoic acid followed by Swern 
oxidation prepared for the introduction of the ethylidene moiety to afford 1.22. Upon heating, the 
latter underwent an intramolecular Diels-Alder reaction to tricyclic core 1.23. In order to introduce 
the A-ring moiety it was necessary to install a ester side chain at C-10. This was achieved by an 
olefination/hydrolysis sequence followed by reaction with acrolein ethyl acetate in presence of zinc 
iodide to afford 1.24. The D-ring subunit was then constructed utilising phenyl(tribromo)mercury 
(Seyfert’s reagent)40 followed by introduction of the stereocentre at C-4 via kinetically controlled 
addition of cyanide to provide 1.25. Intramolecular aldol reaction of 1.25 finally installed the A 
ring. With the tigliane core in place further synthetic manipulations were carried out as outlined in 
scheme 1.3 to afford 1.29. This tigliane system incorporated seven of the required eight 
stereocentres of TPA (1.2) and was the first tigliane core system to be synthesised. 
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Scheme 1.3 Wender's first approach to the tigliane core. 
However, this strategy had its shortcomings in regard to further installing necessary 
functionalisations at C-12 and C-13 in order to complete the synthesis of phorbol.  
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Three years later, in 1989, Wender et al.
36
 provided a newly developed synthetic route for the 
assembly of an altered BC ring system 1.36, ultimately leading to the first total synthesis of (+)-
phorbol 1.1 in 52 steps (scheme 1.4). Synthetic investigations gave direct access to the new BC ring 
system by means of an intramolecular oxidopyryllium [5+2] cycloaddition reaction.  
The starting point of Wender’s synthetic studies was the inexpensive, commercially available 
furfuryl alcohol 1.30. Protection as a silyl ether followed by acylation at the 5 position using lithium 
proprionate gave rise to compound 1.31. Subsequent aldol addition of the resulting enol with 4-
pentenal afforded 1.33 as a diastereomeric mixture (2:1 erythro: threo). The cycloaddition precursor 
1.34 was then accessed by furan oxidation utilising meta–chloroperbenzoic acid. Treatment of 1.34 
with 1,8-diazabicycloundec-7-ene (DBU) gave access to the BC ring system in one synthetic 
operation via a [5+2] oxidopyryllium cycloaddition. This powerful reaction proceeds in 92% yield 
with complete selectivity in regard to the stereocentres at C-8, C-9 and C-11. The tether connecting 
the alkene and pyryllium moiety form a chair-like transition state as shown in 1.35 directing the C-
11 methyl moiety into the equatorial position consequently leading to a minimal steric interaction 
between the methyl and the C-10 oxygen. Thus the chirality installed at the C-11 position 
conveniently controls the stereochemistry at C-8 and C-9. 
At this stage chiral chromatography afforded the desired enantiomer. Successive hydrogenation and 
Wittig olefination followed by oxidation installed the ketone at C-4 position (1.37). Conjugate 
addition of vinyl cuprate followed by kinetic addition of cyanide to the less sterically encumbered 
face of the C-4 carbonyl group gave 1.39. A nitrile oxide cycloaddition of the latter then provided 
1.40, which after hydrogenation followed by dehydration utilising benzoylation and DBU-catalysed 
elimination gave 1.41. In order to avoid unwanted side-reactions of the highly reactive A-ring, a 
sequence of Luche reduction, desilylation and ketal formation utilising 2-methoxypropene and 
pyridinium p-toluenesulfonate (PPTS) was performed to afford 1.42. With the advanced ABC 
tricycle (1.42) at hand, Wender prepared for the construction of the D-ring. This was accomplished 
by introducing the double bond via a sulfoxide elimination reaction to afford 1.45 followed by the 
construction of the gem-dimethylcyclopropane utilising diphenylisopropyl sulfide (1.46, scheme 
1.5). 
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Scheme 1.4 First half of Wender's first total synthesis of (+)-phorbol.
36
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Next, Wender moved on to establish a C-12 ketone reduction stereoselectively. Unfortunately, 
exposing 1.46 to DIBAlH and other common reducing agents did not lead to the desired 
stereochemistry. In addition, deprotection of the C-13 acetal occurred. Thus, he opted for protection 
of the C-12, C-13 diol as a carbonate. TBAF deprotection of the C-20 ether followed by treatment 
of the resulting triflic ester with Bu4NI provided iodide 1.48, which after exposure to t-BuLi and 
PCC gave the exocyclic double bond 1.49 and reoxidation of the C-12 alcohol to the ketone. 
However, NaBH(OAc)3 was found to be the reducing agent of choice in order to selectively give β-
alcohol 1.50 in excellent yield.  
B-Ring functionalization was accomplished in 5 steps from 1.50 to afford the benzoyl ether at C-20. 
The A-ring was revealed via hydrolysis of the acetonide followed by re-oxidation of the C-4 alcohol 
and TMS protection of the C-3 alcohol to afford 1.53. Introduction of the Δ1,2-double bond was then 
accomplished via α-bromination/elimination sequence. Finally, global deprotection afforded the 
desired (+)-phorbol (1.1) in 86% yield. 
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Scheme 1.5 Second half of Wender's first total synthesis of (+)-phorbol.
36
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A second generation approach by Wender et al.
41
 was reported only a year later detailing a more 
direct route to the tricyclic core 1.19. This led to the construction of 1.61 with a ketone imbedded at 
the C-4 position, ultimately simplifying the assembly of the ring A via stereocontrolled introduction 
of the allyl and propynyl groups. 
 
 
Scheme 1.6 Retrosynthetic analysis of Wender's second generation approach to (+)-phorbol.
41
 
5-Hydroxy-2-(hydroxymethyl)-4H-pyran-4-one 1.56 also known as “kojic acid” was used as the 
starting material. Reaction with bromide 1.57 afforded 1.58 which then undergoes a Claisen 
rearrangement to 1.59. Protection of the alcohols with TBSCl and heating in toluene provided the 
cyclised product 1.61 as a single isomer. In the same manner as described earlier for the first 
generation approach the tether forms a chair-like transition state forcing the methyl group into the 
equatorial position for minimal interaction with the C-10 oxygen thus, leading to the tricyclic core 
1.61. Successive Grignard reaction using allylmagnesium bromide, hydroxyl elimination, TBS 
deprotection and oxidation ultimately installed the ketone at C-4. This finally called for the 
stereocontrolled instalment of the propargyl group consequently allowing the concomitant 
zirconium mediated A-ring closure.  
Wender then applied chemistry evolved from his first generation approach to afford the tricyclic 
1.65 and used chemistry previously reported in order to install the D-ring system to afford (+)-
phorbol 1.1 ultimately in a more direct and slightly shorter sequence. 
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Scheme 1.7 Second generation synthesis of (+)-phorbol (1.1).
41
 
 27 | P a g e  
 
Wender’s first asymmetric approach in 1997 was accomplished by synthesising the cycloaddition 
precursor 1.34 using n-proprionyl oxazolidinone 1.68 as a chiral auxiliary with excellent 
diasteroselectivity (98% de) and excellent yield (96%).
37
 In contrast to Wender’s second approach 
to phorbol 1.1 (scheme 1.7), his asymmetric approach addressed many of the difficulties 
encountered thus leading to a more concise synthesis of (+)-phorbol (1.1). 
 
Scheme 1.8 Wender's first asymmetric synthesis of (+)-phorbol.
37
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1.7.2 Efforts by Cha 
In 2001 Cha et al. reported a 41 step formal synthesis of (+)-phorbol (1.1) (scheme 1.9).
38
 The key 
step to produce the oxo-bridged seven-membered ring 1.76 was accomplished by means of a [4+3] 
cycloaddition reaction of furan 1.74 and oxallyl, readily prepared from trichloropropanone 1.75. 
Installation of the allyl and propynyl group at C-4 and C-10 prepared for the assembly of ring A. A 
BOM deprotection/oxidation sequence followed by Wittig olefination afforded 1.80. Cha then 
installed the C-11 methyl group diastereoselectively utilising MeMgBr and CuBr•DMS as reported 
by Hruby to provide 1.81. Subsequent intramolecular Heck reaction of the latter allows C ring 
formation and provides 1.83 as a single isomer. Utilisation of Wender’s protocol for the 
construction of ring A finally affords (+)-phorbol (1.1). 
 29 | P a g e  
 
 
Scheme 1.9 Cha’s formal asymmetric synthesis of (+)-phorbol 1.1.38 
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1.8 Methods describing effort towards the Tigliane Core 
In addition to the pioneering work of Wender and Cha, a considerable number of investigations 
towards the tigliane, daphnane, and ingenane classes have been reported. In particular, methods 
developed by Shibasaki et al. by means of an intramolecular nitrile oxide cycloaddition reaction 
(scheme 1.10) and methods described by Dauben et al. whose synthetic approach is based on a 
stereospecific rhodium(II)actetate catalysed tandem cyclisation-cycloaddition reaction (scheme 
1.11). 
1.8.1 Shibasaki’s Approach 
Shibasaki et al. had a longstanding interest in phorbol and its derivatives as protein kinase C 
activators. Over more than 10 years he designed and studied structural features on the parent polyol 
in order to provide a pharmacophore model for protein kinase C interaction. Early on, Nishizuka 
suggested that C-12 and C-13 ester chains are necessary for the hydrophobic interaction thus 
making it possible for phorbol to enter the membrane and as such activate protein kinase C.
14
 
Wender’s calculations (see figure 1.4) showed that in addition to the C-12 and C-13 esters, the C-
20, C-3 and C-4 alcohols have significant impact on the interaction.
15
  
Shibasaki et al.
42
 designed a general precursor for the synthesis of a variety of phorbol analogues 
for biological testing (1.99, scheme 1.10). The synthesis for precursor 1.99 started with the 
commercially available (+)-carene leading to 1.89 in 4 steps. Removal of the acetyl group utilising 
Me2CuLi followed by enolisation and TMS protection of the resulting alcohol arrived at 1.90. Next, 
instalment of the primary alcohol was accomplished with formaldehyde and Yb(OTf)3 to afford 
1.91. Compound 1.93 was then prepared via the formation of zirconium enolate followed by 
selenylation, which after oxidation with m-chloroperbenzoic acid installed the desired double bond 
at the Δ11,12- position. Next, protection of the primary alcohol as a pivaloyl ether was followed by 
instalment of the C-12 alcohol moiety via epoxidation at the Δ11,12- double bond and treatment with 
aluminium amalgam for a period of 4 days to afford alcohol 1.94. The allyl group at C-9 was 
prepared by treating 1.94 with vinylmagnesium bromide. In order to achieve the desired 
stereochemistry at the C-12 alcohol, an oxidation/reduction sequence was necessary. The C-12 
alcohol was then protected as a TBS ether followed by protection of the C-9 alcohol as a SEM ether 
giving rise to precursor 1.99. 
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Scheme 1.10 Shibasaki’s synthesis to precursor 1.99.42a 
With the availability of precursor 1.99 the side chain at C-8 was accomplished via a Wittig reaction 
of phosphonium salt 1.100 and 1.99 to afford 1.101 as the E-stereoisomer. Reduction of the ester 
with DIBAlH followed by TBDPS protection of the resulting primary alcohol arrived at 1.102. 
Successive PMB deprotection, tosylation and nitration, using NaI as a catalyst, afforded 1.103 
which was used for the intramolecular cyclisation to form ring B over two steps. Construction of 
ring A started with the instalment of an ethyl ketone via the corresponding alkyne. Aldol cyclisation 
and dehydration of the resulting alcohol using MsCl afforded phorbol skeleton 1.106. Global 
deprotection followed by instalment of a long chain myristate group at the C-12 moiety finally 
afforded phorbol analogue 1.107, which was evaluated biologically and compared to the natural 
tumor promoter PMA (see table 1.2).
43
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Scheme 1.11 Shibasaki’s synthesis of phorbol analogue 1.107.43 
It can be clearly seen that the phorbol analogue 1.107 presented shows inhibition at higher 
concentrations such as 1 and 10 µM. However, no biological response was observed at a nanomolar 
range. 
  
 33 | P a g e  
 
Entry Compound Concentration Inhibition, % 
1.107 
 
10 nM 0 
100 nM 0 
1 µM 30 
10 µM 70 
PMA 
 
10 nM 40 
100 nM 80 
1 µM 100 
10 µM 100 
Table 1.2 Effect of phorbol analogues on the inhibition of [
3
H]PDBu binding to PKC.
43
 
In terms of biological inhibition of PKC the C-11 methyl group does not appear to be of 
significance in regard to the overall potency of the molecule. Shibasaki showed via biological 
studies of phorbol analogues missing a methyl or acetyl group that the C-13 acetyl moiety is of 
considerable more importance. In models lacking this moiety a significant decrease in potency is 
observed. Shibasaki went to great length in order to synthesise a number of phorbol analogues for 
biological testing. However, only 1.107 was shown to have inhibitory effects. 
An important aspect of Shibasaki’s work was the binding affinity of phorbol esters to the protein 
kinase C. The necessity of a highly specific interaction between DAG and PKC for PKC activation 
is well known. Thus, Shibasaki et al. designed a phorbol analogue, phorbol 12(1-pyrenebutyrate) 13 
diazoacetate 1.108,
44
 possessing a photo labile diazoacetyl group at the C-13 position in order to 
gain a deeper understanding of the interaction between the amino acid residues of PKC isozymes 
with phorbol. Crosslinking experiments confirmed the importance of the C-13 moiety for a specific 
PKC-ligand interaction as it is located in close proximity to the PKC. 
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Moreover, introduction of a trifluorodiazoproprionyl moiety as the photo labile group at C-13 
(PPTD 1.109, figure 1.15) would give further evidence for a specific interaction to the amino acid 
residues.
45
 It is known that the trifluorodiazopropionyl group can react with thiols such as 
mercaptoethanol and dithiothreitol in a cysteine rich environment. Binding affinities of PPDA and 
PPTD were comparable to the natural PMA to specific isozymes of PKC.  
Further agonist/antagonist studies with modifications of the C-12 side chain (1.110 and 1.111, 
figure 1.15) were undertaken by Shibasaki et al.
46
 It was shown that 1.111 exhibits similar 
biological activity to the natural PMA. However, 1.110 has shown to have a two orders of 
magnitude lower affinity to the PKC. This is thought to be due to the hydrophilicity of the poly 
(ethylene glycol) C-12 side chain preventing the translocation of the complex to the membrane, 
where the protein kinase C activation occurs. 
 
 
Figure 1.14 Photo-affinity ligands for PKC cross-linking experiments.
44-45
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1.8.2 Dauben’s Efforts towards the Tigliane Core 
Dauben et al. took a markedly different approach to constructing the tigliane skeleton (scheme 
1.12). They envisioned formation of the BC-ring system via an intramolecular rhodium catalysed 
cycloaddition reaction of 1.117 with 1.119 with the A,D-ring in place.
47
 Compound 1.117 could be 
constructed in five steps from ethyl (cyclopentene)carboxylate 1.112 and 1-(ethylsulfinyl)-1-
(ethylthio)-ethane 1.113. Conjugate addition of the latter two reagents followed by cleavage of the 
sulfoxide group provided 1.115.  
 
 
Scheme 1.12 Dauben's efforts towards the tigliane core 1.122.
47
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The second fragment 1.119 was prepared in a two-step reduction/oxidation sequence from ester 
1.118. Compound 1.120 was then obtained by aldol addition of 1.117 with aldehyde 1.119 followed 
by introduction of the diazo moiety via a diazo transfer approach to afford 1.121. Intramolecular 
rhodium catalysed cycloaddition finally gave rise to the tigliane skeleton 1.122. 
1.8.3 Evans’ Approach 
More recently, the Evans group established a macrocyclic approach towards the tigliane and 
daphnane tricyclic core by means of a transannular aldol reaction (scheme 1.13).
48
 The 
dimethylphosphonate 1.124 was accessed in five steps in an overall yield of 67% from benzyl-3-
propionyl-2-oxazolidinone.  
 
Scheme 1.13 Evans’ approach towards the tigliane core.48 
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Aldehyde 1.123 is obtained in 8 steps from tri-O-triacetyl-D-glucal. Subsequent coupling of the 
prepared starting materials 1.124 and 1.123 via a Horner-Wadsworth-Emmons reaction smoothly 
afforded E-alkene 1.125. Further synthetic manipulations afforded the monocyclic compound 1.126 
which was converted to the tricyclic tigliane core 1.129 via two consecutive transannular aldol 
reactions. 
1.9 Synthetic Routes to Diterpenes Related to Phorbol 
1.9.1 Inoue’s Strategy towards the Daphnane Diterpene Resiniferatoxin 
Resiniferatoxin (1.145, scheme 1.14) is a member of the daphnane family and was isolated from 
Euphorbia resinifera.
49
 This tetracyclic diterpene bears a unique ortho ester functionality between 
C-9, C-13 and C-14 and has been widely studied as a potent inhibitor of the vanilloid receptor.
50
 
Wender et al. reported the first total synthesis of resiniferatoxin in 1997
51
 utilising previously 
developed chemistry for the synthesis of phorbol, i.e. oxidopyryllium cycloaddition reaction. 
Absolute stereochemistry was controlled in the first step of the synthesis via epoxidation of 1.130 
with diisopropyltryptamine to afford 1.131 in 51% yield and 98% ee. Successive epoxide opening 
and acid catalysed lactone formation followed by introduction of the C-11 methyl moiety afforded 
intermediate 1.132. Addition of TBS-protected furfuryl alcohol 1.133 gave rise to 1.134 which after 
ketone reduction at C-9 and furan oxidation utilising m-chloroperbenzoic acid afforded the 
oxidopyryllium cycloaddition precursor 1.135 in quantitative yield over two steps. The BC-ring was 
then accessed via the proposed cycloaddition utilising DBU in good yield (84%). 
 
Wender’s A-ring construction was then accomplished using zirconium-mediated chemistry reported 
for the total synthesis of (+)-phorbol (1.1) to provide 1.139. The daphnane skeleton was achieved 
by introducing the isopropenyl moiety selectively utilising isopropenylmagnesium bromide 
attacking from the β-face of the C-13 carbonyl. Oxo-bridge opening occurs via the selective C-20 
TBS deprotection followed by iodination of the resultant alcohol and iodo ether elimination 
utilising Rieke zinc to afford 1.141 in 39% yield over four steps. Ring B was then furnished with 
the desired C-20 alcohol protected as a benzyl ether. Following this, instalment of the phenyl ester 
at C-14 occurred, which by treatment under mild acidic conditions converted to ortho ester 1.143. 
Introduction of the Δ1,2-double bond via bromination/elimination sequence followed by successive 
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benzoylation at C-20 and global deprotection finally arrived at the first total synthesis of 
resiniferatoxin 1.145. 
 
Scheme 1.14 Wender’s total synthesis of resiniferatoxin.51  
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Recently, a second approach to the complex core of resiniferatoxin 1.145 appeared in the 
literature.
52
 Inoue et al. accessed the daphnane core 1.151 via a concise radical coupling reaction, 
which involved three components (scheme 1.15). Firstly, the alkoxy bridgehead 1.146 
prefunctionalised with the desired five stereocentres, the synthesis of which required 21 steps from 
commercially available materials. Secondly, the five-membered ring A 1.148 and thirdly, allyl 
stannane 1.147.  
 
 
Scheme 1.15 Inoue's approach to resiniferatoxin.
52
 
The three components are fused in an intramolecular radical reaction employing 1,1'-
azobis(cyclohexane-1-carbonitrile) (V-40) in chlorobenzene to form the desired coupling adduct 
1.149 in reasonable yield over two steps (56%). Further modifications prepared for the construction 
of seven-membered ring B utilising a xanthate function in a second radical reaction to afford 1.151. 
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1.9.2 Baran’s Total Synthesis of (+)-Ingenol 
(+)-Ingenol (1.10, figure 1.12) is another important natural product that has attracted widespread 
efforts towards its synthesis. One derivative of ingenol, ingenol mebutate (1.7, Picato®, figure 1.16) 
is a FDA approved drug and as such its concise synthesis was highly desirable. Due to its very 
unique in/out-[4.4.1]bicyclododecane core, synthesis of ingenol has proven to be very challenging.  
 
Figure 1.15 Ingenol mebutate (Picato®). 
In 2002 Winkler
53
 presented a racemic total synthesis of ingenol followed by an independent 
approach by Tanino
54
 a year later. In 2004 Wood et al. reported the first asymmetric total synthesis 
of ingenol requiring 32 steps to complete.
55
 
More recently, an elegant total synthesis of (+)-ingenol (1.10) requiring only 14 steps from 
commercially available (+)-carene (1.152) was published by Baran et al. as a collaborative effort 
with LEO Pharma (developer of ingenol mebutate, Picato®, scheme 1.16).
56
 The key to this success 
lies in what is referred to as the cyclase and the oxidation phase, respectively. Drawing inspiration 
from nature Baran et al. constructs the carbon skeleton 1.158 (cyclase phase) followed by the 
oxidation phase to introduce necessary functionalities leading to (+)-ingenol (1.10) in an overall 
1.2% yield.  
Ortho chlorination of (+)-carene 1.152 followed by ozonolysis affords ketone 1.154. Allene 1.156 
can then be accessed as a single diastereomer in a one pot reaction via a halogen-metal exchange 
/alkylation sequence and subsequent aldol addition at C-8. 
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Scheme 1.16 Baran's total synthesis of (+)-ingenol.
56
 
Grignard addition followed by double protection of C-9 and C-7 alcohols provided the precursor for 
the rhodium catalysed Pauson-Khand reaction which forms ring A and B, respectively and 
completes the cyclase phase. Next, installation of the C-11 methyl via Grignard addition was 
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accomplished. Within three steps of initiating the oxidase phase the ingenane core 1.161 was 
obtained. Further oxidative manipulations and deprotections then afforded (+)-ingenol (1.10). This 
was a great achievement for Baran et al. and LEO Pharma, however, utilisation of stoichiometric 
amounts of osmium tetroxide still remains an unattractive feature for the commercialisation and 
processing on large scale. Furthermore, this collaborative effort led to (+)-ingenol, thus introduction 
of the C-3 side chain is necessary for the synthesis of ingenol mebutate 1.7. 
1.10 Project Background and Aim 
The Williams group has had a longstanding interest in the vibsanin family of natural products 
successfully synthesising a number of the family members (figure 1.17).
57
  
 
 
Figure 1.16 Williams’ total syntheses of vibsanin family members. 
Of particular interest was (-)-5-epi-vibsanin E (1.170, scheme 1.17) due to the experience gained in 
the total synthesis.
57d
 When considering (-)-5-epi-vibsanin E and (-)-phorbol 1.169 both contain a 
common seven-membered ring within their core structure (scheme 1.17).  
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Scheme 1.17 Natural products containing seven-membered rings. 
The Williams’ group initial approach to the seven-membered ring of (-)-5-epi-vibsanin E 1.170 was 
via the Zercher reaction,
58
 a methodology that has shown to provide γ-keto esters from β-keto esters 
via ring expansion (scheme 1.18).
59
 As such 3-methylcyclohexenone 1.171 was treated with 
Grignard 1.172 in a 1,4 addition reaction to afford 1.173. Dehydrogenation utilising activated IBX 
followed by Baylis-Hillman reaction afforded allylic alcohol 1.175. Exposing 1.175 to amberlyst 
afforded the tricyclic core 1.176 followed by the treatment with ethyl cyanoformate (Mander’s 
reagent)
60
 to yield 1.177. The latter was treated with diethyl zinc to afford seven-membered ring 
1.178, however, the diastereomeric centre at the C-10 position was epimeric to that of (-)-5-epi-
vibsanin E 1.170.
61
 
 
 
Scheme 1.18 Williams’ first generation approach to seven-membered rings. 
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In an independent approach towards (-)-5-epi-vibsanin E 1.170 the Davies group applied a formal 
[4+3] cycloaddition reaction between diene 1.178 and diazo compound 1.179 to form 
cycloheptadiene 1.181 through a rhodium catalysed cyclopropanation/Cope rearrangement 
sequence (scheme 1.19).
62
 Reduction of the methyl ester followed by a hetero Diels-Alder reaction 
provided tricyclic core 1.182, which after oxidation and a [4+2] cycloaddition reaction provided 
1.183. However, the product obtained was bis-epimeric at the 5 and 10 positions to the natural (-)-5-
epi-vibsanin E 1.170. 
 
 
Scheme 1.19 Davies’ approach to (-)-5-epi-vibsanin E. 
In 2010 a joint effort between the Williams and the Davies groups, the asymmetric total synthesis of 
(-)-5-epi-vibsanin E 1.170 was achieved (scheme 1.20).
57d
 Their approach successfully constructs 
the seven-membered ring 1.187 enantioselectively (90% ee) via the reaction of diazo compound 
1.185 and diene 1.178 utilising a chiral rhodium tetracarboxylate Rh2(R-PTAD)4 developed by 
Davies et al. This reaction proceeds via an in situ generated cyclopropane 1.186 followed by Cope 
rearrangement of the latter to afford 1.187.  
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Scheme 1.20 Williams’ and Davies’ total synthesis of (-)-5-epi-vibsanin E. 
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Following this, a number of functional group manipulations arrive at the tricyclic core 1.189. 
Conjugate addition and C-alkylation ultimately allowed the elaboration of the C-10 side chain to 
provide the natural product (-)-5-epi-vibsanin E (1.170). With a successful proof of concept in the 
synthesis of (-)-5-epi-vibsanin E 1.170 via competent seven-membered ring formation attention 
towards the synthesis of (-)-phorbol 1.169 could be undertaken. Thus, the aim of this project is the 
first total synthesis of (-)-phorbol 1.169 via a concise asymmetric [4+3] cycloaddition reaction. 
1.11 Retrosynthetic analysis 
As outlined in the general introduction (section 1.5, page 15) it is important to establish a significant 
biological profile of phorbol as a PKC activator and to better understand the structural features 
necessary for specific protein binding. Thus, the synthesis of the non-natural isomer (-)-phorbol 
1.169 is highly desirable.  
 
In analogy to (-)-5-epi-vibsanin E 1.170 the tetracyclic system (1.196, scheme 1.21) hosting the 
seven-membered ring (ring B), was envisaged to be assembled by means of the formal asymmetric 
[4+3] cycloaddition reaction developed by Davies et al.
63
 
The convergent strategy requires the synthesis of a Left Hand Fragment (LHF) (1.197) and a Right 
Hand Fragment (RHF) (1.198), respectively. The left hand fragment can be synthesised either via a 
diazo transfer reaction on an activated methylene group 1.199, or via a direct diazo cross coupling 
reaction between 1.200 and 1.201. The right hand fragment can be assembled from key intermediate 
1.203 via enolisation followed by Sonogashira coupling and metal mediated ring closure to form 
furan 1.198. 
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Scheme 1.21 Retrosynthetic analysis of (-)-phorbol using Davies seven-membered ring 
formation. 
In the synthetic direction treating 1.204 with rhodium in the presence of 1.205 would give advanced 
intermediate 1.206. The choice of electron withdrawing group on the diazo compound 1.204 is 
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important in regard to removal at the later stage of the synthesis. Both an ester function and a 
sulfone have been shown to successfully undergo cycloaddition reactions. However, the ease of 
removal of the sulfone function compared to that of an ester dictated choice.  
 
 
Scheme 1.22 Proposed strategy for the synthesis of (-)-phorbol 1.169. 
In the event, removal of the sulfone with sodium-mercury amalgam or samarium diiodide
64
 
followed by enone epoxidation
65
 would give rise to 1.207. Due to the hindered β-face of the 
molecule the epoxidation is expected to occur from the less hindered α-face affording the desired 
stereochemistry at C-4. With 1.207 at hand oxo-bridge opening can be affected by treatment with 
diisobutylaluminium hydride (DIBALH) and nickel cyclooctadiene as reported by Lautens et al.
66
 
Under these reaction conditions the likely event of ketone reduction is expected to accompany 
epoxide ring opening. In the absence of such an event further treatment with lithium aluminium 
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hydride (LiAlH4) should conveniently afford the reduced ketone 1.208. Treatment with activated 
IBX will introduce the desired enone functionality in one step.
67
 Finally, removal of the carefully 
chosen protecting groups will unmask the target (-)-phorbol 1.169. The following text will outline 
the progress towards the total synthesis of (-)-phorbol 1.169. 
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2 Investigations towards the Synthesis of the Right Hand Fragment 
2.1 Introduction 
The construction of the right hand fragment 2.1 is viewed as being achievable both asymmetrically, 
and via a fall back racemic strategy utilising chiral chromatography to resolve the enantiomers. The 
latter approach would be desirable in regard to the production of novel stereoisomers for biological 
evaluation.  
The first disconnective transformation to the right hand fragment involves the metal catalysed (Au, 
Pt, Pd) cyclisation reaction of 2.2 to the furan (scheme 2.1).
68
 The precursor for the furan synthesis 
is a result of epoxidation utilising meta-chloroperbenzoic acid of the enolised double bond. 
 
Scheme 2.1 Retrosynthetic analysis of the right hand fragment of (-)-phorbol (1.169). 
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 Compound 2.3 can be accessed via enolisation/triflation of the corresponding advanced 
intermediate 2.4 followed by a Sonogashira coupling
69
 utilising a protected propargyl alcohol. 
Compound 2.4 could then be derived from either direct cyclopropanation of 2.7 using 
dimethyldiazomethane or the employment of sulfur ylid chemistry for direct treatment of quinone 
2.7. However, due to the nature of the quinone this could interfere with regiochemistry and 
selectivity, thus, leading to unwanted side reactions. To bypass this problem “masking” one side of 
the quinone via a Diels-Alder reaction followed by the introduction of the gem-
dimethylcyclopropane moiety would afford the masked CD ring system 2.5, which could then be 
liberated simply by heating. 
Lastly, quinone bearing a methoxy group at 2-position is known and could easily be accessed via 
oxidation of 2-methoxy-6-methylphenol 2.8.
70
 
2.2 Approach 
Construction of quinone 2.7 started with the commercially available ortho-vanillin 2.9 which was 
converted to 2.8 via a classical Wolff-Kishner reduction in 83% yield. Oxidation of the resulting 2-
methoxy-6-methylphenol via oxygen transfer using the N,N′-
bis(salicylidene)ethylenediaminocobalt(II)-complex (“salcomine”) 2.10 gave rise to the desired 
quinone 2.7 in 56 % yield.
70
 
 
Scheme 2.2 Synthesis of methoxy-quinone 2.7. 
Diels-Alder reaction of 2.7 with cyclopentadiene was performed in the racemic series to provide 
2.11 along with 15% of the exo-adduct 2.12 (scheme 2.3). 
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Scheme 2.3 Diels-Alder reaction of 2.7 with cyclopentadiene. 
Figure 2.1 represents a 
1
H NMR spectrum of both isomers 2.11 and 2.12 showing the olefinic 
protons in the cyclopentene portion of the molecule at 6.12 and 6.02 ppm, respectively. The isolated 
olefinic protons appear as partially resolved singlets at 5.89 ppm. 
 
Figure 2.1 Diels-Alder isomers 2.11 and 2.12. 
For the synthesis of (-)-phorbol (1.169), however, an enantioselective approach was desired. 
Quinones of type 2.7 are known to undergo regiospecific Diels-Alder reactions with the less 
electron rich enone.
71
 Thus, performing an enantioselective Diels-Alder reaction would block one 
side of the molecule directing the cyclopropanation to the opposite face hopefully leading to the 
desired absolute stereochemistry. Enantioselective Diels-Alder reactions have been studied 
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extensively over the last three decades.
72
 A catalyst that has found widespread use is the 
oxazaborolidine catalyst known as the Corey-Bakshi-Shibata catalyst (CBS, 2.20, scheme 2.4).
73
 In 
order to investigate the enantioselective Diels-Alder reaction we initiated the synthesis of 2.20. 
2.3 Synthesis of the CBS-Oxazaborolidine Catalyst 
The use of CBS oxazaborolidine catalysts have been well established for a wide variety of dienes 
and dienophiles. Corey et al.
71,74
 demonstrated the strength of this catalyst and devised a 
mechanistic model to predict the stereochemical outcome of this reaction.
71,74
 According to their 
studies the transition state model in figure 2.2 clearly shows the coordination of the oxazaborolidine 
catalyst 2.20 to quinone 2.7, blocking the top face. Hence, cyclopentadiene attack can only occur 
from the bottom face of the molecule leading to a cis annelation. 
 
Figure 2.2 Corey's prediction model for enantioselective Diels-Alder reaction. 
The synthesis of (S)-o-tolyl-CBS-oxazaborolidine catalyst 2.20 according to the procedure of Corey 
et al
75
 proved to be very difficult in regard to the last step. The commercially available L-proline 
2.13 was treated with ethyl chloroformate 2.14 under basic conditions to give rise to (S)-proline-N-
ethyl-carbamate methyl ester 2.15 (scheme 2.4). Subsequent reaction with phenylmagnesium 
bromide afforded (S)-(-)-α,α-bis(diphenyl)-2-pyrrolidinemethanol 2.17 in quantitative yield. 
Deprotection of the amine using potassium hydroxide in methanol gave rise to 2.18 in 57% yield. 
Finally, (S)-o-tolyl-CBS-oxazaborolidine catalyst 2.20 could then be accessed via treatment of (S)-
(-)-α,α-bis(diphenyl)-2-pyrrolidinemethanol 2.18 with freshly prepared boroxine 2.19 under 
azeotropic conditions as the reaction produces two equivalents of water. 
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The method reported by Corey et al.
76
 for the preparation of the CBS-oxazaborolidine catalyst 
involved the reaction of amino alcohol 2.18 with boroxine 2.19 using a Soxhlett extractor. In our 
hands this method failed to afford the desired product, rather a polymeric mixture was observed. 
Similar results have been reported by Mathre et al.
77
 It is believed to be caused by dimerisation of 
2.18 in the presence of small quantities of water. Following the procedure of Mathre et al. using a 
Dean Stark apparatus charged with exactly one equivalent of amino alcohol 2.18 followed by 
sequential addition of 0.33 equivalents of boroxine ultimately afforded the desired oxazaborolidine 
catalyst 2.20.  
 
Scheme 2.4 Synthetic route to the CBS-oxazaborolidine catalyst. 
A major hurdle in this synthetic sequence lies in the final condensation of 2.18 and 2.19 to afford 
2.20. Because only small amounts of 2.19 were required to further investigate the proposed 
synthetic pathway, no further optimisation studies were undertaken. Utilizing 2.20 in a Diels-Alder 
approach to 2.21 afforded a 3% isolated yield of the desired product. Using the commercially 
available catalyst (0.5M toluene solution) gave a marked increase in yield (85%, scheme 2.5). This 
was most probably due to the capricious nature of the catalyst, and subsequent reaction. 
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Scheme 2.5 Enantioselective Diels-Alder reaction of 2.7. 
Regardless of the method of activation (table 2.1), Brønsted or Lewis acids (AlBr3 and SnCl4)
74,78
 
the desired product 2.21 was obtained in good yields (77-85%) and stereoselectivity (90% ee). 
Table 2.1 outlines a summary of the reaction conditions trialled.  
 
entry catalyst protonation yield, % ee, % 
1 (S)-CBS AlBr3 85 87 
2 (S)-CBS SnCl4 85 90 
3 Racemic - 93 n/a 
Table 2.1 Protonation studies of 2.19. 
Due to the cost and the difficulty of synthesising the catalyst, all ongoing reactions were performed 
on a racemic series. From the enanioselective studies undertaken we were confident that the desired 
stereochemistry could be accessed. 
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2.4 Cyclopropanation Studies 
With 2.21 in hand construction of the D-ring system was envisaged via direct cyclopropanation at 
an early stage of the synthesis. Cyclopropanes are present in a large number of compounds and 
natural products.
79
 These 3-membered rings can be challenging to synthesise due to their ring strain 
requiring highly reactive species such as ylids or carbenes for their synthesis.
80
 There are a number 
of procedures available for the preparation of gem-dimethylcyclopropanes from electron rich 
alkenes.
36,81
 Both Wender with his first formal asymmetric synthesis of phorbol and Corey have 
successfully demonstrated the use of diphenylisopropylsulfide tetrafluoroborate on a large variety 
of substrates. A representation of this approach is depicted in scheme 2.6. 
 
 
Scheme 2.6 Synthesis of gem-dimethylcyclopropane. 
With these established methodologies at hand synthetic investigations into the D-ring were 
commenced utilising the aforementioned diphenylisopropyl tetrafluoroborate 2.23, which was 
synthesised in one step as described by Matsuyama et al.
82
 by reaction of diphenylsulfide with 
isopropyl bromide in the presence of silver. (scheme 2.7) 
 
Scheme 2.7 Synthesis of diphenyldiisopropylsulfonium tetrafluoroborate. 
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Treating 2.24 with LiHMDS (scheme 2.8, table 2.2, entry 1) and a catalytic amount of 
dichloromethane in DME to allow ylid formation followed by treatment with 2.23 surprisingly 
afforded recovered starting material.  
 
Scheme 2.8 Formation of the D-ring. 
All additional attempts at using diphenylisopropylsulfonium tetrafluoroborate under a variety of 
conditions summarised in table 2.2 failed to afford 2.25. 
 
Entry Solvent Base Temperature 
[°C] 
Result 
1 DME LiHMDS -78 RSM 
2 DME LDA -78 RSM 
3 DMF NaH -40 RSM 
4 THF t-BuLi -78 RSM 
Table 2.2 Conditions for the introduction of ring D. 
It was Corey and Chaykovsky
83
 in 1965 that found the more nucleophilic sulfoxonium ylids to be 
useful for the cyclopropanation of electron-deficient alkenes. As such dimethylsulfoxonium 
methylide was introduced. Taylor and co-workers were interested in gem-dimethylcyclopropanes 
and directed their focus on sulfoxonium ylid 2.30.
84
 Table 2.3 outlines a short summary of 
cyclopropanations undertaken by Taylor et al. on a variety of quinone type systems. After only 
three hours reaction time excellent yields were obtained utilising triisopropylsulfoxonium 
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tetrafluoroborate. However, unmasked quinones (entry 3) under the same conditions yield a 
dicyclopropane B as the major compound. 
 
Entry Substrate Product Reaction time, 
h 
yield 
1 
  
3 92 
2 
  
3 95 
3 
 
 
3 
A=7,  
B=36 
Table 2.3 Taylor’s cyclopropanation results using triisopropylsulfoxonium tetrafluoroborate. 
As such we directed our attention towards the isopropyl transfer reagent triisopropylsulfoxonium 
tetrafluoroborate 2.30 as described by Taylor et al. (scheme 2.9). 
The synthesis of 2.30 begins with the preparation of the diisopropylsulfide 2.28 following the 
method of Prakash et al. Subsequent introduction of the isopropyl group as described by Taylor et 
al. using 2-bromopropane and silver tetrafluoroborate unfortunately gave erratic results and as a 
consequence, low yields. Having failed via this approach, 2.29 was synthesised using an alternate 
unpublished route kindly provided by Prof Taylor. Subjecting diisopropylsulfide to MsOH using 
isopropanol as solvent and stirred at 115 °C for a period of three days followed by counter ion 
exchange using HBF4 at room temperature afforded 2.29 in 62% yield.   
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Scheme 2.9 Synthesis of triisopropylsulfoxonium tetrafluoroborate. 
Subsequent oxidation of triisopropylsulfonium tetrafluoroborate can then be performed via two 
alternative routes, i.e. utilising Sharpless conditions or barium hydroxide in presence of 2-
nitrobenzenesulfonyl chloride. It was found that both approaches gave the desired sulfur salt, with 
the later procedure performing best (73%). 
With the sulfur salt 2.30 at hand, the first attempt at introducing the cyclopropane moiety utilising 
NaH and DMF at 0°C afforded a 50% conversion to the desired product 2.25 (scheme 2.8). When 
using an excess of 2.30 and temperatures below 0°C complete conversion to product 2.25 was 
apparent by TLC. However, only 14% of the desired cyclopropane could be isolated. The observed 
low yield of the reaction was thought to be a consequence of a 1,4-addition/elimination process 
(scheme 2.10, path A). For example, a competing elimination of the C-13 methoxide moiety was 
believed to be favoured over cyclopropanation (path B) leading to water-soluble by-products, 
presumably via 2.33. 
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Scheme 2.10 Possible mechanism for the low yield of D-ring formation. 
Despite the low yield enough material was obtained for full characterisation. The diastereoisomer 
readily crystallised from petroleum ether and the X-ray crystal structure was solved (figure 2.3). 
The structure determination revealed the relative stereochemistry of 2.25, showing clearly that 
cyclopropanation is directed by the cyclopentene moiety to the opposite face of the molecule. 
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Figure 2.3 ORTEP (30% ellipsoid probability) structure of the cyclopropanation product 
2.25. 
With 2.25 at hand the conditions in which the retro Diels-Alder reaction could be performed, were 
evaluated. This was then successfully accomplished in 93% yield using a Kugelrohr distillation 
apparatus.  
 
Scheme 2.11 Synthesis of 2.34 via retro Diels-Alder reaction. 
Despite the retro Diels-Alder reaction working in excellent yield, further investigations and initial 
reduction studies on 2.34 demonstrated the unsuitability of the methyl group as a protecting group. 
Furthermore, a 14% yield at such an early stage in synthesis was undesirable, thus, the encountered 
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problems needed to be addressed. Based on the proposed mechanism it was considered that a larger 
(bulkier) protecting group may well block path A. 
2.5 The Effect of C-13 Substituent upon Cyclopropanation 
To improve the yield of cyclopropanation we sought a deeper understanding of the effect exerted by 
the C-13 substitution pattern. Outlined below is the reactivity of 2.25 towards NH2R, NHR2, S and 
OH functionalization at C-13 and the consequences of this upon the following cyclopropanation 
reaction (scheme 2.12). These efforts demonstrate the capricious nature of this system towards 
synthetic manipulations as well as the low tolerance of the cyclopropanation towards an increase in 
electron density at C-13. 
Cyclic amines proved to be feasible nucleophiles towards substitution at C-13, whereas acyclic 
secondary as well as primary amines were unreactive towards this system. This is believed to be a 
consequence of the well-established higher nucleophilicity of cyclic amines. Treating methoxy 
quinone 2.25 with an excess of pyrrolidine or piperazine in water afforded 2.36 and 2.37, 
respectively in good yield. However, treatment of 2.25 under identical conditions using excess 
ethylmercaptane did not afford the desired product 2.38. Surprisingly only recovered starting 
material was observed. 
Moving on to the free hydroxyl at C-13, it was found that the methyl group could be displaced by 
treatment of 2.25 with an excess of potassium carbonate in water to afford 2.39 in excellent yield. 
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Scheme 2.12 Access to C-13 substituted Diels-Alder adducts. 
An X-ray structure of the crystalline 2.37 was obtained after recrystallization from petroleum ether. 
Figure 2.4 outlines an ORTEP representation of 2.37 at 30% ellipsoid probability. Compound 2.37 
crystallised in the monoclinic P21/c space group with two molecules occupying a single unit cell. 
 
Figure 2.4 ORTEP (30% ellipsoid probability) structure of the cyclopropanation product 
2.37. 
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With 2.36, 2.37 and 2.39 at hand we were in a position to probe their effect upon the instalment of 
the D-ring system. When exposing all three systems towards the cyclopropanation protocol (scheme 
2.13), utilising triisopropylsulfoxonium tetrafluoroborate (2.30), the hampering effect of these 
substituents towards cyclopropanations were evident. In all cases the unaltered starting materials 
were recovered. 
 
Scheme 2.13 Cyclopropanation attempts on 2.36, 2.37 and 2.39. 
With this insight, and a proven ability to introduce the desired D-ring system when employing a 
methoxy moity at C-13, we were convinced that a bulkier alkoxy moiety would be well equipped to 
resolve the difficulties encountered. In this regard attention was focused on introduction of more 
hindered alkoxides via a number of approaches as outlined below.  
Quinones bearing other functional groups than methoxy in 6-position (scheme 2.14) rarely appear in 
literature. Having successfully synthesised the methoxy equivalent of quinone 2.7, it was envisaged 
that selective protection of 3-methylcatechol 2.44 followed by the oxidation of the resulting phenol 
could lead to the desired products 2.42 and 2.43. Benzyl as a protecting group was not considered 
for the synthesis as they are labile under conditions required to hydrogenate the double bond of 
quinone following the retro Diels-Alder reaction. Thus, attention was focused on the selective 
protection as a tosyl or the benzoyl ester. However, selective protection proved to be very 
challenging.  
 65 | P a g e  
 
 
Scheme 2.14 Change of C-13 protecting group strategy. 
Treating 3-methylcatechol with benzoyl chloride and a variety of different bases did not afford the 
desired compound 2.43. Unlike benzoyl chloride, the reaction with tosyl chloride afforded the 
corresponding protected 2.42. However, the attempt at the oxidation of 2.42 to the corresponding 
quinone 2.42 only afforded recovered starting material (scheme 2.15).  
 
Scheme 2.15 Synthetic strategy for quinone 2.40. 
The failure to oxidise 2.42 was attributed to both steric and electronic reasons of the tosyl moiety. 
Thus, a careful interplay between steric bulk and stability towards elimination of the alkoxide was 
required. As a result the use of an isopropyl group as a protecting group was explored. From an 
extensive study as early as 1962 by Simpson et al.
85
 it was evident that the isopropyl moiety was a 
good candidate due to its stability under a wide variety of conditions and the ease of deprotection 
under mild conditions employing AlCl3 as reported by Banwell et al.
86
 In addition, some phorbol 
derivatives such as TPA bear an acyl group at the C-13 position. A promising method to access this 
moiety from a C-13 isopropoxy has been reported by Williams et al. 
87
In their work a 
transprotection protocol was demonstrated in which a isopropoxy moiety could be exchanged for an 
acyl moiety in a one-pot reaction. 
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Commercially available 3-methylcatechol was subjected to conditions described by Razafinrabe et 
al.
88
 in which an excess of isopropyl bromide under reflux conditions was employed to afford mono 
protected alcohol 2.45 in 69% yield. 
 
Scheme 2.16 Synthetic outcome of selective protection of 3-methylcatechol. 
Unfortunately only a 29% yield was obtained of the desired product as a mixture of mono and di-
protected alcohols 2.45 and 2.46. Table 2.4 outlines the results of a variety of conditions attempted. 
Entry Solvent System Temperature, 
Duration 
Compound 
2.44 
Compound 
2.45 
Compound 
2.46 
1 DMF/Acetone (2:1) r.t., 40 hours  - No reaction - 
2 DMF/Acetone (2:1) Reflux, o.n. - 29% 43% 
3 DMF/Acetone (1:2) r.t., o.n.  - No reaction - 
4 DMF/Acetone (1:2) reflux, o.n. - 15% 23% 
5 Acetone reflux, o.n. No reaction 
6 Acetone/DMF cat. r.t., o.n. 21% 15% - 
7 Acetone/DMF cat. reflux, o.n. 18% 24% - 
Table 2.4 Conditions for selective protection of 3-methylcatechol. 
Unsatisfied with this outcome the literature was consulted for an alternative procedure. Nicolaou et 
al.
89
 has reported the selective protection of 2,3-dihydroxybenzaldehyde using benzyl bromide and 
sodium hydride as base. With a slight modification of this procedure it was investigated whether the 
use of isopropyl would prove successful under these conditions. Exposing aldehyde 2.47 to 
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isopropylbromide and sodium hydride (scheme 2.17) only returned a 15% yield of monosubstituted 
phenol 2.48.  
 
Scheme 2.17 Selective protection of 2.47 according to Nicolaou et al. 
Subsequent reduction of aldehyde 2.48 afforded the target molecule 2.45 in a discouragely low 
overall yield of 34%. While offering no improvement over the previous effort the material obtained 
from both studies could be combined in order to further explore the following synthetic 
transformations. Gratifyingly, oxidation of 2.45 proceeded smoothly providing 2.49 in 81% yield. A 
thorough survey of the literature and further optimisation studies unfortunately did not offer any 
means to convert the initial low yields of 29% and 15% in order to make the synthetic sequence 
acceptable for a multi-step synthesis. 
Having outlined the synthesis of 2.7 (see scheme 2.2) in excellent yield and with a large quantity of 
material at hand attention was directed towards a direct exchange of the methoxy moiety for the 
isopropyl. As an added advantage, in the event this method should prove successful, it would offer 
an economically viable large scale approach to 2.49 due to the low cost of o-vanillin as a starting 
material.  
Wurm et al. reported the smooth trans esterification of vinylogous methoxy ester on 1,4-
naphthoquinone systems by using primary or secondary alcohols as the solvent and NaOAc as base 
(scheme 2.18).
90
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Scheme 2.18 Wurm’s approach for the direct β-substitution of methoxy to isopropoxy. 
Applying these conditions to 2.7 (scheme 2.19), afforded 2.49 in 44% yield, now facilitating an 
efficient synthetic route to the desired quinone 2.49 via an addition/elimination mechanism starting 
from readily available methoxy quinone 2.7. 
 
 
Scheme 2.19 New approach to isopropoxy quinone 2.49. 
Briefly screening a number of conditions outlined in table 2.5 it was discovered that the change of 
base from sodium acetate to potassium carbonate further improved the initial yield of 44% to afford 
2.49 in an optimised yield of 70%. 
entry base temperature, °C time, h yield, % 
1 NaOAc reflux 5 44 
2 NaOAc r.t. 12 30 
3 K2CO3 reflux 5 70 
4 K2CO3 r.t. 12 53 
Table 2.5 Condition screening for the synthesis of isopropoxy quinone 2.49. 
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It is noteworthy that a reaction time of 4.5 hours was crucial in order to avoid the formation of the 
double addition product 2.52 (figure 2.5). Despite the recovery of starting material along with 2.49, 
exceeding this reaction time did not drive the reaction to completion, but rather increased formation 
of 2.52. 
 
Figure 2.5 By-product 2.52 observed during prolonged reaction times en route to 2.49. 
With the isopropoxy protected quinone 2.49 at hand a racemic Diels-Alder reaction was performed 
under standard conditions with freshly cracked cylcopentadiene in dichloromethane to afford the 
adduct 2.53 in excellent yield (scheme 2.20).  
 
Scheme 2.20 Diels-Alder reaction of 2.49 with cyclopentadiene. 
A crystal structure was obtained from adduct 2.53, which is depicted in figure 2.6 at 30% ellipsoid 
probability. 
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Figure 2.6 ORTEP (30% ellipsoid probability) structure of the Diels-Alder product 2.53. 
Accessing 2.53 set the stage to evaluate the hypothesis that the increased bulk of the protecting 
group (MeO vs. iPrO) would address the issue of the previously observed low yielding 
cyclopropanation.  
Exposing 2.53 to identical conditions as previously reported for 2.25 (scheme 2.21) the gem-
dimethylcyclopropane was introduced in a significantly improved yield of 77% in contrast to 14% 
for 2.25.  
 
Scheme 2.21 Synthetic pathway to advanced intermediate 2.55. 
Subsequent retro Diels-Alder reaction, utilising a Kugelrohr distillation apparatus, proceeded 
smoothly affording the advanced intermediate 2.55 comprising the CD ring system in excellent 
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yield (93%). This was a very exciting development, following such an arduous journey to result in 
the formation of the cyclopropane moiety.  
Compound 2.54 was confirmed by 
1
H NMR using 2D NMR experiments (COSY, HMBC). As can 
be seen in figure 2.7 and 2.8 the Δ1,2-olefinic protons both appear as one singlet at 6.53 ppm and 
correlate to the C-3 (3.48 ppm) and C11 (3.2 ppm) protons, respectively. Assigning the remaining 
correlations of the former reveals the C-12 bridgehead protons to resonating at 1.25 ppm and 1.01 
ppm as a broad doublet and a double of triplets respectively. This can be attributed to a long-range 
W-correlation seen between the C-12 bridgehead protons and the ring fusion (C-12 to C-3 and C-
11).  
The remaining C-4 proton is then assigned to a doublet resonating further downfield at 2.58 ppm 
and, across the six-membered ring, the C-6 proton appears as a singlet at 2.13 ppm. If desired a 
distinction can be made between the C-5 and C-9 carbonyls respectively. From the HMBC NMR 
(see appendix 7) of compound 2.53 a two bond correlation can be seen from the C-4 and C-6 
protons to the C-5 carbonyl carbon at 206.3 ppm. With the C-5 carbonyl assigned the remaining C-9 
carbonyl can be assigned to the signal at 210.3 ppm, which in turn correlates to the C-10 methyl 
moiety at 1.48 ppm. The isopropyl moiety and the geminal methyls at C-7 are then easily 
distinguished from the remaining signals.   
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Figure 2.7 2D Correlation Spectroscopy for compound 2.54. 
 
Figure 2.8 500 MHz 
13
C NMR spectrum for 2.54. 
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Position δH Position δH 
1,2 6.23 (m, 2H) 13 1.49 (s, 3H) 
3 3.50 (m, 1H) 14,15 
1.31 (s, 3H) 
1.30 (s, 3H) 
4 2.59 (d, J = 4.2 Hz, 1H) 16 3.68 (sept, J = 6.0 Hz, 1H) 
6 2.14 (s, 1H) 17 1.26 (d, J = 6.0 Hz, 3H) 
11 3.21 (m, 1H) 18 1.02 (d, J = 6.0 Hz, 3H) 
12 1.68 – 1.65 (m, 1H),  
1.44 (dt, J = 1.7, 9.3 Hz, 1H), 
  
Table 2.6 
1
H NMR data for compound 2.54 (500MHz, CDCl3).  
The relative stereochemistry of compound 2.54 was confirmed via X-ray crystallography and 
readily crystallised from petroleum ether. Compound 2.54 crystallised in the monoclinic P21/c 
space group with two molecules occupying a single unit cell. 
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Figure 2.9 ORTEP (30% ellipsoid probability) structure of the cyclopropanation product 
2.54. 
To put this exciting cyclopropanation result into perspective Harwood et al.
91
 showed that bicyclic 
systems of type 2.61 are difficult to synthesise going to great length to construct 2.59, requiring a 
dibromo cyclopropanation followed by transmetallation, which proceeded in poor yield (scheme 
2.22). It was shown that these compounds are thermally unstable and in the case of Harwood’s 
approach towards the synthesis of the CD ring system of phorbol that 2.60 and 2.61 degrade at 
room temperature within 1 week. 
 
Scheme 2.22 Harwood's synthesis of CD-ring system of phorbol. 
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With a powerful approach to the key intermediate 2.54, the journey was continued so as to gain new 
ground in the advancement towards the right hand fragment. 
2.6 Ring C: Reduction Studies 
As outlined in the retrosynthetic analysis (scheme 2.1) it was envisaged that in the forward direction 
double bond reduction of advanced intermediate 2.55 could be performed under a number of 
conditions utilising reagents such as Mg/MeOH,
92
 Stryker’s reagent93 or classical hydrogenation 
conditions. The latter was, however, not desirable due to the following reason. Triflation of the 
resulting enol would prepare the system for Sonogashira coupling of 2.63 with readily available 
protected propargyl alcohol 2.64. A reduction/protection sequence at C-12 followed by epoxidation 
and metal mediated ring closure should ultimately provide 2.68. 
 
Scheme 2.23 Proposed route to the right hand fragment 2.68. 
Due to literature precedents of similar systems undergoing ring opening upon exposure to Pd/C, the 
first attempts were focused on utilising magnesium in methanol (table 2.7, entry 1) as this has been 
reported to be a mild method for the reduction of α,β-unsaturated double bonds in the presence of 
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isolated alkenes. However, the system was unreactive under these conditions. The same situation 
was faced with Stryker’s reagent (entry 2). 
Forced by these results it was decided to investigate hydrogenation conditions (entries 3-6) driven 
by the benefit a successful outcome would offer. This bold move was motivated by the possibility 
to perform flow hydrogenations utilising an H-Cube® continuous flow reactor, which allows 
precise control over a number of parameters such as temperature and flow rate and catalyst 
exposure time. For comparison reasons studies began by investigating hydrogenation under 
classical conditions. Treating 2.55 under classical hydrogenation conditions afforded, as expected, 
ring-opened product 2.69 along with traces of alcohol 2.70 (scheme 2.24). 
 
Scheme 2.24 Hydrogenation studies on 2.55. 
Next, a series of hydrogenations under flow conditions were performed. It was found that catalyst 
exposure time (flow rate of 3 mL/min vs. 1 mL/min) had no effect on the outcome of the reaction. 
Furthermore, utilising extremely mild conditions involving presaturation of the palladium catalyst 
with hydrogen were investigated.  
Entry Conditions Product 
1 Mg, MeOH No reaction 
2 Stryker’s reagent No reaction 
3 Pd/C, H2 (Classic) 2.69, traces 2.70 
4 Pd/C, H2 (H-Cube®) 2.69, traces 2.70 
5 Pd/C, H2 + pyridine (Classic, H-Cube®) 2.69, traces 2.70 
6 Lindlar®, H2 (H-Cube®) 2.69, traces 2.70 
Table 2.7 Condition screening for the reduction of 2.55. 
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Using the adsorbed hydrogen on the catalyst as the only hydrogen source affected the same 
transformation to afford 2.69 and traces of 2.70. Poisoning the catalyst with pyridine (entry 5) or 
using Lindlar® catalyst (entry 6) unfortunately did not change the course of the reaction. 
Having failed to directly reduce the double bond it was envisaged that reducing the more hindered 
ketone at C-12 and protection of the resultant alcohol would afford a more stable system by 
removing the conjugation ultimately reducing the strain of the three-membered ring D (scheme 
2.25). Accordingly, attempts were made at reducing the C-12 ketone employing Zn(BH4)2 as the 
reducing agent.
94
 In the event of over-reduction, i.e. reduction at C-12 and C-8, respectively, 
selective mild re-oxidation could lead to the desired product 2.72. The advantage of utilising 
Zn(BH4)2 lies in the selective anti-reduction of α-hydroxyketones as reported by Nakata et al.
94b
 
leading to the desired relative configuration. 
 
Scheme 2.25 Alternate approach for reduction of the C-ring. 
When exposing 2.55 to Zn(BH4)2 in diethyl ether, however, no reaction was observed and starting 
material was fully recovered. A series of temperatures and exposure times were employed, yet again 
without success. 
In the total synthesis of (+)-phorbol (1.1), Wender
37
 made use of NaBH(OAc)3 when reducing the 
C-12 ketone on the tigliane core. This prompted deployment of this methodology to the quinone 
system 2.55. Frustratingly, also these attempts were unsuccessful.  
Due to the lacking reactivity of the key intermediate 2.55 towards these mild conditions, a global 
reduction was attempted in the hope of selectively re-oxidising the less hindered alcohol. To affect 
this transformation harsher conditions were employed, i.e. NaBH4 as the reducing agent.  
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Scheme 2.26 Reduction studies to 2.55 utilising NaBH4. 
Even under these more forcing conditions, ketone at C-12 remained unaltered. Instead two 
consecutive reductions, namely a 1,4 and a 1,2-reduction, occurred to afford 2.73. Re-oxidation of 
the resultant alcohol utilising tetrapropylammoniium ruthenate (TPAP) was partially successful. 
However, it was plagued by oxidative reinsertion (i.e. oxygen) of the undesired olefinic bond.  
Moving to the more powerful reducing agent DIBAlH, the diol 2.74 was successfully obtained in 
82% yield which was globally protected to afford disilyl ether 2.75 in 90% yield. Selective 
deprotection utilising citric acid in methanol followed by oxidation under standard conditions using 
TPAP/NMO then afforded the desired ketone 2.76 in 63% yield over 2 steps. 
 
Scheme 2.27 Synthetic pathway to ketone 2.76. 
Due to time limitations further work on this system as outlined in scheme 2.23 is currently 
underway in the Williams laboratory performed by Dr Sharon Chow. Thus, with the right hand 
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fragment in an advanced state it was important to now start investigating the synthesis of the A-ring 
and the subsequent [4+3] cycloaddition reactions. 
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3 Synthetic Investigations Towards the Construction of the Left 
Hand Fragment 
3.1 Introduction 
As outlined in chapter 1.11 (scheme 1.21) the retrosynthetic approach to the seven-membered ring 
of the target molecule (-)-phorbol 1.169 is envisaged to be achieved via a formal [4+3] 
cycloaddition reaction between a diazo compound and a furan.
63a
  
 
 
Scheme 3.1 Retrosynthetis leading to LHF and RHF. 
Diazo compounds have been shown to be extremely versatile reagents and modern organic 
chemistry still benefits from the unique versatility of diazocarbonyl compounds ranging from 
cyclopropanations and C-H insertion to cycloadditions amongst many other useful organic 
reactions.
95
 
3.2 Diazo Transfer Approach 
The standard approach to alkenyldiazoacetates of type 3.1 involves the treatment of the 
corresponding unsaturated ester with diazo transfer reagents such as tosyl azide or more commonly 
4-acetamidobenzenesulfonyl azide (p-ABSA) in presence of base as shown in scheme 3.2.
96
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Scheme 3.2 General diazo transfer transformation. 
While most of the diazo transfer reactions occur on activated methylene groups of 1,3-dicarbonyls it 
has been shown that β,γ-unsaturated carbonyl systems such as 1.199 undergo these type of reactions 
without additional activation.
97
 
 
 
Scheme 3.3 Synthetic plan for diazo transfer to construct the LHF. 
A feasible method to provide the diazo transfer precursor 1.199 was to utilise enamine chemistry 
described by Barco et al.
98
 Enamines are versatile intermediates in organic chemistry and can be 
easily prepared via the reaction of a ketone with secondary amines. In situ formation of enamine 3.5 
(scheme 3.4) from 2-methylcyclopentanone and pyrrolidine followed by condensation with ethyl 
glyoxalate affords compound 3.6 bearing an exocyclic double bond. 
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Scheme 3.4 Forward strategy to diazo transfer precursor 3.6. 
Compound 3.6 was characterised via 
1
H, 
13
C and 2D COSY correlation spectroscopy. A 
representation of the latter can be seen in figure 3.1. Methyl group 9 is represented by a doublet 
signal at 1 ppm while the associated carbon signal shows a resonance at 119.9 ppm in the 
corresponding 
13
C NMR spectrum. The correlation between the methyl 9 and proton 2 can be 
clearly seen from the 2D COSY spectrum (figure 3.1). The exocyclic double bond 5 at a shift of 
6.52 ppm shows correlations to two protons at 4-position.  
Installation of the double bond at the desired position proved overwhelmingly difficult. Classic 
double bond isomerisation methods such as acid catalysed isomerisation failed to afford the desired 
compound 1.199 in acceptable yields.  
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Figure 3.1 2D-COSY spectrum of exocyclic compound 3.6. 
The major compound isolated from the double bond isomerisation reaction (scheme 3.5) was 3.7, 
which seemed to be the more stable enone. The purification of the obtained products from this 
reaction was not straightforward using flash chromatography as the three components possessed 
similar Rf-values on silica. 
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Scheme 3.5 Double bond isomerisation of 3.6 under acidic conditions. 
Initial purification via column chromatography followed by Kugelrohr distillation was able to 
resolve the components to an acceptable degree. As seen in figure 3.2 only a minor amount of 3.7 
was present after purification.  
The 
1
H NMR of 3.6, 1.199 and 3.7 is shown in figures 3.2 and 3.3. The double bond isomerisation 
from the exocyclic 3.6 to 1.199 gives rise to a multiplet resonance between 7.30 and 7.22 ppm in 
comparison to 6.52 ppm. The installation of the Δ4,5- double bond (1.199) correlates to most 
downfield shift at 7.53 – 7.51 ppm. 
 
 
Figure 3.2 Distinction of double bond isomerisation products by 
1
H NMR. 
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Fortunately, sufficient of the desired compound could be obtained in order to further investigate the 
diazo transfer reaction. Furthermore, exocyclic ester 3.6 was believed to be capable of diazotisation 
via deprotonation at the γ-position followed by reaction of the resulting enol (scheme 3.6). If such a 
reaction would prove successful the synthesis of 1.199 would be made redundant thus shortening 
the synthetic sequence.  
 
 
Scheme 3.6 Diazo transfer reaction using either 1.199 or 3.6. 
Initial attempts at performing the diazo transfer reaction in the presence of tosyl azide and 
triethylamine (table 3.1, entry 1) failed to give the desired product in both cases. Rather 
decomposition was observed on prolonged reaction times. In an effort to optimise reaction 
conditions the stronger base DBU (entry 2) was employed to investigate whether the failure could 
be accounted for by the lack of enolisation. However, DBU did not achieve an improvement over 
triethylamine. Unfortunately, reversion to the more reactive diazo transfer reagent p-ABSA (entry 3 
and 4), was likewise met with the same disappointing outcome. 
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entry reagent base solvent product 
1 TsN3 NEt3 MeCN decomposition 
2 TsN3 DBU MeCN decomposition 
3 p-ABSA NEt3 MeCN decomposition 
4 p-ABSA DBU MeCN decomposition 
5 ADMC DBU MeCN decomposition 
6 ADMH DBU MeCN decomposition 
Table 3.1 Screening of diazo transfer reagents and conditions. 
Kitamura et al. discovered the utility of 2-azido-1,3-dimethylimidazolinium chloride (ADMC) 
(3.11, scheme 3.7) as a new diazo transfer reagent with a high substrate tolerance, which has since 
become a highly useful reagent that is now commercially available.
99
 In addition, this newly 
developed reagent offers the advantage of water soluble by-products, which facilitates the 
purification process immensely. Accordingly, 2-azido-1,3-dimethylimidazolinium azide 3.11 was 
formed in situ from 2-chloro-1,3-dimethylimidazolinium chloride 3.10 and sodium azide in 
acetonitrile at 0 °C. Upon addition of 1.199 to the reaction mixture (table 3.1, entry 5-6) no reaction 
was observed under the given conditions.  This could have been due to the well-known sensitivity 
of ADMC toward traces of moisture.  
 
Scheme 3.7 Diazo transfer with Kitamura's salt ADMC. 
To improve upon the hygroscopic nature of ADMC Kitamura et al. reported that a counter anion 
exchange from the chloride to hexafluorophosphate could circumvent this issue and increase the 
stability of the reagent significantly.
99b
 Thus, counter ion exchange was accomplished in excellent 
yields using potassium hexafluorophosphate to afford chloride 3.12. With its improved stability 
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3.12 could be isolated and further converted to the stable azide 3.31 upon treatment with sodium 
azide. 
 
Scheme 3.8 Counter-ion exchange for a more stable Kitamura reagent (ADMF). 
The reaction with 1.199 and the newly prepared diazo transfer reagent was conducted under 
identical conditions using DBU in acetonitrile (table 3.1, entry 6). Unfortunately, the more stable 
reagent did not yield the desired compound 3.9. 
Having failed to obtain the left hand fragment via this otherwise robust method new avenues were 
required in which to achieve the synthesis of this key fragment. One such possibility based on the 
work of Wang et al.,
100
 which describes direct palladium mediated cross coupling of vinyl and aryl 
iodides with ethyldiazo acetate. 
3.3 Diazo Direct Palladium Cross-Coupling Approach 
3.3.1 First generation Approach 
Wang and co-workers discovered that diazo compounds such as ethyldiazo acetate are sufficiently 
nucleophilic reagents to facilitate a direct palladium cross coupling in moderate yields. In Wang’s 
work vinyl and aryl iodides were smoothly fused to the corresponding diazoacetates 3.15 and 3.17 
(scheme 3.9).  
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Scheme 3.9 Wang's direct diazo cross-coupling. 
Utilising this new methodology the synthesis of the left hand fragment 3.9 was approached via a 
newly revised strategy. The alternate retrosynthetic analysis of the left hand fragment begins with 
disconnection of ethyldiazo acetate to generate the necessary precursors for a direct diazo cross 
coupling as described by Wang et al. (scheme 3.8). In turn iodide 1.86 can be synthesised from 
commercially available 2-methylcyclopentanone 3.4. Controlling the stereochemistry at C-2 is not 
necessary as it is eliminated at a later stage in synthesis.  
 
 
Scheme 3.10 Alternate retrosynthetic analysis of the LHF. 
Unfortunately, this methodology could not be directly superimposed. Coupling of ethyl diazoacetate 
with non-aromatic cyclic iodides such as 1.200 has thus far not appeared in the literature. 
Nevertheless, it seemed feasible that such a transformation had high probability. 
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In an attempt to synthesise key fragment 1.200 introduction of the double bond was performed 
using IBX/NMO
67
 to afford a 2:1:1 mixture of products 3.18, 3.19 and 3.20 (scheme 3.11). 
 
 
Scheme 3.11 Alternate forward strategy to the LHF. 
Attempts at purifying the desired compound 3.18 via atmospheric distillation failed due to the 
similar physical properties of all compounds. With this in mind it was envisaged that derivatisation 
of the mixture with iodine would regioselectively afford compound 3.21 and 3.22 facilitating 
purification via silica column chromatography. Unfortunately, compound 1.200 was found to be 
unstable to silica column chromatography, but sufficient material was obtained in order to 
investigate palladium coupling. When performing the cross coupling reaction with ethyldiazo 
acetate, no reaction was observed. Despite repeated attempts under various conditions, treatment of 
1.200 with ethyldiazo acetate returned a complex mixture of products.  
 
In an attempt to understand why the palladium coupling was failing the reaction was repeated 
without attempting further purification. A crude sample was analysed by GC/MS and a peak 
tentatively assigned to compound 3.23 was observed. 
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Scheme 3.12 Possible pyrazole formation during diazo formation. 
The basis of the structural assignment was maintained by the fact that under mass spectrometry 
electron ionisation conditions diazo compounds tend to decompose to the corresponding carbenes. 
As loss of nitrogen from the molecular ion was not observed the conclusion was drawn that under 
the reaction conditions spontaneous cyclisation occurs to afford the more stable pyrazole 3.23 as 
previously reported.
101
 Thus, the complex nature of the mixture in combination with low conversion 
and the unexpected spontaneous cyclisation of the diazo compound proved fatal to this approach 
and as such it was abandoned. 
In a separate approach the effect of tosyl diazomethane 3.29 as an electron withdrawing group was 
briefly investigated in an attempt to circumvent the aforementioned difficulties (scheme 3.13). As 
an added advantage the removal of a sulfone moiety can be achieved in a more straightforward 
manner in contrast to that of an ester (i.e. mild removal with Na/Hg). This would possibly allow a 
smoother transition at a later stage of the synthesis by removal of this handle once construction of 
the seven-membered ring had been achieved. Thus, the synthesis of tosyl diazomethane 3.28 was 
undertaken (scheme 3.13). 
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3.4 Synthesis of Tosyl diazomethane 
Following the route reported by Corey et al.
75
 the synthesis of 3.28 was started with commercially 
available tosyl chloride 3.24. The chloride 3.24 was converted to 3.25 by treatment with an aqueous 
equimolar mixture of sodium sulfate and sodium hydrogen carbonate. 
 
 
Scheme 3.13 Synthesis of tosyl diazomethane 3.28. 
Synthesis of ester 3.26 was achieved by exposure of 3.25 to an aqueous mixture of urethane, formic 
acid and formaldehyde. Subsequent nitrosation gave rise to compound 3.27 in 82% yield. The title 
diazo compound 3.28 was then obtained upon treatment of 3.27 with aluminium oxide in 
dichloromethane in 73% yield. 
With the synthesis of 3.28 completed further attempts in trying to achieve the synthesis of the left 
hand fragment 1.204 could be undertaken. Treating 2-iodocyclopentenone with tosyl diazomethane 
(3.28) utilising Wang’s conditions (i.e. DBU, Pd(PPh3)4, nBu4NBr) unfortunately, afforded the 
same outcome as previously observed with ethyldiazo acetate. Screening a variety of different 
conditions did not lead to the desired compound forcing a re-evaluation of the synthetic strategy. 
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Scheme 3.14 Initial direct diazo coupling of 1.200 to 3.28. 
3.4.1 Second Generation Approach 
Reflecting upon the experience with this system it was quickly realised that the methyl group at C-2 
contributed to additional by-products by affording a competitive pathway to a more stabilised 
alkene 3.7 (scheme 3.5). The methyl group could easily be introduced at a later stage in the total 
synthesis as it is situated alpha to the C-3 carbonyl moiety (compound 1.169, scheme 2.1). This 
could be achieved via deprotection/oxidation sequence to afford ketone 3.30 as outlined in scheme 
3.15. Subsequent enolisation under standard conditions followed by quenching with MeI would 
arrive at the C-2 methyl ketone 3.31 as desired. 
 
 
Scheme 3.15 Possible introduction of the C-2 methyl group. 
Furthermore, the necessity to derail pyrazole formation prompted further simplification of the 
cyclopentene ring ultimately arriving at 3.32 which was chosen as a starting material. 
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Scheme 3.16 Second generation approach to the coupling precursor 3.35. 
The synthetic sequence began with α-halogenation under standard aqueous conditions for enones to 
afford 3.33 in 88% yield. Luche reduction followed by TBS protection gave rise to the coupling 
precursor 3.35 in an overall yield of 72% over three steps. The significantly improved approach 
now made it synthetically feasible to proceed with a thorough investigation towards the direct diazo 
cross coupling reaction. 
While initial attempts in utilising NEt3 and Pd(PPh3)4 in MeCN failed to give the desired product, 
increasing the basicity of the amine by the use of DBU in combination with a slight increase in 
temperature (45 °C) ultimately afforded a desired left hand fragment 3.36. 
 
 
Scheme 3.17 Successful synthetic route to the LHF. 
The reaction is highly concentration dependent, requiring as long as 48 hours while dilute, reducing 
to just 12 hours when starting with a more concentrated solution. To the best of our knowledge this 
represents the first example of a diazo coupling utilising a cyclic vinyl iodide.  
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A possible mechanistic explanation of the direct diazo coupling is depicted in figure 3.18. Wang et 
al.
100
 suggested two different pathways for the construction of such systems. Oxidative addition of 
the palladium source to the substrate followed by diazo anion substitution affords 3.39 (Path B). 
Alternatively, 3.39 is believed to be formed via the coordination of the ethyldiazo acetate anion to 
3.37 to form complex 3.38 from which proton is removed by base (Path A). 
 
 
Scheme 3.18 Plausible mechanism for the direct diazo coupling to afford 3.36. 
Compound 3.36 was characterised via 
1
H, 
13
C NMR spectroscopy, IR, and GC/MS analysis. In 
order to obtain a full carbon spectra, extended acquisition and delay times had to be applied. The 
13
C key resonances are shown in figure 3.3 with the C-7 carbonyl resonating at 166.4 ppm, the 
alkene moiety C-4 at 132.1 ppm and C-1 resonating at 78 ppm. Despite variations in NMR data 
acquisition, a sufficiently strong signal of the C-6 quaternary carbon could not be obtained to prove 
conclusively, most likely due to the nitrogen quadrupole effect. A weaker signal at 44 ppm could be 
obtained and was tentatively assigned to the C-6 carbon. However, strong evidence is obtained from 
IR measurements of the presence of the diazo functionality (figure 3.4). 
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Figure 3.3 
13
C key resonances of compound 3.36. 
The FTIR spectrum of the Left Hand Fragment 3.36 exhibits a broad absorption band at 2085 cm
-1 
that is attributed to the diazo stretch of the molecule while ethyldiazo acetate itself exhibits a broad 
absorption band slightly shifted at 2107 cm
-1
 (figure 3.4) 
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Figure 3.4 Diazo stretch comparison between 3.36 and ethyldiazo acetate. 
Moreover, characterisation using GC/MS under electron ionisation (EI) conditions showed the loss 
of nitrogen while low resolution electrospray ionisation (LRESI) mass measurements showed a 
mass of m/z 333 which corresponds to [M+Na]. In contrast to our previous discussions in regard to 
spontaneous cyclisation of 3.9 to pyrazole 3.23 (scheme 3.12) a direct comparison of the GC/MS 
spectra (figure 3.5) confirms our suspicions thus justifying the new simplified approach.  
 
Figure 3.5 GC/MS fragmentation pattern of compound 3.36. 
For reasons mentioned previously the viability of tosyl diazomethane 3.28 as the coupling partner 
was investigated. Performing the palladium catalysed cross-coupling reaction under identical 
conditions to that of 3.36 proved unsuccessful. Likewise, a change in catalyst to the more reactive 
Pd(dba)2 did not alter the outcome of the reaction.  
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Scheme 3.19 Direct diazo coupling between 3.35 and 1.204. 
With the left hand fragment complete the key transformation could be addressed in the construction 
of the seven-membered ring B of (-)-phorbol 1.169. The following chapter outlines a model study 
of the left hand fragment with a variety of furans to assess the viability of the proposed approach. 
. 
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4 Studies Towards Seven-Membered Ring Formation  
4.1 Introduction 
Seven-membered rings are ubiquitous in biologically active natural products such as frondosin B,
102
 
(±) tremulenolide A,
103
 engelerin A
104
 and phorbol esters.
105
 In addition, a considerable amount of 
carbocyclic seven membered rings are also found in pharmaceuticals and FDA approved drugs such 
as colchicine
106
 with a wide variety of pharmacological properties. Still, only a handful of 
methodologies are known to date to access highly functionalised cycloheptadiene systems. More 
common methods to form seven-membered rings in the last decade included: ring closing 
metathesis (ene-ene and ene-yne metathesis),
107
 cyclisation reaction, ring expansion and 
cycloaddition reactions including the utilisation of Diels-Alder, [4+3], [5+2] and [2+2+2] reactions.  
 
 
Figure 4.1 General representation of natural products containing seven-membered ring cores.  
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4.2 Ring-Closing Metathesis 
Among the most utilised methodologies of recent times in modern synthetic chemistry is ring-
closing metathesis.
107
 This approach is particularly useful as it provides convenient access to 
various ring-size carbocycles and has been widely studied as a C-C bond formation methodology. 
Tungsten complexes were the first catalysts used for the reaction with acyclic olefins and despite 
working nicely, they were quite sensitive. Schrock et al.
108
 introduced in 1990 the first synthesis 
and use of molybdenum imido alkylidene complexes (figure 4.2) that have shown to possess a 
wider substrate tolerance and a greater tendency to be reduced than the Schrock catalysts.
109
 
Another breakthrough was achieved by Grubbs et al.
110
 with the introduction of ruthenium based 
carbene complexes. The first generation catalyst did not provide the level of activity compared to 
Schrock catalysts. However, the applicability in natural product synthesis could not be denied. A 
second generation Grubbs’ catalyst was introduced demonstrating an air and moisture stable 
catalyst with a higher activity than the first generation catalysts. 
 
 
Figure 4.2 Common catalysts for ring-closing metathesis. 
An elegant application of the Grubbs’ catalyst was demonstrated by Ley et al. in the total synthesis 
of thapsigargins from (S)-carvone.
111
 Preparation of precursor 4.2 was accomplished in 14 steps 
followed by the ring closing metathesis utilising the second generation Grubbs’ catalyst to afford 
4.3 in 88% yield. Further synthetic manipulations provided triole 4.4 which serves as a precursor to 
a number of thapsigargin derivatives including thapsivillosin F, nortrilobolide and trilobolide. 
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Scheme 4.1 Ley’s total synthesis of thapsivillosin F 4.5. 
Ley’s approach to this family shows clearly the strength of the ring-closing metathesis in accessing 
five out of the total 17 members of the thapsigargin family. 
4.3 Diels-Alder reaction 
Diels-Alder reactions are more commonly known for the synthesis of cyclohexane rings via the 
reaction of a diene system and an alkene.
112
 When used as an intramolecular approach access to 
seven-membered rings can be achieved. Elegant examples of this approach to natural products 
comprising a seven-membered ring core include the asymmetric total synthesis of caribenol A
113
 
and Chen’s total synthesis of (+)-echinopines A.114 
In the former case intermediate 4.7 was prepared in four steps from cyclopentenone 4.6. Following 
this, cycloaddition precursor 4.8 was synthesised in a 6 step synthetic sequence and an overall yield 
of 62%. The subsequent intramolecular Diels-Alder reaction was then performed utilising 2,6-di-
tert-butyl-4-methylphenol (BHT) catalytically to afford the desired adduct in 92 % yield. 
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Scheme 4.2 Total synthesis of caribenol A (4.10). 
4.4 [4+3]Cycloaddition reaction 
The [4+3] cycloaddition reaction has become a powerful tool for the construction of seven-
membered rings over the last decade and has found widespread application in natural product 
synthesis, including the synthesis of englerin A,
115
 (+)-frondosin B,
116
 (+)-barekol
117
 and (+)-
barekoxide
117
 to mention a few. 
 
 
Figure 4.3 General representation of natural products containing seven-membered rings 
formed via [4+3] cycloaddition reaction. 
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4.4.1 Rhodium-catalysed formal [4+3] Cycloaddition reaction 
One of the most versatile reactions in this regard is the formal [4+3] cycloaddition reaction of 
stabilised diazo compounds with substituted dienes.
63b,95a
 Diazo compounds have been exploited for 
their utility in the formation of stabilised donor/acceptor carbenes via metal catalysed 
decomposition; a methodology that has been widely applied in modern organic chemistry after its 
discovery by Davies et al.
63b,118
 In combination with rhodium catalysts, especially rhodium (II) 
tetracarboxylates, these carbenes have proven to be extremely useful in affording a variety of 
important intermediates for the synthetic organic chemist. The key to this success lies in the 
realisation that the substitution pattern of the carbenes is crucial for their stability and thus their 
ability to undergo controlled reactions.  
Mechanistically construction of the seven-membered ring is a combination of two concomitant 
steps, namely, cyclopropanation followed by Cope rearrangement. Thus, these reactions are referred 
to as formal [4+3] cycloaddition reactions.  
Three common dirhodium species are shown in figure 4.4. Rh2(DOSP)4 and Rh2(PTAD)4 capable of 
undergoing C-H functionalization reactions with high reactivity and selectivity and the achiral 
Rh2(OPiv)4. All three catalysts have proven effective with a wide range of substrates. An added 
advantage for all of them is their solubility in hydrocarbon solvents thus improving substrate 
conversion and stereocontrol. 
 
 
Figure 4.4 Selected rhodium catalysts for the formal [4+3] cycloaddition reaction. 
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4.5 Model Studies with the Left Hand Fragment 
To probe a wide scope of substrates the study began with a number of mono-, di- and trisubstituted 
furans. Both mono- and disubstituted furans could be obtained via commercial sources. However, to 
widen the scope further model trisubstituted furans were synthesised. The catalyst Rh2(R-DOSP)4, 
was initially chosen due to its versatility.  
 
Table 4.1 outlines the results when treating diazo compound 3.36 with a wide range of furans in 
cyclohexane at 60 °C. With most furans the reaction yielded moderate to low yields. After extensive 
screening these conditions were found to be the most favourable. 
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Entry Furan 
Product 
Number 
Product 
Reaction 
Time, h 
Yield,% 
1 
 
4.11 
 
1.5 50 
2 
 
4.12 
 
1.5 47 
3 
 
4.13 
 
2.5 38 
4 
 
4.14 
 
1.5 29 
5 
 
4.15 
 
1 34 
Table 4.1 Model studies of 3.36 with selected furans. 
In the case of electron withdrawing substituents at position C-2 and C-3 of the furan (entries 1-3) 
the yields favoured ester over ketone. This could, however, be due to the poor solubility of 3-
acetylfuran (entry 3) in cyclohexane. The position of the ester (C2 or C3) did not influence the yield 
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of the reaction. Installing a bulky TBS-ether (entry 3) gave a lower yield in comparison to that of 
the esters. A similar outcome was obtained using 3-bromofuran (entry 5). Using 2-methylfuran as a 
substrate with a weak electron donating effect of the methyl moiety likewise afforded a lower yield 
to that of the esters. 
A typical representation of the NMR spectrum of the epoxyazulene core can be seen in figure 4.5. 
The alkene protons Ha and Hc can be seen at 6.60 ppm and 5.57 ppm, respectively. The bridge head 
proton Hb is situated further upfield at 5.03 ppm. Finally, Hd appears as a broad singlet at 4.97 ppm 
suggesting an angle in the vicinity of 90 ° to its adjacent protons. In comparison, substituting the 
methyl function at C-9 to a methyl ester (entry 1) shifts the corresponding signals at Ha-Hc to 6.77, 
5.83 and 5.11 ppm respectively. The signal at Hd is unaffected by the substitution at C-9. This latter 
also holds through in case of the TBS protected substituent (entry 3). However, a multiplet is 
observed rather than a broad singlet.  
 
 
Figure 4.5 
1
H NMR spectrum showing the olefinic protons of cycloaddition product 4.14. 
The relative stereochemistry was confirmed via X-ray crystallography. Compound 4.12 (entry 2) 
readily crystallised from petroleum ether.  
Unfortunately by analysing NOE correlation spectra of compounds 4.11 – 4.15, determination of 
stereochemistry could not be achieved. As the interspace distance of protons important for 
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characterisation such as H4 and H1 were shown to be too great for NOE correlations, the relative 
stereochemistry of these compounds were extrapolated from the crystal data of compound 4.12. 
Based on the theory behind Rh2(R-DOSP)4 catalysis and the fact that this catalyst was used in all 
cases shown in table 4.1, such a hypothesis can be expected to be of rather high accuracy. As can be 
seen in scheme 4.4 orientation of the furan substituents relative to the rhodium carbenoid should 
remain unaltered, due to the steric demand of the catalyst, for the list of structurally similar furans. 
A similar assumption, however, cannot be made for the regiochemistry of the reaction. This is of no 
importance as the connectivity of the product is easily assigned by 2D NMR measurements.  
 
 
Position δH Position δH 
1 2.78 (dd, J= 6.6, 13.2 Hz,1H)  12 4.24 – 4.11 (m, 2H) 
2 1.77 – 1.69 (m, 1H) 
1.14 – 1.13 (m, 1H) 
13 
1.28 (t, J = 7.1 Hz, 3H) 
3 1.77 – 1.69 (m, 1H) 
1.68 – 1.59 (m, 1H) 
14, 15 
0.04 (d, J = 1.5 Hz, 6H) 
4 5.03 – 5.0 (m, 1H) 17 0.91 (s, 9H) 
7 5.03 – 5.0 (m, 1H) 18 3.92 (s, 2H), 
8 6.64 (dd, J = 1.7, 5.9 Hz, 1H) 19, 20 0.09 (s, 6H), 
9 5.64 (d, J = 5.9 Hz, 1H) 22 0.78 (s, 9H), 
Table 4.2 
1
H-NMR data for compound 4.13 (500 MHz, CDCl3). 
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Moving on to di- and trisubstituted furans (table 4.3) dihydrobenzofuranone could be commercially 
obtained, whereas trisubstituted furans (entries 2-3) were synthesised from 1-ethynylcyclohexene
4 
and 4,5-dimethylfuraldehyde, respectively.  
Oxidation of aldehyde 4.19 (scheme 4.3) utilising silver (I) oxide to afford acid 4.20 followed by 
treatment with diazomethane afforded the desired ester 4.21 in excellent yield (97%). 
 
 
Scheme 4.3 Synthetic strategy to 2-methyl-4,5-dimethyl carboxylate. 
With di- and trisubstituted furans (entries 1-3, table 4.3) at hand treatment under identical 
conditions failed to give the corresponding seven-membered rings. However, recent investigations 
in the Williams laboratory have proceeded to afford 4.13, albeit in low yield. Optimisation studies 
and investigations of both systems are currently ongoing. 
  
                                                 
4
 Furan (entry 2, table 4.3) was kindly provided by Dr Sharon Chow 
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Entry Furan Product 
Number 
Product Reaction 
Time 
Yield 
1 
 
4.16 
 
1.5 - 24 - 
2 
 
4.17 
 
1.5 - 24 - 
3 
 
4.18 
 
1.5 - 24 - 
Table 4.3 Cycloaddition studies with di- and trisubstituted furans. 
From the experiments above no obvious trend could be observed. This is believed to be the 
consequence of a number of factors. It is well-known that cyclopropanation is sterically prevented if 
substrates are highly functionalised. Thus, in regard to trisubstituted furans it is believed that lack of 
reactivity preventing the cyclopropanation is of steric nature. When stoichiometric amounts of these 
furans were used, analysis revealed a complex mixture containing unaltered furan. It is believed this 
arises from decomposition of the carbene in absence of a reaction with the furan. A known 
competing reaction to that of cyclopropanation is C-H insertion. The lack of products arising from 
such an event further confirmed suspicions. A brief investigation of chiral catalysts such as Rh2(S-
DOSP)4 and Rh2(S-PTAD)4 revealed no improvement. 
The reported mechanism involves a least hindered approach of the furan to give a cyclopropanated 
intermediate 4.23 (scheme 4.4). Cope rearrangement of the cyclopropane through a boat transition 
state then affords the seven-membered ring. 
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Scheme 4.4 Proposed cycloaddition mechanism. 
Although the formation of seven-membered rings from monosubstituted furans were demonstrated 
with success difficulties were now faced with constructing a trisubstituted seven –membered ring as 
dictated by the requirements of the retrosynthetic analysis of phorbol. 
As an alternative approach reversion back to the [4+3] cycloaddition reaction between a diazo 
compound and a diene system as previously reported for the total synthesis of (-)-5-epi-vibsanin E 
1.170 (scheme 1.15). A small scale trial reaction involving the left hand fragment 3.36 was reacted 
with diene 4.25 using Rh2(S-PTAD)4 in hexanes at -27 °C. Monitoring the reaction with GC/MS 
revealed a mass of m/z 390 tentatively assigned to the desired product. Current investigations by the 
Williams group are aimed on improving upon these results.  
 
 
Scheme 4.5 Fallback strategy to the tigliane core.
 110 | P a g e  
 
4.6 Triazole Cycloadditions with Furans 
4.6.1 Introduction 
1,2,3-Triazoles have long been known for their versatility in organic synthesis. Huisgen was the 
first to investigate the scope of the 1,3-dipolar cycloaddition reaction between dipolarphiles such as 
alkynes or alkenes with 1,3-dipoles such as azides and nitrileoxides to give a five-membered 
heterocycle via a concerted mechanism.
119
 The cycloaddition between an alkyne and an organic 
azide results in the formation of a triazole. However, under the conditions employed by Huisgen et 
al. this reaction proceeded with poor regioselectivity affording a mixture of 1,4- and 1,5-substituted 
triazoles (scheme 4.6). 
 
Scheme 4.6 Huisgen 1,3-dipolar cycloaddition vs. Sharpless. 
This lack of regioselectivity was addressed by Sharpless et al.
120
 in 2001 only months after  Meldal 
et al.
121
 reported a novel regiospecific copper(I) catalysed 1,3-dipolar cycloaddition reaction of 
terminal alkynes to azides on solid phase and translated this method to primary, secondary and 
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tertiary alkyl azides, aryl azides, and azido sugar providing an array of 1,4-substituted [1,2,3]-
triazoles in peptide backbones. The described method worked in excellent yield and was fully 
compatible with solid phase peptide synthesis, all amino acids and all protecting groups.
122
  
Sharpless’ investigations revealed the use of copper (I) as a catalyst to be crucial in obtaining the 
1,4-product exclusively with excellent regiocontrol.
120
 Sharpless improved this protocol to be 
especially useful in what he would refer to as “click chemistry”,123 a methodology described by 
Sharpless and co-workers as “chemistry that generates substances by joining small units together 
with heteroatom links”. Furthermore, the term click chemistry refers to what an organic chemist 
would call “ideal reactions and reaction conditions” including readily available starting materials, 
non-sensitive substrates, high yields, excellent scope and generation of by-products that can be 
easily removed by filtering or flash chromatography. 
The intermediate formed in the cycloaddition step can also undergo a ring-chain isomerism leading 
to diazoimine 4.29. This isomerisation was noted at the time, but it was not until 2009 that Fokin et 
al. showed its usefulness in rhodium carbenoid chemistry.
124
 He showed successfully that in situ 
formed diazoimine decomposes in presence of metals to form azavinyl carbenes that can undergo a 
wide variety of C-H functionalization reaction. 
 
 
Scheme 4.7 Isomerisation to diazoimine and resulting carbenoid chemistry. 
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Rhodium stabilised carbenes have been widely studied and applied in C-H activation and C-H 
insertion processes in synthetic organic chemistry and have shown to possess diverse reactivity as 
discussed in previous chapters. Formation of these carbenes occurs via decomposition of diazo 
compounds in the presence of rhodium. However, the synthesis of diazo compounds is limited to 
the extent that a robust synthetic route to all alkenyldiazoactetate types has not been established. 
Furthermore, upon diazo transfer spontaneous cyclisation of the corresponding diazo species can 
occur to afford pyrazoles 4.31 (scheme 4.8). This phenomenon was also observed as previously 
discussed in the synthesis of the left hand fragment (scheme 3.10) 
 
 
 
Scheme 4.8 Pyrazole formation of alkenyldiazoacetates. 
This of course limits the rhodium carbene formation to a certain extent and for quite some time 
researchers were seeking alternatives to diazo compounds in order to expand the scope of rhodium 
carbenoid chemistry. 1,2,3-Sulfonyl triazoles were known in the literature to act as masked diazo 
compounds.
124c
 However, it was not until Fokin and co-workers reported a straightforward 
synthesis of these triazoles via the copper(II) catalysed azide/alkyne cycloaddition reaction utilising 
copper(I) thiophene-2-carboxylate and azide to afford the desired triazole (4.33) in good to 
excellent yield (scheme 4.9).
124b 
 
 
Scheme 4.9 Fokin's synthesis of 1,2,3-sulfonyl triazole 4.33. 
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Triazoles were thus found to serve as precursors to reactive and reasonably stable azavinyl carbenes 
(4.36). Fokin and co-workers have demonstrated the strength of these compounds in their utilisation 
of a wide variety of transformations (figure 4.6).
125
 It was found that in particular triazoles bearing a 
sulfonyl group at the N1 position undergo “ring chain isomerism” to the diazoimine 4.35 more 
easily.  
 
 
Scheme 4.10 Azavinyl carbene formation. 
This is believed to be due to the ring strain between N1 and N2 being perturbed by sulfonyl assisted 
weakening. Decomposition of the generated diazoimine in the presence of a rhodium catalyst results 
in the formation of a metal carbene which undergoes C-H-activation and C-H-insertion reactions. 
Figure 4.6 is a good representation of the inherent diversity of C-H functionalization chemistry. 
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Figure 4.6 Previous synthetic work on 1,2,3-sulfonyl triazoles and proposed reaction with 
furans. 
In regard to seven-membered ring formation it was contemplated whether the scope of this project 
could be extended by utilising the proposed 1,2,3-sulfonyl triazoles. This would not only lead to a 
fall-back strategy, but would further add to the advances in this field. To the best of our knowledge, 
the reaction of 1,2,3-triazoles with furans to obtain the epoxybenzoannulene core has not been 
reported to date.  
Synthesis of the triazoles starts with commercially available ketones. Enolisation/triflation utilising 
LDA and McMurry’s reagent afforded 4.38 in good yields. Subsequent cobalt-catalysed Kumada 
coupling of 4.38 with ethynylmagnesium bromide provided acetylenes 4.32. Finally, triazole 4.33 
can be synthesised by reaction of 4.32 with mesylazide catalysed by copper thiophene-2-
carboxylate (CuTC).
126
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Scheme 4.11 Synthetic route to 1,2,3-sulfonyl triazoles. 
Figure 4.7 shows the triazoles synthesised via the aforementioned method (scheme 5.6). 
 
 
Figure 4.7 Synthesised triazoles. 
Our exploratory study started with cyclohexene-triazole 4.33 using the non-chiral catalyst 
Rh2(OPiv)4 and selected furans (entry 1-3, table 4.4). When utilising monosubstituted furans for the 
cycloaddition reaction (entries 1-2) good yields were obtained. The position and nature of the 
substituents did not vary the yield significantly.  
 
Entry Furan Product 
Number 
Product Yield 
1 
 
4.41 
 
65 
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2 
 
4.42 
 
76 
     
3 
 
4.43 
 
72 
Table 4.4 Model studies with cyclohexene triazole. 
Figure 4.8 shows a crystal structure of compound 4.41 as an ORTEP representation with 30% 
ellipsoid probability. From the crystal structure the relative stereochemistry has been assigned as 
depicted in table 4.4 (entry 1). The relative stereochemistry of entry 2 was assigned by analogy. 
 
Figure 4.8 ORTEP (30% ellipsoid probability) of compound 4.41.  
An unusual tetracyclic product, however, was observed in the rhodium catalysed reaction of 
dihydrobenzofuranone and triazole 4.33 (entry 3). Interestingly, this reaction leads to a clean [3+2] 
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cycloaddition reaction with both achiral Rh2(OPiv)4 and chiral Rh2(S-nttl)4 as the rhodium source to 
afford 4.43 in 72% yield.  
According to literature it is believed that these kinds of products arise from effective charge 
stabilisation of both the electron-rich dihydrobenzofuranone and the rhodium carbene formed, thus 
leading to zwitterionic intermediate 4.46 (scheme 4.12).
127
 
 
 
Scheme 4.12 Plausible mechanistic explanation for the [3+2] cycloaddition reaction of 
compound 4.43. 
This zwitterionic intermediate 4.46 would be expected to be stabilised by the presence of two 
electron withdrawing oxygens. The loss of rhodium initiates the ring closure from the cyclohexene 
moiety to the furan portion ultimately leading to the observed tetracyclic compound 4.43. 
As can be seen in figure 4.9 slow hydrolysis of the imine was observed in both the neat sample as 
well as in CDCl3 solution upon storage. Upon hydrolysis a shift from a characteristic imine signal at 
8.98 ppm to 9.98 ppm can be seen. 
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Figure 4.9 
1
H NMR Spectra of the conversion of imine 5.15 to aldehyde 5.19. 
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5 Conclusion and Future Work 
The objective of this thesis was to explore a [4+3] cycloaddition approach to the non-natural (-)-
phorbol via the fusion of two fragments, namely, a right hand (1.198) and a left hand fragment 
(1.197). The justification for attempting the synthesis of non-natural (-)-phorbol 1.169 was driven 
by biological importance to further understanding the PKC mechanism involved in cancer. The 
fusion of 1.197 and 1.198 was envisaged to proceed via a formal [4+3] cycloaddition utilising 
rhodium catalysis to afford the seven-membered core of the tigliane skeleton. The results stemming 
from the synthetic studies herein are summarised in the following text in three separate segments. 
Firstly, a conclusion and future work section for the right hand fragment is given. Secondly, the left 
hand fragment and a model study of its application in the proposed formal [4+3] cycloaddition 
reaction are outlined in a similar manner. Thirdly, a novel approach to seven-membered rings 
utilising 1,2,3-sulfonyl triazoles with furans is presented. 
5.1 Right Hand Fragment 
In conclusion, advanced intermediate 2.55 was successfully synthesised from commercially 
available o-vanillin in 22% yield over six steps. Successive Wolff-Kishner reduction of o-vanillin 
followed by oxidation of phenol 2.6 afforded quinone 2.7 in moderate yield. A major hurdle in this 
synthetic sequence was the construction of ring D via cyclopropanation of 2.7. This reaction was 
plagued by elimination of the methoxy moiety upon treatment with triisopropylsulfoxonium 
tetrafluoroborate, however, this was overcome by introduction of a more robust alcohol protecting 
group, i.e. isopropoxy.  
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Scheme 5.1 Synthetic route to advanced intermediate 2.55. 
In order to prepare this advanced intermediate 2.55 for furan formation reduction of the α,β-
unsaturation was necessary. Direct double bond reduction of 2.55 has proven very challenging 
affording a ring expansion by the opening of the cyclopropane moiety under a variety of conditions. 
To overcome this ring expansion a three step sequence of reduction/protection/oxidation was 
successfully employed affording advanced intermediate 2.76. 
 
 
Scheme 5.2 Reduction studies on compound 2.55. 
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With 2.76 at hand the completion of the right hand fragment can be achieved by triflation of the 
corresponding C-8 ketone (scheme 5.3) using LDA and triflic anhydride followed by palladium 
catalysed Sonogashira coupling with a protected propargyl alcohol. Subsequent epoxidation at Δ8,9-
double bond utilising meta-chloroperbenzoic acid followed by metal mediated ring closure (Pt, Au, 
Pd) would provide the desired right hand fragment. 
  
 
Scheme 5.3 Proposed synthetic route for completion of the RHF. 
5.2 Left Hand Fragment 
In conclusion, a left hand fragment 3.36 was successfully synthesised via direct diazo coupling 
approach between 2-iodocyclopentenone 3.32 and ethyldiazo acetate. A major hurdle in the 
synthesis was pyrazole formation of alkenyldiazoacetates. In addition, the methyl group that is 
required for the synthesis of (-)-phorbol 1.169 was dismissed at this stage. α-Halogenation followed 
by Luche reduction and TBS protection of the resultant alcohol provided 3.35 in 72% over three 
steps. Diazo coupling between 3.35 and ethyldiazo acetate was accomplished utilising Pd(PPh3)4 
and DBU in 60% yield. 
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Scheme 5.4 Synthetic route to LHF. 
With the successfully synthesised diazo compound 3.36, initial cycloaddition reactions with mono 
substituted furans have proven promising. Five examples employing furans with different 
substitution patterns, i.e. electron withdrawing and electron-donating, have been demonstrated to 
successfully provide the AB-ring system of our target molecule. 
 
 
Scheme 5.5 Formal [4+3] cycloaddition reaction between LHF and furans. 
Once a viable synthesis of the right hand fragment is in place future studies will be focused at the 
rhodium catalysed [4+3] formal cycloaddition with newly developed protocols from our 
collaborators laboratory with left hand fragment as outlined in our retrosynthetic analysis (scheme 
1.22).  
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In the event that a reaction between the left and right hand fragments does not occur, a fall-back 
strategy could be deployed as follows. It is envisaged that in place of a trisubstituted furan as the 
right hand fragment, the synthesis of diene 5.6 and consequent reaction with diazo compound 3.36 
would proceed in parallel with that successfully demonstrated for (-)-5-epi-vibsanin E 1.170 by 
Williams et al. As mentioned in chapter 4.5 (page 113) initial investigations with a model diene 
have been undertaken and have shown promising results, However, optimisation of the reaction 
conditions has yet to be performed, due to lack of time. Introduction of the tertiary hydroxyl group 
could then be potentially performed selenium dioxide. 
 
Scheme 5.6 Cycloaddition approach to compound 5.7. 
5.3 Triazoles 
In conclusion, a novel synthesis has been achieved for the formal [4+3] cycloaddition reaction 
between 1,2,3-sulfonyl triazole 4.33 and various furans. Building on this novel approach additional 
triazoles have been synthesised and are being investigated in order to probe the scope of the 
reaction with regard to the triazole coupling partner. Furthermore, in the unusual case where a [3+2] 
cycloaddition reaction was observed to afford 5.19 (see chapter 4.6, scheme 4.12) further studies 
with the aim to force this reaction over the usually observed [4+3] cycloaddition could hold a novel 
approach to this type of polycyclic compound. 
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Scheme 5.7 Formal [4+3] cycloaddition reaction of triazoles and furans. 
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6 Experimental  
6.1 General 
6.1.1 Reactions 
All reactions were performed in oven dried glassware under a positive pressure of argon unless 
otherwise stated. All reagents and solvents were dried, distilled or purified before use according to 
Perrin and Amarego’s “Purification of Laboratory chemicals” 3rd edition.128  
Tetrahydrofuran and toluene were freshly distilled from Na°/benzophenone. N,N-
Dimethylformamide, methylene chloride, acetonitrile and cyclohexane were freshly distilled from 
calcium hydride under argon.  Anhydrous N,N-diisopropylamine and 1,8-diazabicycloundec-7-ene 
(DBU) were distilled from calcium hydride under argon and stored over pre-dried sodium 
hydroxide pellets. n-Butyllithium was used as a solution in either hexanes or heptanes. Argon was 
dried by passing through a drying tube containing 4Å molecular sieves, silica gel beads and 
Drierites.  
6.1.2 Purification 
Thin layer chromatography was performed using E. Merck silica gel 60 F254 pre-coated plates. 
Column chromatography was undertaken on silica gel (Flash silica gel 230-400 mesh). Other 
chromatographic methods involved using Celite 545®. Petroleum spirit refers to the hydrocarbon 
fraction with boiling points between 40 – 60 °C. 
6.1.3 Characterisation 
1
H and 
13
C NMR spectra were recorded on Bruker AV300 (300.13MHz; 75.47MHz), AV400 
(400.13MHz; 100.62MHz) and DRX500 (500.13MHz; 125.76MHz) instruments. Coupling 
constants are given in hertz (Hz) and chemical shifts are reported as δ values in parts-per-million 
(ppm) with the solvent resonance as the internal standard (
1
H-NMR: CDCl3: δ7.26; acetone-d6: 
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δ2.04; 13C-NMR: CDCl3: δ77.0; acetone-d6: δ29.84 and δ 206.26). Data are reported as followed: 
chemical shift, multiplicity (s = singlet, br s = broad singlet, d = doublet, t = triplet, q = quartet, quin 
= quintuplet, sext = sextuplet, sept = septet, m = multiplet), coupling constants (Hz), and 
integration.  
Low resolution electrospray ionisation mass spectrometry measurements (LRESIMS) were 
recorded in a positive ionisation mode on a Bruker Esquire HCT instrument with a Bruker ESI 
source.  
High resolution electro spray ionization (HRESIMS) accurate mass measurements were recorded in 
positive ionisation mode on a Bruker MicrOTOF-Q (quadrupole – Time of Flight) instrument with 
a Bruker ESI source using sodium formate as a reference calibrant.  
GC/MS data were recorded on a Shimadzu GC-17A VR.3, mass-spectrometer: MS QP5050A, 
ionisation at 70 eV, column: DB-5ms 30 m 0.25 mm, carrier-gas: He, total flow 32.2 mL/min, 
column flow 1.3 mL/min, injector temperature: 250 °C, standard program: 2 min at 100 °C, 
followed by a temperature increase of 16 °C/min and held at 250 °C for 20 min. 
Melting points were determined on a DigiMelt Stanford Research Systems melting point apparatus 
and are uncorrected.  
Analytical enantioselective HPLC was performed on an Agilent 1200 series liquid chromatograph 
(flow rate of 0.5 mL min-1, gradient elution using isopropanol/hexane with the following program: 
0 min, IPA/hex 5/95; 4 min, IPA/hex 5/95; 34 min, IPA/hex 40/60; 44 min, IPA/hex 40/60; 46 min, 
IPA/hex 5/95; 50 min, IPA/hex 5/95) equipped with UV (254 nm) and ALP (Advanced Laser 
Polarimeter, PDR-Chiral Inc.) detectors and a Chiralpak AD column (4.6 x 250 mm, Daicel 
Chemical Industries Ltd.). 
X-Ray crystallographic data was obtained from the University of Queensland; crystallographic 
structures were solved by the author using WinGX unless otherwise stated.  
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6.2 Experimental Procedures Right Hand Fragment 
 
2-Methoxy-6-methylphenol 
Hydrazine hydrate (22.4 mL, 460.08 mmol) was added to a solution of o-vanillin (20 g, 131.5 
mmol) in triethyleneglycol (100 mL) and the resulting mixture was heated to 110 ºC for 10 minutes. 
Potassium hydroxide pellets (45.7 g, 745.8 mmol) were then added in small portions and the 
reaction mixture heated to 130 ºC overnight. The reaction was quenched with H2O (20 mL), 
acidified with conc. HCl to pH 7 and extracted with CHCl3 (3 x 80 mL). The combined organic 
layers were washed with brine, dried over Na2SO4 and the solvent removed under reduced pressure. 
Vacuum distillation of the crude oil gave rise to the desired product as white crystals (15 g, 83 %). 
Spectroscopic data matched that as described in literature.
70
 
1
H NMR (300 MHz, CDCl3) δ 6.76 – 6.69 (m, 3H), 5.68 (br s, 1H), 3.88 (s, 3H), 2.26 (s, 3H) 
 
2-Methoxy-6-methylcyclohexa-2,5-diene-1,4-dione 
Oxygen was bubbled through a solution of 2-methoxy-6-methylphenol (15 g, 108.9 mmol) and 
N,N′-bis(salicylidene)ethylenediaminocobalt(II) (3.56 g, 10.9 mmol) in dry DMF (70 mL) over 
night. The resulting mixture was poured onto ice and the crude product was filtered off. The filtrate 
was continuously extracted with Et2O (5 x 70 mL). The organic layers were dried over MgSO4 and 
concentrated in vacuo yielding a brown solid. The combined products were purified via flash 
column chromatography (ethyl acetate / petroleum ether = 1:1) and further recrystallised from 
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ethanol to afford the titled compound as a bright yellow solid (9.3 g, 56 %). Spectroscopic data 
matched that as described in literature.
70
 
m.p. 148 °C – 149 °C 
1
H NMR (300 MHz, CDCl3) δ 6.55 – 6.53 (m, 1H), 5.88 (d, J = 2.5 Hz, 1H), 3.82 (s, 3H), 2.07 (d, J 
= 1.5 Hz, 3H) 
13
C NMR (400 MHz, CDCl3) δ 187.4, 182.4, 158.8, 143.6, 133.8, 107.3, 56.3, 15.5 
HRMS (EI) Calculated for C8H8NaO3: 175.0366; Found: 175.0359 
 
(1S,4R,4aS,8aR)-6-Methoxy-4a-methyl-1,4,4a,8a-tetrahydro-1,4-
methanonaphthalene-5,8-dione 
(S)-(−)-o-Tolyl-CBS-oxazaborolidine (0.5 mL, 0.031 mmol) was diluted with anhydrous CH2Cl2 
(0.125 mL, 0.02M solution) and cooled to -40°C under an argon atmosphere. A freshly prepared 
1M solution of AlBr3 in anhydrous CH2Br2 was then added dropwise, whereby a strong orange 
colour was observed immediately. After stirring the solution at -40°C for 30 minutes, the mixture 
was cooled to -78°C and quinone 2.7 dissolved in anhydrous CH2Cl2 (1.972 mmol, 0.2M) was 
added followed by the addition of freshly distilled cyclopentadiene (7.89 mmol). The reaction 
mixture was then stirred at that temperature for 5 hours, after which complete conversion to product 
was observed via TLC. The reaction was quenched with methanol (2 mL) and the solvent 
concentrated under reduced pressure yielding a brown oil that was purified via column 
chromatography (ethyl acetate/petroleum spirit = 1:3) to afford the titled compound 2.24 as a 
yellow solid (85%, 87% ee, rt = 19.8min). Spectroscopic data matched that as described in 
literature.
71
 
m.p. 81°C – 82°C 
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1
H NMR (300 MHz, CDCl3) δ 6.12 (dd, J = 2.8, 5.6 Hz, 1H), 6.02 (dd, J = 2.8, 5.6 Hz, 1H), 5.89 
(s, 1H), 3.71 (s, 3H), 3.42 (br s, 1H), 3.12 (br s, 1H), 2.84 (d, J = 3.8 Hz, 1H), 1.68 (d, J = 9.0 Hz, 
1H), 1.55 (d, J = 9.0 Hz, 1H), 1.48 (s, 3H)  
13
C NMR (400 MHz, CDCl3) δ 198.5, 197.6, 162.5, 137.5, 135.2, 113.9, 57.7, 56.4, 53.8, 52.7, 
48.7, 46.5, 26.5 
X-Ray Data: (see Appendix 8.2) 
 
(1aS,1aS,3R,6S, 6aR, 7aR)-1a-Methoxy-1,1,2a-trimethyl-1a,2a,3,6,6a,7a-hexahydro-
1H-3,6-methanocylopropa[b]naphthalene-2,7-dione 
Triisopropylsulfoxonium tetrafluoroborate 2.30 (199 mg, 0.80 mmol) was added in one portion to a 
stirring suspension of NaH (31 mg, 1.28 mmol) in dry DMF (4 mL) at 0 °C under an argon 
atmosphere. The reaction mixture was stirred for 5 minutes before dropwise addition of Diels-Alder 
adduct 2.24 (70 mg, 0.32 mmol) as a solution in dry DMF (0.5 mL). The cooling bath was removed 
and the reaction mixture warmed to room temperature. On completion – monitored by TLC – the 
reaction mixture was quenched with saturated NH4Cl (5 mL) and extracted with EtOAc (3 x 15 
mL). The combined organic layers were dried over MgSO4 and the solvent removed under reduced 
pressure yielding a brown oil, which was purified via column chromatography (ethyl 
acetate/petroleum spirit = 5:1) to afford the titled compound as a yellow oil (12 mg, 14%). 
1
H NMR (300 MHz, CDCl3) δ 6.25 (dd, J = 2.9, 5.6 Hz, 1H), 6.18 (dd, J = 2.9, 5.6 Hz, 1H), 3.45 
(br s, 1H), 3.24 (s, 3H), 3.18 (br s, 1H), 2.56 (d, J = 4.2 Hz, 1H), 1.96 (s, 1H), 1.63 (dt, J = 1.8, 9.3 
Hz, 1H),  1.46 (s, 3H), 1.42 (dt, J = 1.8, 9.3 Hz, 1H), 1.30 (d, J = 10.0 Hz, 6H) 
13
C NMR (500 MHz, d6-benzene) δ 208.2, 204.1, 137.4, 136.9, 77.0, 58.9, 58.5, 57.0, 53.3, 51.1, 
47.1, 46.9, 34.1, 26.4, 23.1, 19.4 
HRMS (EI) Calculated for C16H20NaO3: 283.1305; Found: 283.1297 
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X-Ray Data: (see Appendix 8.2) 
 
(1S,6R)-1-Methoxy-3,7,7-trimethylbicyclo[4.1.0]hept-3-ene-2,5-dione 
The retro Diels-Alder reaction was performed by heating compound 2.25 (10 mg, 0.04 mmol) at 
143°C at 530 Torr using a Kugelrohr apparatus. Compound 2.25 was placed in the terminal 5 mL 
round bottom flask of a triple bulb (5 mL each) Kugelrohr short path distillation apparatus. The 
glassware assembly was connected to a vacuum pump (530 Torr) and placed into a Kugelrohr oven 
preheated to 140°C with one bulb remaining outside for cooling with dry ice. The yellow residual 
oil in the terminal bulb was then washed with Et2O and the solvent removed under reduced pressure 
to afford the titled compound as a yellow oil (6.2 mg, 84%) 
1
H NMR (300 MHz, CDCl3) δ 6.51 – 6.48 (m, 1H), 3.37 (s, 3H), 2.33 (d, J = 1.81 Hz, 1H), 2.04 (d, 
J = 1.53 Hz, 3H), 1.40 (s, 3H), 1.32 (s, 3H) 
13
C NMR (400 MHz, CDCl3) δ 195.1, 194.0, 149.7, 137.2, 75.6, 57.1, 44.8, 39.3, 23.2, 16.7, 16.2 
HRMS (EI) Calculated for C11H14NaO3: 217.0835; Found: 217.0839 
 
2-Isopropoxy-6-methylcyclohexa-2,5-diene-1,4-dione 
According to a modified procedure of Wurm et.al.
90
 methoxyquinone 2.7 (1.5 g, 9.9 mmol) and 
sodium acetate (3 g) were dissolved in dry isopropanol (90 mL) and refluxed for 5 hours. Prolonged 
hours should be avoided due to disubstitution of the isopropyl group. The reaction mixture was 
 131 | P a g e  
 
concentrated to dryness and purified via column chromatography (ethyl acetate / petroleum ether = 
1 : 5) to afford the titled compound as a yellow solid (0.8 g, 44%). 
1
H NMR (300 MHz, CDCl3) δ 6.52 – 6.50 (m, 1H), 5.83 (d, J = 2.4 Hz, 1H), 4.45 (sept, J = 6.0 Hz, 
1H), 2.05 (d, J = 1.7 Hz, 3H), 1.39 (d, J = 6.0 Hz, 6H) 
13
C NMR (400 MHz, CDCl3) δ 187.8, 182.8, 157.0, 143.7, 133.5, 107.8, 72.3, 21.1, 15.6 
HRMS (EI) Calculated for C10H12NaO3: 203.0827; Found: 203.0824 
 
(1S,4R,4aS)-6-Isopropoxy-4a-methyl-1,4,4a,8a-tetrahydro-1,4-
methanonaphthalene-5,8-dione 
Quinone 2.49 (220 mg, 1.22 mmol), was dissolved in dichloromethane (10 mL) and freshly cracked 
cyclopentadiene (1.5 mL, 18.33 mmol) was added in one single portion at room temperature. The 
resulting mixture was stirred at ambient temperature overnight. The crude residue was purified via 
column chromatography (ethyl acetate / petroleum ether = 5:1) to afford the titled compound as a 
yellow oil (278 mg, 93%). 
1
H NMR (300 MHz, CDCl3) δ 6.12 (dd, J = 2.9, 6.1 Hz, 1H), 6.03 (dd, J = 2.9, 6.1 Hz, 1H), 5.86 (s 
br, 1H), 4.35 (sept, J = 6.0 Hz, 1H), 3.42 (s br, 1H), 3.10 (s br, 1H), 2.82 (d, J = 3.8 Hz, 1H), 1.67 
(dt, J = 1.7, 9.2 Hz, 1H), 1.59 (s, 3H), 1.54 (dt, J = 1.7, 9.2 Hz, 1H), 1.47 (s, 3H), 1.34 (dd, J = 4.4, 
6.1 Hz, 6H) 
13
C NMR (400 MHz, CDCl3) δ 198.8, 197.8, 160.8, 137.5, 135.1, 114.6, 72.3, 57.5, 53.9, 48.7, 
46.4, 26.5, 21.0 
X-Ray Data: (see Appendix 8.2) 
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(1aS,2aS,3R,6S,6aR,7aR)-1a-Isopropoxy-1,1,2a-trimethyl-1a,2a,3,6,6a,7a-
hexahydro-1H-3,6-methanocyclopropa[b]naphthalene-2,7-dione 
Triisopropylsulfoxonium tetrafluoroborate 2.30 (404 mg, 1.53 mmol) was added in one portion to a 
stirring suspension of NaH (98 mg, 2.44 mmol) in dry DMF (15 mL) at 0 °C. The reaction mixture 
was stirred for 5 minutes before drop wise addition of Diels-Alder adduct 2.53 (150 mg, 0.61 
mmol) as a solution in dry DMF (1 mL). The cooling bath was removed and the reaction mixture 
warmed to room temperature. On completion – monitored by TLC – the reaction mixture was 
quenched with saturated NH4Cl (5 mL) and extracted with EtOAc (3 x 30 mL). The combined 
organic layers were dried over MgSO4 and the solvent removed under reduced pressure yielding a 
brown oil, which was purified via column chromatography (ethyl acetate/petroleum spirit = 5:1) to 
afford the titled compound as a yellow oil (124 mg, 70%). 
1
H NMR (500 MHz, CDCl3) δ 6.23 (m, 2H), 3.68 (sept, J = 6.0 Hz, 1H), 3.50 (m, 1H), 3.21 (m, 
1H), 2.59 (d, J = 4.2 Hz, 1H), 2.14 (s, 1H), 1.68 – 1.65 (m, 1H), 1.49 (s, 3H), 1.44 (dt, J = 1.7, 9.3 
Hz, 1H), 1.31 (s, 3H), 1.30 (s, 3H), 1.26 (d, J = 6.0 Hz, 3H), 1.02 (d, J = 6.0 Hz, 3H) 
13
C NMR (500 MHz, CDCl3) δ 210.3, 206.4, 137.4, 137.0, 76.2, 72.6, 59.0, 58.4, 53.1, 51.0, 48.2, 
47.4, 33.9, 26.9, 23.7, 23.5, 22.9, 19.5 
HRMS (EI) Calculated for C18H24NaO3: 311.1618; Found: 311.1630 
X-Ray Data: (see Appendix 8.2) 
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(1S,6R)-1-Isopropoxy-3,7,7-trimethylbicyclo[4.1.0]hept-3-ene-2,5-dione 
The retro Diels-Alder reaction was performed by heating compound 2.54 (127 mg, 0.49 mmol) at 
161°C at 500 Torr using a Kugelrohr apparatus. Compound 2.54 was placed in the terminal 10 mL 
round bottom flask of a triple bulb (10 mL each) Kugelrohr short path distillation apparatus. The 
glassware assembly was connected to a vacuum pump (500 Torr) and placed into a Kugelrohr oven 
preheated to 140°C with one bulb remaining outside for cooling with dry ice. The yellow residual 
oil in the terminal bulb was then washed with Et2O and the solvent removed under reduced pressure 
to afford the titled compound as a yellow oil (83%) 
1
H NMR (500 MHz, CDCl3) δ 6.51 – 6.50 (m, 1H), 3.75 (sept, J = 6.2 Hz, 1H), 2.43 (d, J = 1.8 Hz, 
1H), 2.04 (d, J = 1.8 Hz, 3H), 1.38 (s, 3H), 1.28 (s, 3H), 1.18 (d, J = 6.2 Hz, 3H), 1.16 (d, J = 6.2 
Hz, 3H) 
13
C NMR (400 MHz, CDCl3) δ 195.7, 194.2, 149.5, 137.0, 73.6, 72.9, 45.4, 38.3, 23.4, 23.2, 22.7, 
16.4, 16.3 
HRMS (EI) Calculated for C13H18NaO3: 245.1148; Found: 245.1146 
 
(7R)-7-Isopropoxy-2,6,6-trimethylcycloheptane-1,4-dione 
Hydrogenation was performed on the H-Cube® Hydrogenator using a 10% Pd/C cartridge. A 
0.02M solution of 2.55 in ethyl acetate was pumped through the system with a flow rate of 1 
mL/min at room temperature. After one cycle the colourless solution was concentrated to dryness 
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and purified via column chromatography (ethyl acetate/petroleum ether = 1:2) to afford the titled 
compound as a colourless oil. 
1
H NMR (500 MHz, CDCl3) δ 3.68 (s, 1H), 3.57 (sept, J = 6.2 Hz, 1H), 3.06 (t, J = 13.0 Hz, 1H), 
2.83 (d, J = 11.9 Hz, 1H), 2.64 – 2.56 (m, 1H), 2.37 – 2.32 (m, 2H), 1.26 (t, J = 7.2 Hz, 2H), 1.25 
(d, J = 7.0 Hz, 2H), 1.19 (dd, J = 6.3, 6.3 Hz, 6H), 1.02 (s, 3H), 0.91 (s, 3H) 
13
C NMR (500 MHz, CDCl3) δ 212.3, 210.1, 92.0, 72.7, 53.8, 45.6, 41.6, 36.3, 26.3, 25.6, 22.9, 
21.4, 18.9, 14.2 
 
 
Diisopropylsulfide 
Acetone (1 mL, 13.6 mmol) and 2-propanethiol (1.53 mL, 16.32 mmol) were dissolved in 
dichloromethane (10 mL). A freshly prepared solution of BF3*H2O (1eq. of water was added slowly 
to a cooled solution of BF3*Et2O, 1.2 mL) was added and the reaction mixture was stirred for one 
hour followed by the addition of triethylsilane (2 mL, 13.6 mmol). The resulting cloudy solution 
was stirred and warmed to room temperature overnight.  The solution was then poured onto ice – 
water and extracted with DCM (3 x 15 mL). The organic layer was washed with water (20 mL), 
saturated NaHCO3 (20 mL) and brine (20 mL), dried over MgSO4 and the solvent was removed 
under reduced pressure to afford a colourless oil, which was purified via distillation giving rise to 
the titled compound in 25% yield. The spectral data for 2.28 match those reported. 
84a 
1
H NMR (400 MHz, CDCl3) δ 2.98 (sept, J = 6.7 Hz, 2H), 1.25 (d, J = 6.7 Hz, 12H) 
13
C NMR (400 MHz, CDCl3) δ 33.4, 23.6 
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Triisopropylsulfonium tetrafluoroborate 
Isopropanol (30 mL, 393.01 mmol) was added to a stirring solution of diisopropylsulfide (5.8 g, 
49.14 mmol) and freshly distilled methanesulfonic acid (31.9 mL, 491.4 mmol). The mixture was 
stirred at 115°C for 3 days resulting in a brown solution which was cooled to room temperature and 
treated with an excess of HBF4 (50 mL, 491.4 mmol). The mixture was stirred for further 30 
minutes and then washed with H2O (100 mL) and extracted with CH2Cl2 (3 x 100 mL). The organic 
layer was dried over MgSO4 and the solvent was removed under reduced pressure to afford the 
titled compound as cream coloured plates (53%).
 
Spectroscopic data matched that as described in 
literature.
84b,129
 
1
H NMR (400MHz, d6-acetone) δ 4.16 (sept, J = 6.8 Hz, 3H), 1.67 (d, J = 6.8 Hz, 18H) 
13
C NMR (400MHz, d6-acetone) δ 43.4, 19.8 
 
Triisopropylsulfoxonium tetrafluoroborate 
Method A: Ruthenium chloride (1.04 g, 5 mmol) was added to a vigorously stirred solution of 2.29 
(3.1 g, 12.5 mmol) in a mixture of MeCN: CCl4: H2O = 1: 1: 1.5 (42 mL) and the solution was 
stirred for 10 minutes. NaIO4 (18.7 g, 87.5 mmol) was then added in portions and the resulting 
mixture stirred at room temperature overnight giving rise to a bright yellow suspension which was 
filtered through a Celite® pad and washed with water (200 mL). To quench the residual RuO4, 
methanol (15 mL) was added to the filtrate, whereas a colour change was immediately observed 
from yellow to dark brown. The water/methanol mixture was then concentrated in vacuo and the 
resulting grey residue suspended in acetone (50 mL), stirred for 20 minutes and filtered. 
Concentration of the filtrate under reduced pressure gave rise to a yellow oil. The oil was diluted in 
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hot methanol (15 mL) and diethyl ether was added dropwise until the solution remained turbid. The 
mixture was cooled with an ice bath to afford the titled compound as white plates (52%). 
Spectroscopic data matched that as described in literature.
84b,129
 
Method B: To a solution of triisopropylsulfonium tetrafluoroborate (7.77g, 31.1 mmol) in water 
(400 mL) at 0 °C was added 2-nitrobenzenesulfonyl chloride (13.9 g, 62.7 mmol) followed by 
barium hydroxide octahydrate (29.7 g, 94 mmol). The resulting cream suspension was stirred at that 
temperature for 10 minutes after which H2O2 (30% solution in H2O; 20 mL, 188 mmol) was added 
over a period of 1 hour. On completion, the resulting mixture was stirred for further 45 minutes at 0 
°C after which the cooling bath was removed and the suspension stirred at ambient temperature 
overnight. The resulting mixture was then filtered through a pad of Celite® and thoroughly washed 
with water (250 mL). After concentrating the aqueous solution in vacuo, the residue was 
redissolved in dichloromethane, dried over MgSO4 and filtered again through a pad of Celite® and 
thoroughly washed with dichloromethane. The filtrate was concentrated to give a beige precipitate. 
Recrystallization from methanol/diethyl ether gave rise to the desired compound as a white solid 
(5.54 g, 67%). Spectroscopic data matched that as described in literature.
84b,129
 
1
H NMR (500MHz, d6-acetone) δ 4.69 (sept, J = 6.8 Hz, 3H), 1.75 (d, J = 6.8 Hz, 18H) 
13
C NMR (500MHz, d6-acetone) δ 53.2, 15.8 
HRMS (EI) Calculated for C9H21OS
+
: 177.1308; Found: 177.1302  
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1-Ethyl-2-methyl (S)-pyrrolidine-1,2-dicarboxylate 
L-Proline (3 g, 26.1 mmol) was dissolved in anhydrous methanol (20 mL) under a positive pressure 
of argon. Anhydrous K2CO3 (3.6 g, 26.1 mmol) was added while maintaining the argon flow and 
the resulting solution was stirred for 10 minutes. Subsequent addition of ethyl chloroformate (6.2 g, 
57.3 mmol) gave rise to a white solution, which was then cooled to 0°C and stirred at that 
temperature for 8 hours. The solvent was removed under reduced pressure, the residue was 
suspended in water and extracted with CHCl3 (3 x 60 mL). The organic layer was washed with 
brine, dried over MgSO4, filtered and concentrated to dryness yielding the desired compound as a 
yellow oil in 62% yield. The crude product was used in the next step without further purification. 
The spectral data for 2.15 match those reported in literature.
130
  
1
H NMR (300 MHz, CDCl3) δ 4.45 – 4.25 (m, 1H), 4.23 – 4.0 (m, 2H), 3.72 (d, J = 5.1 Hz, 2H), 
3.65 – 3.37 (m, 2H), 2.36 – 2.09 (m, 2H), 2.06 – 1.81 (m, 3H), 1.31 – 1.15 (m, 3H) 
 
Ethyl (S)-2-(hydroxydiphenylmethyl)pyrrolidine-1-carboxylate 
Compound 2.15 (2.48 g, 12.33 mmol) was diluted in anhydrous THF (20 mL) under an argon 
atmosphere and cooled to 0°C using an ice/NaCl bath. The freshly prepared Grignard reagent (4.92 
g, 63.7 mmol) was added to the solution via cannula and the mixture was stirred at 0°C for 3 hours. 
On completion the reaction was quenched with saturated NH4Cl (12 mL), neutralised with 2N HCl 
and extracted with CHCl3 (3 x 40 mL). The organic layer was washed with brine, dried over MgSO4 
and the solvent was removed under reduced pressure to afford the titled compound as an orange oil, 
which solidified upon standing.
 
The spectral data for 2.17 match those reported in literature.
130
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 1
H NMR (300 MHz, CDCl3) δ 7.48 – 7.27 (m, 10H), 4.93 (dd, J = 3.8, 8.8 Hz, 1H), 4.22 – 4.01 (m, 
2H), 3.97 – 3.70 (m, 1H), 3.48 – 3.35 (m, 1H), 3.03 – 2.86 (m, 1H), 2.15 – 2.0 (m, 1H), 1.99 – 1.89 
(m, 1H), 1.89 – 1.82 (m, 1H), 1.55 – 1.41 (m, 1H), 1.23 (t, J  = 7.1 Hz, 3H) 
 
(S)-Diphenyl(pyrrolidine-2-yl)methanol 
Potassium hydroxide (1.3 g, 22.14 mmol) was added to a methanolic solution of 2.17 (2 g, 6.15 
mmol) and the reaction mixture was heated to reflux overnight. After cooling the solution to room 
temperature, methanol was removed under reduced pressure, the residue suspended in water (20 
mL) and the mixture extracted with CHCl3 (3 x 30 mL). The organic extracts were washed with 
brine, dried over MgSO4 and evaporation of the solvent afforded compound 2.18 as a brown oil in 
90% yield, which solidified upon standing. The spectral data for 2.18 match those reported in 
literature.
130
 
1
H NMR (300 MHz, CDCl3) δ 7.54 – 7.28 (m, 10H), 4.55 (dd, J = 5.5, 10.5 Hz, 1H), 3.80 – 3.66 
(m, 1H), 3.30 – 3.20 (m, 1H), 2.07 – 1.80 (m, 2H), 1.79 – 1.62 (m, 2H), 1.32 – 1.01 (m, 2H) 
 
Tri-o-tolylboroxine 
O-tolylboronic acid (5 g, 36.77 mmol) was charged in a flask equipped with a Dean Stark trap and 
dehydrated by azeotropic distillation with toluene (3 x 60 mL). After cooling the residue to room 
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temperature a white solid was formed in quantitative yield that was dried on high vacuum. The 
spectral data for 2.19 match those reported in literature.
130
 
1
H NMR (300 MHz, CDCl3) δ 8.22 (dd, J = 1.6, 7.4 Hz, 3H), 7.50 (td, J = 1.6, 7.4 Hz, 3H), 7.35 – 
7.27 (m, 6H), 2.82 (s, 9H) 
 
(3aS)-3,3-diphenyl-1-(o-tolyl)hexahydro-1H-pyrrolo[1,2-c][1,3,2]oxazaborol-7-ium 
According to the procedure of Corey et al. a 100 mL 2-necked flask equipped with a stir bar, glass 
stopper and a 50 mL pressure-equalizing funnel (containing a cotton plug and ~10 g of 4Å mol 
sieve and functioning as a Soxhlet extractor) fitted on top with a reflux condenser and an argon inlet 
adaptor was charged with compound 2.18 (14.32 mmol), boroxine 2.19 (5.73 mmol) and dry 
toluene (40 mL). The resulting mixture was refluxed overnight. The reaction mixture was then 
cooled to 60°C and the addition funnel and the condenser were quickly replaced by a short 
distillation head. The remaining residue was distilled with toluene (3 x 50 mL) and lastly kept as a 
solution in toluene under argon.
130
 
 
4a-Methyl-6-(pyrrolidine-1-yl)-1,4,4a,8a-tetrahydro-1,4-methanonaphthalene-5,8-
dione 
Diels-Alder product 2.25 (99 mg, 0.45 mmol) was suspended in H2O and pyrrolidine (0.5 mL) was 
added. The reaction mixture was stirred at room temperature overnight, whereas the titled 
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compound was formed as a beige precipitate which was filtered and washed with H2O (48 mg, 
41%) 
1
H NMR (300 MHz, CDCl3) δ 6.11 – 6.09 (m, 1H), 6.07 – 6.06 (m, 1H), 5.56 (br s, 1H), 3.42 (br s, 
1H), 3.04 (br s, 1H), 2.80 (d, J = 3.8 Hz, 1H), 2.02 – 1.83 (m, 4H), 1.67 – 1.65 (m, 1H), 1.56 – 1.53 
(m, 1H), 1.46 (s, 3H) 
HRMS (EI) Calculated for C16H19NNaO2: 280.1308; Found:280.1310 
X-Ray Data: (see Appendix 8.2) 
 
6-Hydroxy-4a-methyl-1,4,4a,8a-tetrahydro-1,4-methanonaphthalene-5,8-dione 
Diels-Alder adduct 2.24 (30 mg, 0.21 mmol) was dissolved in a 1M solution of K2CO3 in 
MeOH/H2O (1:1) and the resulting mixture was heated to reflux overnight. Concentrated 
hydrochloric acid was then added until a pH of 4 was observed and the reaction mixture was 
extracted with ethyl acetate (3 x 30 mL), dried over MgSO4 and the solvent was removed under 
reduced pressure to afford the titled compound as a beige solid (21 mg, 88%). 
1
H NMR (500 MHz, CDCl3) δ 6.11 (d, J = 0.8 Hz, 1H), 6.07 (t, J = 1.84 Hz, 2H), 3.46 – 3.42 (m, 
1H), 3.13 – 3.10 (m, 1H), 2.88 (d, J = 3.8 Hz, 1H), 1.73 – 1.68 (m, 1H), 1.61 – 1.57 (m, 2H), 1.52 
(s, 3H) 
13
C NMR (400 MHz, CDCl3) δ 200.2, 198.5, 158.2, 136.4, 135.8, 115.2, 58.2, 54.3, 51.4, 49.1, 
46.8, 26.0 
LRMS (ESI) Calculated for: C12H11O3 (M-H
+
): 203.08; Found: 202.9 
HRMS (EI) Calculated for C12H12O3Na: 227.0679; Found: 227.0677 
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6.3 Experimental Procedures Left Hand Fragment 
 
Ethyl (E)-2-(3-methyl-2-oxocyclopentylidene)acetate 
According to the procedure of Barco et al.
98
 a solution of 2-methylcylopentanone (2 mL, 18.7 
mmol), pyrrolidine (3.2 mL, 37.4 mmol) and catalytic amounts of p-toluenesulfonic acid in toluene 
(20 mL) were refluxed using a Dean-Stark trap until no further water was collected. The reaction 
mixture was cooled to room temperature and ethyl glyoxalate (50% in toluene; 4.5 mL, 21.8 mmol) 
was added in one portion. The resulting mixture was heated to reflux for further 3 hours until 
complete conversion to product was observed by TLC. The resulting reaction mixture was cooled to 
room temperature and 4N HCl (10 mL) was carefully added. The mixture was further stirred for 20 
minutes at r.t. and extracted washed with water (3 x 30 mL). The organic layer was dried over 
MgSO4 and concentrated in vacuo to afford 3.6 as a crude brown oil, which was purified via 
Kugelrohr distillation to afford the titled compound as a yellow oil (1.2 g, 45 %). 
1
H NMR (300 MHz, CDCl3) δ 6.52 (dd, J = 3.6, 3.6 Hz, 1H), 4.23 (q, J = 7.0 Hz, 2H), 3.35 – 3.24 
(m, 1H), 2.84 – 2.70 (m, 1H), 2.41 – 2.26 (m, 2H), 1.58 – 1.43 (m, 1H), 1.31 (t, J = 7.0  Hz, 3H), 
1.18 (d, J = 6.7 Hz, 3H) 
13
C NMR (500 MHz, CDCl3) δ 208.9, 166.4, 150.8, 119.9, 60.8, 43.8, 28.5, 27.6, 14.2, 14.2 
HRMS (EI) Calculated for C10H14NaO3: 205.0835; Found: 205.0834 
 
Ethyl 2-(4-methyl-5-oxocyclopent-1-en-1-yl)acetate 
To a solution of 3.6 (0.5 mL, 2.8 mmol) in EtOH (5 mL) was added dilute hydrochloric acid (1M, 
0.2 mL) and the resulting mixture stirred at r.t. for 3 hours. The reaction mixture was neutralised by 
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adding solid NaHCO3 to the solution. The filtrate was concentrated to dryness and the crude oil 
purified via Kugelrohr distillation to afford the titled compound as a yellow oil (0.1 g, 20%).  
1
H NMR (400 MHz, CDCl3) δ 7.53 – 7.51 (m, 1H), 4.33 – 4.23 (m, 1H), 5.15 (q, J = 7.1 Hz, 2H), 
3.23 – 3.21 (m, 2H), 2.94 – 2.86 (m, 1H), 2.45 – 2.38 (m, 1H), 2.27 – 2.19 (m, 1H), 1.26 (t, J = 7.1 
Hz, 3H), 1.19 (d, J = 7.6 Hz, 3H) 
13
C NMR (400 MHz, CDCl3) δ 210.9, 170.6, 158.8, 137.8, 60.93, 39.5, 35.9, 30.5, 14.1, 13.8 
HRMS (EI) Calculated for C10H14NaO3: 205.0835; Found: 205.0834 
 
2-Iodocyclopent-2-en-1-one 
Potassium carbonate (396 mg, 2.87 mmol), iodine (909 mg, 3.58 mmol) and DMAP (58 mg, 0.48 
mmol) were added to a solution of cyclopetenone (0.2 mL, 2.39 mmol) in a mixture of THF/H2O 
(10 mL, 1:1) at room temperature and the resulting reaction mixture was stirred for 1.5 hours. The 
mixture was diluted with EtOAc, thoroughly extracted with Na2S2O3 and 1N HCl, dried over 
MgSO4 and concentrated in vacuo. The crude product was purified via flash column 
chromatography (ethyl acetate/dichloromethane, 1:1) to afford the titled compound as a pale yellow 
solid (300 mg, 60%). Spectroscopic data matched that as described in literature.
131
 
1
H NMR (500 MHz, CDCl3) δ 8.02 (t, J = 2.9 Hz, 1H), 2.80 – 2.76 (m, 2H), 2.53 – 2.49 (m, 2H) 
 
2-Iodocyclopent-2-en-1-ol 
A solution of 2-iodocyclopentenone (0.7 g, 3.4 mmol) in MeOH (1 mL) was added to a mixture of 
CeCl3•7H2O (1.23 g, 3.4 mmol) in MeOH (10 mL) at 0 °C and stirred for 5 minutes. NaBH4 (0.15 
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g, 4.0 mmol) was then added portionwise and the resulting mixture stirred at 0 °C for 1 hour. The 
cooling bath was removed and the solution stirred for further 60 minutes at ambient temperature. 
The reaction mixture was quenched with water (10 mL) and the mixture extracted with Et2O (3 x 20 
mL). The combined organic layers were dried over MgSO4 and concentrated in vacuo to give the 
titled compound as an off white solid (0.4 g, 56 %). Spectroscopic data matched that as described in 
literature.
132
 
1
H NMR (500 MHz, CDCl3) δ 6.30 – 6.28 (m, 1H), 4.72 – 4.68 (m, 1H), 2.53 – 2.46 (m, 1H), 2.37 
– 2.29 (m, 2H), 1.89 – 1.84 (m, 1H), 1.71 (br s, 1H) 
13
C NMR (500 MHz, CDCl3) δ 142.6, 100.2, 82.3, 32.8, 31.4 
 
t-Butyl[(2-iodocyclopent-2ene-1yl)oxy]dimethylsilane 
Imidazole (243 mg, 3.6 mmol), DMAP (52 mg, 0.4 mmol) and TBS-Cl (258 mg, 1.7 mmol) were 
added successively to a solution of 3.34 (300 mg, 1.4 mmol) in dry CH2Cl2 (30 mL) and the 
resulting mixture was stirred at room temperature. Progress was monitored via GC/MS and TLC 
and complete conversion to product was observed after 3 hours. The reaction mixture was quenched 
with H2O and extracted with further CH2Cl2. The combined organic layers were dried over MgSO4 
and the solvent removed under reduced pressure yielding the desired product as a colourless oil (87 
mg, 81 %).  
1
H NMR (500 MHz, CDCl3) δ 6.23 (m, 1H), 4.72 (m, 1H), 2.45 (m, 1H), 2.23 (m, 2H), 1.80 (m, 
1H), 0.94 (s, 9H), 0.17 (s, 3H), 0.13 (s, 3H) 
13
C NMR (500 MHz, CDCl3) δ 141.6, 101.3, 82.3, 32.7, 32.6, 25.9, 25.6, 18.3, -4.4, -4.5 
HRMS (EI) Calculated for C11H21INaOSi: 347.0299; Found: 347.0297 
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Ethyl 2-(5-(tert-butyldimethylsilyl)oxy)cyclopent-1-en-1-yl)-2-diazoacetate 
The following reaction was performed according to the procedure of Wang et al.
100
 Ethyl 
diazoacetate (15% solution in toluene, 0.38 mL, 0.54 mmol), DBU (0.05 mL, 0.33 mmol) and 
nBu4NBr (70 mg, 0.22 mmol) were added to a solution of iodocompound 3.35 (70 mg, 0.22 mmol) 
in dry MeCN (7 mL). Pd(PPh3)4 (25 mg, 0.02 mmol) was then added in one portion and the reaction 
mixture stirred at 45 °C oil bath temperature for 24 hours. Upon completion – progress monitored 
via GC/MS – the solvent was evaporated and the crude oil purified via column chromatography 
(ethyl acetate/petroleum ether, 8:1) to afford the titled compound as a yellow oil (26 mg, 39%). 
1
H NMR (500 MHz, CDCl3) δ 6.22 (m, 1H), 4.94 (m, 1H), 4.26 (q, J = 7.0 Hz, 2H), 2.54 (m, 1H), 
2.30 (m, 2H), 1.80 (m, 1H), 1.30 (t, J = 7.0 Hz, 3H), 0.90 (s, 9H), 0.17 (s, 3H), 0.13 (s, 3H) 
13
C NMR (500 MHz, CDCl3) δ 166.4, 127.6, 78.3, 60.8, 33.9, 31.0, 25.8, 17.9, 14.5, - 3.9, - 4.8 
GC/MS (EI) m/z (%) 282 (M
+•
, %), 197, 151, 77, 76, 75, 59, 45 
IR (neat, νmax, cm
-1
): 2086 (s), 1704 (s), 1234 (s), 1141 (s), 1063 (s), 834 (s), 774 (s) 
LRMS (ESI) Calculated for C15H26N2O3SiNa: 333.2; Found: 333.1 
HRMS (EI) Calculated for C15H26N2O3SiNa: 333.1605, Found: 333.1598 
 
Ethyl (tolsylmethyl)carbamate 
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Urethane (5.2 g, 58.4 mmol), formic acid (13.2 mL) and formaldehyde (37 weight % in water, 7 
mL) were added to a stirring solution of 3.25 (10.4 g, 58.4 mmol) in water (70 mL) and gently 
refluxed for 2 hours resulting in a milky solution. The reaction mixture was cooled and the formed 
precipitate filtered, washed with water and recrystallised from ethanol to afford the titled compound 
in 50% yield. The spectral data for 3.26 match those reported in literature. 
75
 
1
H NMR (300 MHz, CDCl3) δ 7.79 (d, J = 8.31 Hz, 2H), 7.35 (d, J = 8.31 Hz, 2H), 5.55 – 5.47 (m, 
1H), 4.54 (d, J = 7.0 Hz, 2H), 3.98 (q, J = 7.0 Hz, 2H), 2.44 (s, 3H), 1.13 (t, J = 7.0 Hz, 3H) 
 
Ethyl nitroso(tosylmethyl)carbamate 
Compound 3.26 (4 g, 15.55 mmol) was weighed in under argon and dissolved in dichloromethane 
(20 mL). The flask was shielded from light and pyridine (1.88 mL, 23.33 mmol), isomalynitrite (3.2 
mL, 23.33 mmol) and TMSCl (5.13 mL, 40.43 mmol) were added successively. The reaction 
mixture was allowed to stir 24 hours at room temperature, whereby complete conversion to product 
was observed by TLC. The reaction mixture was slowly poured onto a 10% NaHCO3 solution (180 
mL) and stirred for 30 minutes and then extracted with Et2O (3 x 150 mL). The organic layer was 
washed with water (200 mL), 1M HCl (200 mL) and brine (200 mL), dried over MgSO4, filtered 
and concentrated to dryness yielding a yellow oil, which was triturated with cyclohexane (10 mL) to 
afford the titled compound as yellow crystals (7.4 g, 49%). The spectral data for 3.27 match those 
reported in literature.
75
 
1
H NMR (300 MHz, CDCl3) δ 7.70 (d, J = 8.4 Hz, 2H), 7.36 (d, J = 8.4 Hz, 2H), 5.12 (s, 2H), 4.52 
(q, J = 7.2 Hz, 2H), 2.47 (s, 3H), 1.43 (t, J = 7.2 Hz, 3H) 
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1-(diazomethyl)sulfonyl-4-methylbenzene 
Al2O3 (10 g, activated, basic, Brockmann I standard grade, 150 mesh, 58Å) was cooled with an 
ice/NaCl bath. Anhydrous diethyl ether (50 mL) was then added and the mixture was stirred for 10 
minutes. Compound 3.27 (0.5 g, 1.75 mmol) was then dissolved in anhydrous CH2Cl2 (5 mL) and 
added to the solution at 0°C, whereas the reaction was shielded from light all the time. After stirring 
the solution at room temperature for 2 hours, complete conversion was observed by TLC, the 
solution decanted and the Al2O3 was washed with further portions of diethyl ether (3 x 20 mL). The 
solvent was removed under reduced pressure to afford a yellow oil, which solidified upon treatment 
with cold petroleum ether in a dry ice/acetone bath. The solid was washed with further portions of 
petroleum ether (3 x 20 mL) to afford the titled compound as a bright yellow solid (250 mg, 73%). 
The spectral data for 3.28 match those reported in literature.
75
 
1
H NMR (300 MHz, CDCl3) δ 7.76 (d, J = 8.4 Hz, 2H), 7.34 (d, J = 8.4 Hz, 2H), 5.25 (s, 1H), 2.45 
(s, 3H) 
 
1-(Furan-3-yl)ethan-1-ol 
A solution of 3-furaldehyde (1 mL, 11.6 mmol) in anhydrous Et2O (10 mL) was added to 
methylmagnesium bromide (3M in Et2O, 15 mmol) at 0 °C under an argon atmosphere. After 
stirring at the set temperature for one hour the reaction mixture was quenched with H2O (0.2 mL) 
and the supernatant layer was decanted. After removing the solvent under reduced pressure, the 
titled compound was afforded as a yellow oil, which was used in the next step without further 
purification. Spectral data were in accordance to the literature.
133
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1
H NMR (400 MHz, CDCl3) δ 7.38 (d, J = 1.4 Hz, 2H), 6.42 (t, J = 1.4 Hz, 1H), 4.90 – 4.82 (m, 
1H), 1.74 – 1.67 (m, 1H), 1.49 (d, J = 6.5 Hz, 3H) 
13
C NMR (400 MHz, CDCl3) δ 143.3, 138.5, 130.3, 108.5, 63.0, 24.0 
 
1-(Furan-3-yl)ethan-1-one 
IBX (2.3 g, 8.4 mmol) was added to a solution of 1-(furan-3-yl)ethan-1-ol (0.78 g, 6.9 mmol) in 
DMSO (10 mL) and the resulting mixture stirred for one hour at ambient temperature. Et2O (15 
mL) was added and the organic layer extracted with NaHCO3, dried over Na2SO4. Removing the 
solvent under reduced pressure afforded the titled compound as a white solid (0.59 g, 76%). 
Spectral data were in accordance to the literature.
133
 
1
H NMR (500 MHz, CDCl3) δ 8.02 – 8.01 (m, 1H), 7.44 (t, J = 1.4 Hz, 1H), 6.77 – 6.76 (m, 1H), 
2.44 (s, 3H) 
13
C NMR (500 MHz, CDCl3) δ 192.4, 147.5, 144.3, 128.1, 108.6, 27.81 
6.3.1 General procedure for rhodium catalysed [4+3] cycloaddition reactions of diazo 
compound 3.36 with furans 
Diazo compound 3.36 (1 eq.) was dissolved in dry cyclohexane (0.3 M), furan (3 eq.) was added 
followed by the addition of Rh2(R-DOSP)4 (0.01 eq.) in one portion, whereas cease of nitrogen was 
observed. The reaction mixture was heated to 80 °C oil bath temperature until complete conversion 
was observed via TLC. The solvent was evaporated and the crude mixture purified via flash column 
chromatography (ethyl acetate/petroleum ether = 1 : 5) to afford the titled compound as a slight 
yellow oil. 
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8-Ethyl 4-Methyl 1-((tert-butyldimethylsilyl)oxy)-2,3,3a,7-tetrahydro-4,7-
epoxyazulene-4,8(1H)-dicarboxylate 
Compound 4.11 was prepared via general method 6.3.1 with diazo compound 3.36 (23 mg, 0.074 
mmol) and 2-methylfuroate (31 µl, 0.222 mmol). Purification via column chromatography (ethyl 
acetate/petroleum ether = 1:4) afforded the title compound (15.1 mg, 50%).  
1
H NMR (500 MHz, CDCl3) δ 6.77 (dd, J = 1.7, 5.9 Hz, 1H), 5.83 (d, J = 5.9 Hz, 1H), 5.11 (br s, 
1H), 5.03 (d, J = 5.4 Hz, 1H), 4.22-4.16 (m, 2H), 3.86 (s, 3H), 2.85 (dd, J = 6.5, 13.2 Hz, 1H), 1.86 
- 1.73 (m, 2H), 1.68 – 1.58 (m, 1H), 1.38 – 1.32 (m, 1H), 1.29 (t, J = 7.0 Hz, 3H), 0.79 (s, 9H), 0.05 
(s, 6H)  
13
C NMR (500 MHz, CDCl3) δ 170.7, 165.1, 154.9, 142.9, 140.7, 130.7, 124.2, 89.4, 78.3, 70.6, 
60.3, 52.6, 45.9, 35.3, 25.7, 23.1, 17.9, 14.2, -3.8, -5.3 
LRMS (ESI) Calculated for C21H32O6SiNa: 431.2; Found: 431.1 
HRMS (EI) Calculated for C21H32O6SiNa: 431.1860; Found: 431.1858 
 
Diethyl 1-((tert-butyldimethylsilyl)oxy)-1,2,3,3a,4,7-hexahydro-4,7-epoxyazulene-
5,8-dicarboxylate 
Compound 4.12 was prepared via general method 6.3.1 with diazo compound 3.36 (57 mg, 0.184 
mmol) and 3-ethylfuroate (77 µl, 0.552 mmol). Purification via column chromatography (ethyl 
acetate/petroleum ether = 1:4) afforded the title compound (36.5 mg, 47%).  
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1
H NMR (500 MHz, CDCl3) δ 7.45 (d, J = 1.9 Hz, 1H), 5.46 (d, J = 5.8 Hz, 1H), 5.06 (br s, 1H), 
5.05 (d, J = 5.3 Hz, 1H), 4.18 (m, 4H), 2.92 (quin, J = 6.5 Hz, 1H), 1.79 (quin, J = 6.5 Hz, 1H), 1.72 
(dd, J = 5.9, 13.4 Hz, 1H), 1.60 – 1.53 (m, 2H), 1.30 (t, J = 7.2 Hz, 3H), 1.26 (t, J = 7.2 Hz, 3H), 
0.75 (s, 9H), 0.03 (d, J = 4.4 Hz, 6H) 
13
C NMR (500 MHz, CDCl3) δ 164.9, 163.4, 156.8, 150.1, 131.5, 128.5, 80.7, 77.9, 76.7, 70.6, 
60.5, 60.3, 43.4, 35.0, 25.6, 23.7, 17.9, 14.3, 14.2, -3.9, -5.3 
HRMS (EI) Calculated for C22H34O6SiNa: 445.2107; Found: 445.2103 
 
Ethyl 1-(((tert-butyldimethylsilyl)oxy)-4-(((tert-butyldimethylsilyl)oxy)methyl)-
1,2,3,3a,4,7-hexahydro-4,7-epoxyazulene-8-carboxylate 
Compound 4.13 was prepared via general method 6.3.1 with diazo compound 3.36 (30 mg, 0.097 
mmol) and furan (62 µl, 0.29 mmol). Purification via column chromatography (ethyl 
acetate/petroleum ether = 1:4) afforded the title compound (1.8 mg, 38%). 
1
H NMR (500 MHz, CDCl3) δ 6.64 (dd, J = 1.7, 5.9 Hz, 1H), 5.64 (d, J = 5.9 Hz, 1H), 5.03 – 5.0 
(m, 2H), 4.24 – 4.11 (m, 2H), 3.92 (s, 2H), 2.78 (dd, J = 6.6, 13.2 Hz, 1H), 1.77 – 1.69 (m, 2H), 
1.68 – 1.59 (m, 1H), 1.28 (t, J = 7.1 Hz, 3H), 0.91 (s, 9H), 0.78 (s, 9H), 0.09 (s, 6H), 0.04 (d, J = 
1.5 Hz, 6H) 
13
C NMR (500 MHz, CDCl3) δ 165.6, 157.0, 141.7, 130.8, 126.0, 90.2, 78.1, 70.6, 66.7, 59.9, 44.7, 
35.8, 25.9, 25.7, 22.8, 18.4, 18.0, 14.3, -3.8, -5.2 
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Ethyl-1-((tert-butyldimethylsilyl)oxy)-4-methyl-1,2,3,3a,4,7-hexahydro-4,7-
epoxyazulene-8-carboxylate 
Compound 4.14 was prepared via general method 6.3.1 with diazo compound 3.36 (46 mg, 0.148 
mmol) and 2-methylfuran (40 µl, 0.445 mmol). Purification via column chromatography (ethyl 
acetate/petroleum ether = 1:4) afforded the title compound (1.6 mg, 29%).  
1
H NMR (500 MHz, CDCl3) δ 6.60 (dd, J = 1.7, 5.9 Hz, 1H), 5.57 (d, J = 5.9 Hz, 1H), 5.03 (d, J = 
5.2 Hz, 1H), 4.97 (s br, 1H), 4.25 – 4.11 (m, 2H), 2.50 (dd, J = 5.9, 13.0 Hz, 1H), 1.78 – 1.72 (m, 
1H), 1.70 – 1.60 (m 2H), 1.56 (s, 3H), 1.28 (t, J = 7.1 Hz, 3H), 1.19 – 1.08 (m, 1H), 0.77 (s, 9H), 
0.04 (d, J = 1.5 Hz, 6H) 
13
C NMR (500 MHz, CDCl3) δ 165.7, 156.4, 141.2, 131.2, 128.8, 86.7, 77.9, 70.8, 60.0, 49.5, 35.7, 
25.7, 23.4, 22.6, 18.0, 14.3, -3.9, -5.3 
 
Ethyl 5-bromo-1-((tert-butyldimethylsilyl)oxy)-1,2,3,3a,4,7-hexahydro-4,7-
epoxyazulene-8-carboxylate 
Compound 4.15 was prepared via general method 6.3.1 with diazo compound 3.36 (28 mg, mmol) 
and 3-bromofuran (40 µl, 0.27 mmol). Purification via column chromatography (ethyl 
acetate/petroleum ether = 1:4) afforded the title compound (1.3 mg, 34%).  
1
H NMR (500 MHz, CDCl3) δ 6.72 (d, J = 1.9 Hz, 1H), 5.07 (d, J = 4.7 Hz, 1H), 5.04 (d, J = 5.8 
Hz, 1H), 4.91 (d, J = 1.9 Hz, 1H), 4.25 – 4.11 (m, 2H), 2.92 – 2.85 (m, 1H), 1.82 – 1.73 (m, 2H), 
1.62 – 1.50 (m, 2H), 1.29 (t, J = 7.3 Hz, 3H), 0.97 (s, 9H), 0.05 (d, J = 3.2 Hz, 6H) 
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13
C NMR (400 MHz, CDCl3) δ 165.0, 155.3, 140.0, 129.6, 115.4, 84.3, 78.0, 70.5, 60.2, 43.1, 35.0, 
25.6, 23.7, 17.9, 14.23, -3.8, -5.3 
6.4 Experimental Procedures for 1,2,3-sulfonyl triazoles 
6.4.1 General procedure for triflation chemistry 
Method A: To a solution of diisopropylamine (1.2 eq.) in anhydrous tetrahydrofuran (40 mL) was 
added drop wise  n-butyl lithium (1.2 eq., 2M in hexanes) at 0 °C under argon atmosphere. After 30 
minutes the reaction mixture was cooled to -78 °C and a solution of ketone in THF (1 eq.) was 
added dropwise and the resulting mixture was stirred for 2 hours. PhNTf2 in THF (1 eq.) was then 
added dropwise and the mixture allowed to warm to room temperature overnight. The resulting 
reaction mixture was quenched with saturated NH4Cl (20 mL) and extracted with Et2O (3 x 80 ml). 
The combined organic layers were dried over Na2SO4 and the filtrate concentrated in vacuo. The 
residue was passed through a silica plug (100% hexanes to 20% ethyl acetate) to afford the 
corresponding trilfate as a colourless oil.  
Method B: LiHMDS (1M; 1.2 eq.) was cooled to -78 °C and a solution of ketone in anhydrous 
THF (1 eq.) was added dropwise under an argon atmosphere. The resulting mixture was stirred for 1 
hour followed by the drop wise addition of PhNTf2 (1 eq. in THF). The mixture was stirred at -78 
°C for another 2 hours and then left to warm to room temperature overnight. The reaction was 
quenched with saturated NH4Cl and extracted with pentanes (5 x 70 mL) and 1N HCl (70 mL). The 
organic layer was dried over Na2SO4 and the solvent removed under reduced pressure. The residual 
oil was purified via column chromatography using pure pentanes as the eluent to afford the titled 
compound as a colourless oil. 
 
Cyclohept-1-en-1-yl-trifluoromethanesulfonate 
 152 | P a g e  
 
Compound 6.5 was prepared via method B with cycloheptanone (3 g, 26.8 mmol). Column 
chromatography was performed with pure petroleum ether to afford the titled compound as a 
colourless oil (6.1 g, 93%). The spectral data for 6.5 match those reported in literature.
134
  
1
H NMR (300 MHz, CDCl3) δ 5.88 (t, J = 6.6 Hz, 1H), 2.53 – 2.50 (m, 2H), 2.18 – 2.14 (m, 2H), 
1.75 – 1.63 (m, 6H) 
13
C NMR (400 MHz, CDCl3) δ 153.1, 123.1, 119.8, 117.3, 33.2, 29.9, 26.3, 24.8, 24.7 
 
1-Ethynylcyclohept-1-ene 
A solution of ethynylmagnesium bromide (0.5M in THF; 160 mL, 80.3 mmol) was warmed to 40 
°C and Co(acac)3 (0.48 g, 1.34 mmol) was added in one portion followed by the addition of triflate 
(6.53 g, 26.8 mmol). The resulting mixture was stirred for 3 hours until complete conversion to 
product was observed. Saturated NH4Cl was added carefully and the mixture extracted thoroughly 
with pentanes (5 x 70 mL). The combined organic extracts were washed with brine, dried over 
MgSO4 and the solvent removed in vacuo. The oily residue was purified via flash chromatography 
using petroleum ether as eluent to afford the titled compound as a yellow oil (2.8 g, 88%). The 
spectral data for 6.6 match those reported in literature.
134
 
1
H NMR (300 MHz, CDCl3) δ 6.39 (t, J = 6.8 Hz, 1H), 2.84 (s, 1H), 2.34 (m 1H),  
13
C NMR (400 MHz, CDCl3) δ 141.6, 125.8, 87.3, 74.2, 33.9, 32.0, 29.1, 26.5, 26.3 
6.4.2 General procedure for the CuTC catalysed cycloaddition.  
Acetylene (1 mmol, 1eq.) was added to a solution of CuTC (0.1 eq.) in anhydrous toluene and the 
resulting solution stirred at ambient temperature for 10 minutes. A mesyl azide solution in toluene 
(1 eq. in 10 mL) was then added drop wise and the resulting mixture stirred at rt overnight. The 
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solvent was evaporated and the residue purified via column chromatography using ethyl acetate / 
petroleum ether= 1:4 as the solvent system. The orange oil solidified upon standing and was 
recrystallised at -20 °C from ethyl acetate/petroleum ether to afford the title compound as a white 
solid. 
 
4-(Cyclohept-1-en-1-yl)-1-(methylsulfonyl)-1H-1,2,3-triazole 
Compound 4.40 was prepared via general method 6.4.2 with acetylene 6.6 (1.3 g, 10.6 mmol). 
Purification via column chromatography (ethyl acetate/petroleum ether = 1:4) and recrystallization 
from ethyl acetate/petroleum ether afforded the titled compound as a white solid (1.4 g, 54%). 
Spectral data for compound 4.40 are in accordance with literature.
126
 
1
H NMR (500 MHz, CDCl3) δ 7.91 (s, 1H), 6.82 (t, J = 6.7 Hz, 1H), 3.49 (s, 3H), 2.64 – 2.58 (m, 
2H), 2.38 – 2.29 (m, 2H), 1.88 – 1.78 (m, 2H), 1.70 – 1.55 (m, 4H) 
13
C NMR (500 MHz, CDCl3) δ 150.2, 133.1, 132.2, 117.6, 42.6, 32.0, 30.9, 28.5, 26.5, 26.4, 14.2 
 
4-(Cyclohex-1-en-yl)-1-(methylsulfonyl)-1H-1,2,3-triazole 
Compound 4.33 was prepared via general method 6.4.2. Recrystallization from ethyl 
acetate/petroleum ether afforded 4.33 in 82% yield. Spectral data for compound 4.33 are in 
accordance with literature.
126
 
1
H NMR (500 MHz, CDCl3) δ 7.89 (s, 1H), 6.72 (m, 1H), 3.49 (s, 3H), 2.36 – 2.24 (m, 2H), 2.23 – 
2.22 (m, 2H), 1.80 – 1.77 (m, 2H), 1.70 – 1.68 (m, 2H) 
13
C NMR (500 MHz, CDCl3) δ 149.0, 128.1, 125.6, 117.3, 42.6, 26.2, 25.3, 22.2, 22.0 
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6.4.3 General procedure for rhodium catalysed [4+3] cycloaddition reactions of 1,2,3-
sulfonyl triazoles with furans 
Furan (3 eq.) was added in one portion to a suspension of triazole in cyclohexane (0.3M solution). 
Rh(II) catalyst (0.01 eq.) was then added to the mixture and the sample immersed in a 70°C oil bath 
until starting material appeared to be consumed by TLC analysis. The reaction mixture was 
concentrated and purified via flash column chromatography (ethyl acetate/petroleum spirit = 1:2) to 
afford the titled compound. 
 
Methyl (E)-9-[[(methylsulfonyl)imino]methyl]-1,2,3,4,4a,8a-hexahydro-5H-5,8-
epoxybenzo[7]annulene-5-carboxylate 
Compound 4.41 was prepared via general method 6.4.3 with triazole 4.33 (34.7 mg, 0.153 mmol) 
and 2-methylfuroate (49 µl, 0.46 mmol). Purification via column chromatography (ethyl 
acetate/petroleum ether = 1:4) afforded the title compound as pale yellow crystals (32.3 mg, 65% 
yield.  
1
H NMR (500 MHz, CDCl3) δ 9.02 (s, 1H), 6.64 (dd, J = 2.0, 5.9 Hz, 1H), 6.13 (d, J = 5.9 Hz, 1H), 
5.54 (br s, 1H), 3.86 (s, 3H), 3.17 (m, 1H), 3.07 (s, 3H), 2.75 (dd, J = 4.6, 12.9 Hz, 1H), 2.11 – 1.83 
(m, 4H), 1.51 – 1.43 (m, 1H), 1.35 – 1.19 (m, 4H) 
13
C NMR (400 MHz, CDCl3) δ 169.7, 163.6, 139.0, 131.7, 128.2, 88.5, 76.6, 52.8, 43.6, 40.4, 29.8, 
27.6, 26.8, 24.9 
HRMS (EI) Calculated for C15H19O5NSNa: 348.0876; Found: 348.0882 
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Ethyl (E)-9-[[(methylsulfonyl)imino]methyl]-2,3,4,4a,5,8-hexahydro-1H-5,8-
epoxybenzo[7]annulene-6-carboxylate 
Compound 4.42 was prepared via general method 6.4.3 with triazole 4.33 (60 mg, 0.22 mmol) and 
3-ethylfuroate (89 µl, 0.66 mmol). Purification via column chromatography (ethyl 
acetate/petroleum ether = 1:2) afforded the title compound as colourless oil (57 mg, 76% yield.  
1
H NMR (500 MHz, CDCl3) δ 8.98 (br s, 1H), 7.42 (m, 1H), 5.48 (br s, 1H), 5.03 (m, 1H), 4.21 – 
4.17 (m, 2H), 3.14 (d, J = 14.0 Hz, 1H), 3.05 (s, 3H), 2.79 – 2.74 (m, 1H), 2.02 – 1.92 (m, 3H), 1.82 
– 1.79 (m, 1H), 1.50 – 1.30 (m, 2H), 1.29 – 1.25 (m, 3H), 0.98 – 0.86 (m, 1H) 
13
C NMR (500 MHz, CDCl3) δ 165.0, 163.5, 163.2, 148.3, 135.6, 130.6, 79.9, 76.4, 60.7, 41.0, 
40.3, 29.5, 28.2, 27.7, 25.0, 14.1 
 
(E)-N-[(1-oxo-2,3,4,5a,7,8,9,10,10a,10b-decahydro-1H-indeno[2,1-b]benzofuran-6-
yl)methylene]methanesulfonamide 
Compound 4.43 was prepared via general method 6.4.3 with triazole 4.33 (136 mg, 0.6 mmol) and 
dihydrobenzofuranone (245 mg, 1.8 mmol). Purification via column chromatography (ethyl 
acetate/hexanes = 5:1) afforded the title compound as a yellow oil (148 mg, 72% yield). 
1
H NMR (400 MHz, CDCl3) δ 8.98 (s, 1H), 6.06 (d, J = 9.6 Hz, 1H), 3.36 (d, J = 8.7 Hz, 1H), 3.12 
(s, 3H), 3.07 (d, J = 12.7 Hz, 1H), 2.77 – 2.68 (m, 1H), 2.58 – 2.49 (m, 1H), 2.46 – 2.28 (m, 4H), 
2.24 – 2.14 (m, 1H), 2.02 – 1.96 (m, 2H), 1.83 (d, J = 12.7 Hz, 1H), 1.57 – 1.43 (m, 1H), 1.38 – 
1.12 (m, 3H) 
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13
C NMR (400 MHz, CDCl3) δ 195.3, 179.2, 176.5, 163.6, 127.7, 116.6, 91.9, 56.6, 46.9, 40.3, 
36.5, 28.1, 27.8, 25.3, 24.0, 21.6 
HRMS (EI) Calculated for C17H22O4NS: 336.1259; Found: 336.1275 
 
4,5 –Dimethylfuran-2-carboxylic acid 
Silver oxide was prepared by adding a NaOH (471 mg, 11.8 mmol) in water (2 mL) to an aqueous 
solution of silver nitrate (1 g, 5.89 mmol) at 0°C and the resulting mixture was stirred for 10 
minutes. Compound 4.19 (0.36 mL, 2.94 mmol) was then added drop wise to the solution and 
stirred for further 30 minutes. The resulting precipitate was filtered and washed thoroughly with 
portions of water. The filtrate was acidified with conc. HCl, the resulting precipitate filtered off and 
washed with water (10 mL) to afford the titled compound as a yellow solid (295 mg, 36%).Spectral 
data for compound 4.20 are in accordance to literature.
135
 
1
H NMR (300 MHz, CDCl3) δ 7.11 (s, 1H), 2.31 (s, 3H), 2.00 (s, 3H), 1.26 (s, 1H) 
13
C NMR (500 MHz, CDCl3) δ 163.1, 154.5, 140.6, 123.5, 117.6, 12.0, 9.7 
 
Methyl 4,5-dimethylfuran-2-carboxylate 
To a solution of carboxylic acid (20 mg, 0.14 mmol) in diethyl ether (10 mL) was added drop wise 
a solution of freshly prepared diazomethane in Et2O. Upon completion - progress was monitored via 
TLC - the reaction mixture was stirred for further 20 minutes open to air followed by evaporation of 
the solvent to yield the titled compound as an orange oil (20 mg, 91%). 
1
H NMR (300 MHz, CDCl3) δ 6.97 (s, 1H), 3.86 (s, 3H), 2.28 (s, 3H), 1.97 (s, 3H) 
13
C NMR (500 MHz, CDCl3) δ 159.3, 153.0, 141.5, 121.4, 117.1, 51.7, 11.8, 9.7 
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Mesyl azide 
Methanesulfonyl chloride (1.4 mL, 17.5 mmol) was dissolved in acetone (15 mL) and NaN3 (1.7 g, 
26.2 mmol) was added portion wise over 30 minutes. The resultant mixture was stirred at ambient 
temperature for 1 hour. The precipitate was filtered and washed with further portions of acetone; the 
filtrate was evaporated to give the titled compound as a colourless oil (2 g, 97%). 
1
H NMR (300 MHz, CDCl3) δ 3.26 (s, 3H) 
13
C NMR (500 MHz, CDCl3) δ 42.8 
 
 
Ethynylmagnesium bromide solution 
According to a procedure of Roy et al.
136
 ethyl bromide (16.4 g, 150.1 mmol) was added portion 
wise to a solution of magnesium (4 g, 165.1 mmol) in THF (150 mL) and an internal temperature of 
45 °C was maintained. The resultant mixture was stirred at ambient temperature for further 30 
minutes. Acetylene gas was purified by ppassing the gas through two cold traps (cooled with dry 
ice/acetone) before bubbling it through the previously prepared ethylmagnesium bromide solution 
at such a rate to maintain the internal temperature at a maximum of 40 °C. After the exothermic 
reaction has subsided, the ethynylmagnesium bromide solution was used as such without further 
purification.  
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8.1 Appendix A: Supporting NMR spectra for Chapter 2 
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8.2 Appendix B: Supporting NMR Spectra for Chapter 3 
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8.3 Appendix C: Supporting NMR Spectra for Chapter 5 
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8.4 Appendix D: X-Ray diffraction data 
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Table 1.  Crystal data and structure refinement for 2.25. 
Empirical formula  C16 H20 O3 
Formula weight  260.33 
Temperature  293(2) K 
Wavelength  1.54184 Å 
Crystal system  Orthorombic 
Space group  Pbca 
Unit cell dimensions a = 7.9803(6) Å = 90°. 
 b = 16.4730(10) Å = 90°. 
 c = 20.843(2) Å  = 90°. 
Volume 2740.0(4) Å3 
Z 8 
Density (calculated) 1.262 Mg/m3 
Absorption coefficient 0.690 mm-1 
F(000) 1120 
Theta range for data collection 4.24 to 62.51°. 
Index ranges -9<=h<=6, -18<=k<=18, -20<=l<=23 
Reflections collected 6413 
Independent reflections 2175 [R(int) = 0.0315] 
Completeness to theta = 62.51° 99.6 %  
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2175 / 0 / 172 
Goodness-of-fit on F2 0.799 
Final R indices [I>2sigma(I)] R1 = 0.0420, wR2 = 0.1186 
R indices (all data) R1 = 0.0574, wR2 = 0.1299 
Largest diff. peak and hole 0.150 and -0.175 e.Å-3 
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Table 2.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 103) 
for 540tk1.  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
O(3) 1414(2) 6213(1) 2644(1) 59(1) 
O(2) 511(2) 6857(1) 5180(1) 69(1) 
O(1) 1838(2) 7770(1) 3061(1) 51(1) 
C(11) 1119(2) 6345(1) 3206(1) 41(1) 
C(4) 691(2) 6713(1) 4610(1) 46(1) 
C(1) 967(2) 7207(1) 3429(1) 40(1) 
C(3) 806(2) 7379(1) 4144(1) 42(1) 
C(5) 836(2) 5840(1) 4395(1) 44(1) 
C(8) 4049(2) 5740(1) 3795(1) 57(1) 
C(2) -686(2) 7517(1) 3698(1) 45(1) 
C(10) 968(2) 5626(1) 3667(1) 43(1) 
C(13) -446(3) 5062(1) 3428(1) 61(1) 
C(14) -2210(2) 6979(1) 3753(1) 59(1) 
C(16) 3617(2) 7739(1) 3144(1) 58(1) 
C(6) 2483(2) 5468(1) 4684(1) 54(1) 
C(9) 2689(2) 5142(1) 3648(1) 52(1) 
C(15) -1146(3) 8390(1) 3551(1) 63(1) 
C(12) 2615(3) 4691(1) 4293(1) 60(1) 
C(7) 3921(2) 5945(1) 4403(1) 57(1) 
________________________________________________________________________________
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Table 3.   Bond lengths [Å] and angles [°] for 540tk1. 
_____________________________________________________ 
O(3)-C(11)  1.214(2) 
O(2)-C(4)  1.220(2) 
O(1)-C(1)  1.3900(19) 
O(1)-C(16)  1.430(2) 
C(11)-C(1)  1.499(2) 
C(11)-C(10)  1.529(2) 
C(4)-C(3)  1.469(3) 
C(4)-C(5)  1.510(2) 
C(1)-C(3)  1.523(2) 
C(1)-C(2)  1.522(2) 
C(3)-C(2)  1.527(3) 
C(5)-C(10)  1.561(2) 
C(5)-C(6)  1.570(3) 
C(8)-C(7)  1.314(3) 
C(8)-C(9)  1.498(3) 
C(2)-C(14)  1.509(3) 
C(2)-C(15)  1.515(3) 
C(10)-C(13)  1.544(2) 
C(10)-C(9)  1.589(3) 
C(6)-C(7)  1.510(3) 
C(6)-C(12)  1.520(3) 
C(9)-C(12)  1.537(3) 
 
C(1)-O(1)-C(16) 114.00(13) 
O(3)-C(11)-C(1) 118.95(16) 
O(3)-C(11)-C(10) 118.90(16) 
C(1)-C(11)-C(10) 122.12(15) 
O(2)-C(4)-C(3) 120.32(17) 
O(2)-C(4)-C(5) 118.96(17) 
C(3)-C(4)-C(5) 120.71(15) 
O(1)-C(1)-C(11) 114.88(14) 
O(1)-C(1)-C(3) 117.19(14) 
C(11)-C(1)-C(3) 119.18(14) 
O(1)-C(1)-C(2) 114.39(14) 
C(11)-C(1)-C(2) 120.19(14) 
C(3)-C(1)-C(2) 60.21(11) 
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C(4)-C(3)-C(1) 120.82(15) 
C(4)-C(3)-C(2) 117.67(15) 
C(1)-C(3)-C(2) 59.86(11) 
C(4)-C(5)-C(10) 120.56(15) 
C(4)-C(5)-C(6) 108.78(14) 
C(10)-C(5)-C(6) 103.20(14) 
C(7)-C(8)-C(9) 108.12(18) 
C(14)-C(2)-C(15) 112.17(17) 
C(14)-C(2)-C(1) 121.93(15) 
C(15)-C(2)-C(1) 117.00(17) 
C(14)-C(2)-C(3) 119.71(17) 
C(15)-C(2)-C(3) 116.89(16) 
C(1)-C(2)-C(3) 59.93(12) 
C(11)-C(10)-C(13) 108.72(15) 
C(11)-C(10)-C(5) 116.21(14) 
C(13)-C(10)-C(5) 113.55(14) 
C(11)-C(10)-C(9) 107.74(14) 
C(13)-C(10)-C(9) 108.72(14) 
C(5)-C(10)-C(9) 101.32(14) 
C(7)-C(6)-C(12) 100.21(16) 
C(7)-C(6)-C(5) 106.51(14) 
C(12)-C(6)-C(5) 100.43(15) 
C(8)-C(9)-C(12) 99.53(16) 
C(8)-C(9)-C(10) 106.91(15) 
C(12)-C(9)-C(10) 100.79(15) 
C(9)-C(12)-C(6) 93.75(14) 
C(8)-C(7)-C(6) 107.38(18) 
_____________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
  
 210 | P a g e  
 
Table 4.   Anisotropic displacement parameters (Å2x 103)for 540tk1.  The anisotropic 
displacement factor exponent takes the form: -22[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
______________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
______________________________________________________________________________ 
O(3) 81(1)  63(1) 35(1)  -4(1) 6(1)  7(1) 
O(2) 100(1)  70(1) 36(1)  -12(1) 4(1)  -9(1) 
O(1) 46(1)  51(1) 55(1)  13(1) 0(1)  -4(1) 
C(11) 36(1)  50(1) 36(1)  -3(1) 1(1)  -2(1) 
C(4) 46(1)  53(1) 39(1)  -8(1) 1(1)  -8(1) 
C(1) 38(1)  43(1) 39(1)  2(1) 1(1)  -2(1) 
C(3) 43(1)  41(1) 42(1)  -9(1) -3(1)  -5(1) 
C(5) 50(1)  44(1) 36(1)  -1(1) 7(1)  -12(1) 
C(8) 44(1)  62(1) 63(1)  14(1) 3(1)  6(1) 
C(2) 41(1)  51(1) 44(1)  -11(1) -2(1)  3(1) 
C(10) 46(1)  44(1) 39(1)  -7(1) 5(1)  -7(1) 
C(13) 65(1)  54(1) 63(1)  -16(1) 1(1)  -15(1) 
C(14) 38(1)  78(1) 61(1)  -23(1) 4(1)  -1(1) 
C(16) 48(1)  62(1) 64(1)  11(1) 4(1)  -10(1) 
C(6) 69(1)  54(1) 40(1)  7(1) -3(1)  -2(1) 
C(9) 60(1)  48(1) 48(1)  -1(1) 8(1)  5(1) 
C(15) 64(1)  61(1) 64(1)  -11(1) -8(1)  18(1) 
C(12) 73(1)  49(1) 59(1)  10(1) 5(1)  2(1) 
C(7) 53(1)  58(1) 60(1)  8(1) -13(1)  -4(1) 
______________________________________________________________________________  
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Table 1.  Crystal data and structure refinement for 2.53. 
Empirical formula  C15 H18 O3 
Formula weight  246.31 
Temperature  293(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21/c 
Unit cell dimensions a = 6.365(2) Å = 90°. 
 b = 21.464(5) Å = 100.69(3)°. 
 c = 9.837(3) Å  = 90°. 
Volume 1320.6(7) Å3 
Z 4 
Density (calculated) 1.239 Mg/m3 
Absorption coefficient 0.085 mm-1 
F(000) 528 
Theta range for data collection 3.26 to 29.00°. 
Index ranges -6<=h<=8, -28<=k<=26, -13<=l<=13 
Reflections collected 11398 
Independent reflections 3132 [R(int) = 0.0280] 
Completeness to theta = 29.00° 89.1 %  
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3132 / 0 / 163 
Goodness-of-fit on F2 1.175 
Final R indices [I>2sigma(I)] R1 = 0.0581, wR2 = 0.1701 
R indices (all data) R1 = 0.0857, wR2 = 0.1890 
Largest diff. peak and hole 0.200 and -0.169 e.Å-3 
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Table 2.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 103) 
for 860tk3.  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
O(1) 3033(2) 4256(1) 4591(1) 55(1) 
O(3) 948(3) 4703(1) 2319(2) 83(1) 
C(10) 1318(3) 4150(1) 2300(2) 45(1) 
C(9) 673(3) 3781(1) 993(2) 39(1) 
C(2) 2831(3) 3223(1) 3642(2) 48(1) 
O(2) 2485(3) 2254(1) 2626(2) 70(1) 
C(4) 1011(3) 3067(1) 1140(2) 43(1) 
C(1) 2467(3) 3845(1) 3581(2) 42(1) 
C(3) 2149(3) 2813(1) 2498(2) 45(1) 
C(8) -1810(3) 3828(1) 518(2) 46(1) 
C(5) -1317(3) 2805(1) 752(2) 60(1) 
C(11) -2248(3) 3254(1) -411(2) 61(1) 
C(12) 1847(3) 4064(1) -76(2) 60(1) 
C(7) -2778(3) 3623(1) 1711(2) 60(1) 
C(13) 4245(4) 4056(1) 5926(2) 66(1) 
C(14) 6554(4) 3994(1) 5834(2) 80(1) 
C(6) -2481(3) 3016(1) 1846(2) 67(1) 
C(15) 3864(5) 4557(1) 6913(2) 85(1) 
________________________________________________________________________________
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Table 3.   Bond lengths [Å] and angles [°] for 860tk3. 
_____________________________________________________ 
O(1)-C(1)  1.328(2) 
O(1)-C(13)  1.458(2) 
O(3)-C(10)  1.211(2) 
C(10)-C(9)  1.502(2) 
C(10)-C(1)  1.488(2) 
C(9)-C(4)  1.550(2) 
C(9)-C(12)  1.525(2) 
C(9)-C(8)  1.566(2) 
C(2)-C(1)  1.353(2) 
C(2)-C(3)  1.431(2) 
O(2)-C(3)  1.223(2) 
C(4)-C(3)  1.499(2) 
C(4)-C(5)  1.565(3) 
C(8)-C(7)  1.489(3) 
C(8)-C(11)  1.529(3) 
C(5)-C(6)  1.486(3) 
C(5)-C(11)  1.529(3) 
C(7)-C(6)  1.320(3) 
C(13)-C(15)  1.499(3) 
C(13)-C(14)  1.495(4) 
 
C(1)-O(1)-C(13) 120.13(14) 
O(3)-C(10)-C(9) 120.53(16) 
O(3)-C(10)-C(1) 119.09(16) 
C(9)-C(10)-C(1) 120.37(14) 
C(10)-C(9)-C(4) 115.56(13) 
C(10)-C(9)-C(12) 106.77(15) 
C(4)-C(9)-C(12) 112.38(14) 
C(10)-C(9)-C(8) 108.78(14) 
C(4)-C(9)-C(8) 101.94(13) 
C(12)-C(9)-C(8) 111.40(14) 
C(1)-C(2)-C(3) 123.15(16) 
C(3)-C(4)-C(9) 118.54(14) 
C(3)-C(4)-C(5) 111.43(15) 
C(9)-C(4)-C(5) 102.96(14) 
C(2)-C(1)-O(1) 127.01(16) 
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C(2)-C(1)-C(10) 121.71(15) 
O(1)-C(1)-C(10) 111.27(14) 
O(2)-C(3)-C(2) 120.07(16) 
O(2)-C(3)-C(4) 119.70(16) 
C(2)-C(3)-C(4) 120.23(15) 
C(7)-C(8)-C(11) 100.17(16) 
C(7)-C(8)-C(9) 106.73(14) 
C(11)-C(8)-C(9) 100.86(14) 
C(6)-C(5)-C(11) 100.02(17) 
C(6)-C(5)-C(4) 106.87(16) 
C(11)-C(5)-C(4) 99.98(15) 
C(8)-C(11)-C(5) 93.34(15) 
C(6)-C(7)-C(8) 107.39(19) 
C(15)-C(13)-O(1) 104.47(18) 
C(15)-C(13)-C(14) 112.4(2) 
O(1)-C(13)-C(14) 109.49(17) 
C(7)-C(6)-C(5) 108.00(18) 
_____________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
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Table 4.   Anisotropic displacement parameters (Å2x 103)for 860tk3.  The anisotropic 
displacement factor exponent takes the form: -22[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
______________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
______________________________________________________________________________ 
O(1) 74(1)  44(1) 42(1)  0(1) -1(1)  -7(1) 
O(3) 110(1)  40(1) 80(1)  -8(1) -35(1)  15(1) 
C(10) 41(1)  34(1) 56(1)  1(1) -4(1)  -1(1) 
C(9) 38(1)  36(1) 43(1)  5(1) 5(1)  1(1) 
C(2) 52(1)  44(1) 44(1)  9(1) -5(1)  -2(1) 
O(2) 88(1)  37(1) 76(1)  4(1) -10(1)  13(1) 
C(4) 48(1)  37(1) 43(1)  -3(1) 5(1)  4(1) 
C(1) 44(1)  39(1) 42(1)  1(1) 4(1)  -8(1) 
C(3) 42(1)  34(1) 57(1)  5(1) 5(1)  3(1) 
C(8) 40(1)  45(1) 47(1)  3(1) -4(1)  4(1) 
C(5) 65(1)  40(1) 66(1)  2(1) -13(1)  -12(1) 
C(11) 62(1)  55(1) 55(1)  -2(1) -15(1)  -5(1) 
C(12) 56(1)  64(1) 64(1)  20(1) 17(1)  5(1) 
C(7) 37(1)  78(2) 63(1)  8(1) 7(1)  3(1) 
C(13) 103(2)  53(1) 38(1)  9(1) 1(1)  -21(1) 
C(14) 95(2)  71(2) 62(1)  4(1) -21(1)  8(1) 
C(6) 43(1)  81(2) 73(1)  24(1) 3(1)  -15(1) 
C(15) 123(2)  88(2) 45(1)  -8(1) 20(1)  -24(2) 
______________________________________________________________________________  
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Table 1.  Crystal data and structure refinement for 2.37. 
Empirical formula  C16 H19 N O2 
Formula weight  257.33 
Temperature  293(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21/c 
Unit cell dimensions a = 7.5182(18) Å = 90°. 
 b = 18.417(8) Å = 93.68(2)°. 
 c = 9.558(2) Å  = 90°. 
Volume 1320.7(7) Å3 
Z 4 
Density (calculated) 1.294 Mg/m3 
Absorption coefficient 0.085 mm-1 
F(000) 552 
Theta range for data collection 2.93 to 28.97°. 
Index ranges -9<=h<=10, -23<=k<=24, -12<=l<=11 
Reflections collected 5845 
Independent reflections 2958 [R(int) = 0.0546] 
Completeness to theta = 28.97° 84.7 %  
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2958 / 0 / 172 
Goodness-of-fit on F2 0.952 
Final R indices [I>2sigma(I)] R1 = 0.0686, wR2 = 0.1619 
R indices (all data) R1 = 0.1343, wR2 = 0.2098 
Largest diff. peak and hole 0.198 and -0.201 e.Å-3 
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Table 2.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 103) 
for 895tk5.  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
O(1) 3856(3) 5296(1) 2966(2) 54(1) 
O(2) 9101(3) 7127(1) 2437(2) 53(1) 
N(1) 9317(3) 6260(1) 4833(2) 36(1) 
C(1) 8062(4) 6166(2) 3797(3) 30(1) 
C(2) 6512(4) 5786(2) 3939(3) 36(1) 
C(10) 8262(4) 6568(2) 2451(3) 32(1) 
C(4) 5729(4) 5783(2) 1320(3) 32(1) 
C(3) 5268(4) 5616(2) 2800(3) 34(1) 
C(9) 7414(3) 6243(2) 1112(3) 30(1) 
C(5) 4238(4) 6204(2) 461(3) 42(1) 
C(8) 6677(4) 6855(2) 99(3) 39(1) 
C(13) 11122(4) 6553(2) 4703(3) 44(1) 
C(15) 10890(4) 6125(2) 7012(3) 45(1) 
C(16) 9164(4) 5930(2) 6221(3) 45(1) 
C(7) 5489(4) 7310(2) 938(3) 46(1) 
C(14) 12199(4) 6183(2) 5886(3) 45(1) 
C(6) 4052(4) 6926(2) 1168(3) 51(1) 
C(12) 8892(4) 5803(2) 482(3) 48(1) 
C(11) 5264(4) 6431(2) -795(3) 51(1) 
________________________________________________________________________________
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Table 3.   Bond lengths [Å] and angles [°] for 895tk5. 
_____________________________________________________ 
O(1)-C(3)  1.233(3) 
O(2)-C(10)  1.208(3) 
N(1)-C(1)  1.334(3) 
N(1)-C(16)  1.469(3) 
N(1)-C(13)  1.474(4) 
C(1)-C(2)  1.373(4) 
C(1)-C(10)  1.500(4) 
C(2)-C(3)  1.424(4) 
C(10)-C(9)  1.516(4) 
C(4)-C(9)  1.547(4) 
C(4)-C(3)  1.510(4) 
C(4)-C(5)  1.553(4) 
C(9)-C(12)  1.530(4) 
C(9)-C(8)  1.564(4) 
C(5)-C(6)  1.502(5) 
C(5)-C(11)  1.527(4) 
C(8)-C(11)  1.533(4) 
C(8)-C(7)  1.496(4) 
C(13)-C(14)  1.510(4) 
C(15)-C(16)  1.503(4) 
C(15)-C(14)  1.508(4) 
C(7)-C(6)  1.321(5) 
 
C(1)-N(1)-C(16) 121.6(2) 
C(1)-N(1)-C(13) 126.6(2) 
C(16)-N(1)-C(13) 110.7(2) 
N(1)-C(1)-C(2) 123.8(2) 
N(1)-C(1)-C(10) 117.9(2) 
C(2)-C(1)-C(10) 117.9(2) 
C(1)-C(2)-C(3) 123.9(3) 
O(2)-C(10)-C(9) 121.2(3) 
O(2)-C(10)-C(1) 120.7(2) 
C(9)-C(10)-C(1) 118.1(2) 
C(9)-C(4)-C(3) 118.1(2) 
C(9)-C(4)-C(5) 103.2(2) 
C(3)-C(4)-C(5) 113.3(2) 
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O(1)-C(3)-C(2) 122.4(3) 
O(1)-C(3)-C(4) 118.0(2) 
C(2)-C(3)-C(4) 119.5(2) 
C(10)-C(9)-C(12) 105.4(2) 
C(10)-C(9)-C(4) 114.2(2) 
C(12)-C(9)-C(4) 112.4(3) 
C(10)-C(9)-C(8) 110.6(2) 
C(12)-C(9)-C(8) 112.1(2) 
C(4)-C(9)-C(8) 102.3(2) 
C(6)-C(5)-C(11) 100.2(3) 
C(6)-C(5)-C(4) 106.8(2) 
C(11)-C(5)-C(4) 99.7(2) 
C(11)-C(8)-C(7) 99.7(3) 
C(11)-C(8)-C(9) 100.6(2) 
C(7)-C(8)-C(9) 105.8(2) 
N(1)-C(13)-C(14) 102.9(2) 
C(16)-C(15)-C(14) 103.9(2) 
N(1)-C(16)-C(15) 103.9(2) 
C(6)-C(7)-C(8) 108.2(3) 
C(13)-C(14)-C(15) 102.9(3) 
C(7)-C(6)-C(5) 107.4(3) 
C(8)-C(11)-C(5) 93.9(2) 
_____________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
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Table 4.   Anisotropic displacement parameters (Å2x 103)for 895tk5.  The anisotropic 
displacement factor exponent takes the form: -22[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
______________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
______________________________________________________________________________ 
O(1) 40(1)  73(2) 49(1)  12(1) 1(1)  -27(1) 
O(2) 68(2)  44(1) 45(1)  12(1) -11(1)  -29(1) 
N(1) 33(1)  44(2) 30(1)  5(1) 1(1)  -8(1) 
C(1) 33(2)  29(2) 29(1)  -1(1) 3(1)  0(1) 
C(2) 33(2)  43(2) 31(2)  7(1) 5(1)  -5(1) 
C(10) 30(1)  31(2) 36(2)  3(1) 1(1)  -2(1) 
C(4) 32(2)  30(2) 34(1)  -3(1) 3(1)  -5(1) 
C(3) 31(2)  33(2) 39(2)  3(1) 4(1)  -3(1) 
C(9) 27(1)  31(2) 31(1)  1(1) 5(1)  0(1) 
C(5) 30(2)  55(2) 40(2)  8(2) -3(1)  -4(2) 
C(8) 38(2)  47(2) 33(2)  12(1) 3(1)  -4(2) 
C(13) 39(2)  50(2) 41(2)  4(2) -3(1)  -15(2) 
C(15) 53(2)  47(2) 35(2)  3(1) -8(2)  -1(2) 
C(16) 41(2)  63(2) 31(2)  10(2) 1(1)  -5(2) 
C(7) 46(2)  35(2) 57(2)  14(2) 6(2)  9(2) 
C(14) 39(2)  49(2) 47(2)  3(2) -7(2)  -10(2) 
C(6) 36(2)  55(2) 61(2)  14(2) 7(2)  17(2) 
C(12) 44(2)  49(2) 52(2)  -3(2) 16(2)  6(2) 
C(11) 49(2)  66(3) 37(2)  11(2) -7(2)  -11(2) 
______________________________________________________________________________  
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Table 1.  Crystal data and structure refinement for 5.16. 
Empirical formula  C15 H19 N O5 S 
Formula weight  325.39 
Temperature  293(2) K 
Wavelength  1.54180 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 5.5067(2) Å = 79.253(4)°. 
 b = 8.1430(4) Å = 83.454(4)°. 
 c = 18.1212(8) Å  = 76.625(4)°. 
Volume 774.53(6) Å3 
Z 2 
Density (calculated) 1.395 Mg/m3 
Absorption coefficient 2.072 mm-1 
F(000) 344 
Theta range for data collection 4.98 to 62.41°. 
Index ranges -6<=h<=4, -9<=k<=7, -20<=l<=20 
Reflections collected 4843 
Independent reflections 2444 [R(int) = 0.0311] 
Completeness to theta = 62.41° 99.1 %  
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2444 / 0 / 199 
Goodness-of-fit on F2 1.242 
Final R indices [I>2sigma(I)] R1 = 0.0594, wR2 = 0.1621 
R indices (all data) R1 = 0.0676, wR2 = 0.1690 
Largest diff. peak and hole 0.890 and -0.483 e.Å-3 
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Table 2.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 103) 
for 1054tk6.  U(eq) is defined as one third of the trace of the orthogonalized U ij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
S(1) 1533(1) 7440(1) 9669(1) 27(1) 
O(5) 2378(4) 5703(3) 9538(1) 34(1) 
O(1) 404(4) 7981(3) 12781(1) 29(1) 
O(4) 2739(4) 8709(3) 9212(1) 34(1) 
N(1) 1695(5) 7652(3) 10556(1) 29(1) 
C(5) 2515(5) 6453(4) 11813(2) 27(1) 
C(1) 2502(6) 7336(4) 13231(2) 30(1) 
C(2) 4370(6) 8378(4) 12855(2) 34(1) 
C(11) 3468(6) 5415(4) 13160(2) 29(1) 
C(6) 3384(5) 5122(4) 12357(2) 27(1) 
C(9) 7013(7) 2795(5) 13343(2) 42(1) 
C(10) 6101(6) 4653(4) 13440(2) 39(1) 
C(14) 2421(5) 6292(4) 11036(2) 27(1) 
C(7) 4343(6) 3299(4) 12251(2) 33(1) 
C(15) -1702(6) 8053(4) 9591(2) 34(1) 
O(3) -631(5) 7433(5) 14226(1) 63(1) 
C(3) 3841(6) 8906(4) 12148(2) 34(1) 
C(4) 1607(6) 8216(4) 12034(2) 30(1) 
C(8) 6972(7) 2599(5) 12526(2) 40(1) 
O(2) 2981(6) 7772(7) 14470(2) 111(2) 
C(12) 1662(6) 7542(4) 14043(2) 36(1) 
C(13) -1582(9) 7637(8) 14988(2) 76(2) 
________________________________________________________________________________
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Table 3.   Bond lengths [Å] and angles [°] for 1054tk6. 
_____________________________________________________ 
S(1)-O(4)  1.438(2) 
S(1)-O(5)  1.438(2) 
S(1)-N(1)  1.662(2) 
S(1)-C(15)  1.750(3) 
O(1)-C(4)  1.438(3) 
O(1)-C(1)  1.431(4) 
N(1)-C(14)  1.288(4) 
C(5)-C(6)  1.359(4) 
C(5)-C(4)  1.518(4) 
C(5)-C(14)  1.446(4) 
C(1)-C(12)  1.519(4) 
C(1)-C(2)  1.507(4) 
C(1)-C(11)  1.556(4) 
C(2)-C(3)  1.316(5) 
C(11)-C(6)  1.525(4) 
C(11)-C(10)  1.543(4) 
C(6)-C(7)  1.497(4) 
C(9)-C(10)  1.516(5) 
C(9)-C(8)  1.523(5) 
C(7)-C(8)  1.531(5) 
O(3)-C(12)  1.288(4) 
O(3)-C(13)  1.447(4) 
C(3)-C(4)  1.515(4) 
O(2)-C(12)  1.186(4) 
 
O(4)-S(1)-O(5) 117.37(13) 
O(4)-S(1)-N(1) 105.73(13) 
O(5)-S(1)-N(1) 113.26(13) 
O(4)-S(1)-C(15) 109.66(14) 
O(5)-S(1)-C(15) 108.75(15) 
N(1)-S(1)-C(15) 100.78(14) 
C(4)-O(1)-C(1) 101.9(2) 
C(14)-N(1)-S(1) 118.3(2) 
C(6)-C(5)-C(4) 118.0(2) 
C(6)-C(5)-C(14) 123.9(3) 
C(4)-C(5)-C(14) 118.1(3) 
 227 | P a g e  
 
O(1)-C(1)-C(12) 109.1(3) 
O(1)-C(1)-C(2) 103.2(2) 
C(12)-C(1)-C(2) 115.0(3) 
O(1)-C(1)-C(11) 107.1(2) 
C(12)-C(1)-C(11) 111.0(2) 
C(2)-C(1)-C(11) 111.0(2) 
C(3)-C(2)-C(1) 107.5(3) 
C(6)-C(11)-C(10) 110.6(3) 
C(6)-C(11)-C(1) 111.4(2) 
C(10)-C(11)-C(1) 113.4(2) 
C(5)-C(6)-C(11) 120.4(3) 
C(5)-C(6)-C(7) 125.8(3) 
C(11)-C(6)-C(7) 113.8(2) 
C(10)-C(9)-C(8) 110.7(3) 
C(9)-C(10)-C(11) 112.0(3) 
N(1)-C(14)-C(5) 118.9(3) 
C(8)-C(7)-C(6) 111.2(3) 
C(12)-O(3)-C(13) 116.6(3) 
C(2)-C(3)-C(4) 107.6(3) 
O(1)-C(4)-C(5) 107.1(2) 
O(1)-C(4)-C(3) 102.5(2) 
C(5)-C(4)-C(3) 109.3(3) 
C(7)-C(8)-C(9) 110.9(3) 
O(2)-C(12)-O(3) 123.0(3) 
O(2)-C(12)-C(1) 123.7(3) 
O(3)-C(12)-C(1) 113.3(3) 
_____________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
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Table 4.   Anisotropic displacement parameters (Å2x 103)for 1054tk6.  The anisotropic 
displacement factor exponent takes the form: -22[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
______________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
______________________________________________________________________________ 
S(1) 26(1)  31(1) 22(1)  0(1) -3(1)  -7(1) 
O(5) 40(1)  32(1) 28(1)  -4(1) -3(1)  -4(1) 
O(1) 25(1)  38(1) 23(1)  -4(1) -2(1)  -6(1) 
O(4) 34(1)  38(1) 30(1)  3(1) 0(1)  -15(1) 
N(1) 30(1)  32(1) 25(1)  0(1) -5(1)  -8(1) 
C(5) 24(1)  31(2) 24(1)  -2(1) -1(1)  -7(1) 
C(1) 26(2)  36(2) 29(2)  -3(1) -6(1)  -7(1) 
C(2) 30(2)  37(2) 37(2)  -8(1) -4(1)  -10(1) 
C(11) 28(2)  35(2) 22(1)  1(1) -2(1)  -9(1) 
C(6) 22(1)  33(2) 26(1)  -3(1) -1(1)  -9(1) 
C(9) 44(2)  43(2) 34(2)  -1(2) -13(2)  3(2) 
C(10) 38(2)  43(2) 32(2)  -3(1) -12(1)  -3(2) 
C(14) 21(1)  30(2) 28(2)  -3(1) 0(1)  -5(1) 
C(7) 40(2)  32(2) 26(1)  0(1) -4(1)  -8(1) 
C(15) 26(2)  42(2) 36(2)  -5(1) -6(1)  -7(1) 
O(3) 47(2)  125(3) 30(1)  -26(1) 10(1)  -39(2) 
C(3) 35(2)  31(2) 37(2)  -4(1) 0(1)  -12(1) 
C(4) 32(2)  32(2) 23(1)  -1(1) -2(1)  -6(1) 
C(8) 42(2)  34(2) 37(2)  -4(1) -9(1)  2(2) 
O(2) 54(2)  253(5) 53(2)  -73(2) 7(2)  -54(3) 
C(12) 33(2)  44(2) 32(2)  -9(1) -6(1)  -5(1) 
C(13) 56(3)  153(5) 30(2)  -31(2) 11(2)  -38(3) 
______________________________________________________________________________  
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Table 1.  Crystal data and structure refinement for 2.54. 
Empirical formula  C18 H24 O3 
Formula weight  288.39 
Temperature  293(2) K 
Wavelength  1.54180 Å 
Crystal system  Monoclinic 
Space group   
Unit cell dimensions a = 8.3706(8) Å = 90°. 
 b = 17.019(2) Å = 99.617(8)°. 
 c = 11.1609(9) Å  = 90°. 
Volume 1567.6(3) Å3 
Z 4 
Density (calculated) 1.222 Mg/m3 
Absorption coefficient 0.650 mm-1 
F(000) 624 
Crystal size 0.4 x 0.2 x 0.1 mm3 
Theta range for data collection 4.79 to 62.48°. 
Index ranges -9<=h<=9, -19<=k<=11, -10<=l<=12 
Reflections collected 6198 
Independent reflections 2484 [R(int) = 0.0393] 
Completeness to theta = 62.48° 99.1 %  
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2484 / 0 / 190 
Goodness-of-fit on F2 1.343 
Final R indices [I>2sigma(I)] R1 = 0.0736, wR2 = 0.1842 
R indices (all data) R1 = 0.0868, wR2 = 0.1963 
Largest diff. peak and hole 0.471 and -0.341 e.Å-3 
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Table 2.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 103) 
for 1112tk-111-75.  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
O(3) 2000(2) 7615(1) 3820(2) 55(1) 
O(1) 1160(2) 6337(1) 2391(2) 47(1) 
O(2) 766(3) 8092(1) -1068(2) 59(1) 
C(4) 991(3) 7985(2) 21(2) 43(1) 
C(3) 1149(3) 7178(2) 523(2) 43(1) 
C(2) 1625(3) 7034(1) 1884(2) 41(1) 
C(1) 1803(3) 7720(2) 2737(2) 41(1) 
C(8) -1290(3) 8435(2) 2399(3) 48(1) 
C(11) -268(4) 9629(2) 1868(3) 56(1) 
C(15) -443(3) 6324(2) 2727(3) 50(1) 
C(10) 1645(3) 8571(2) 2270(2) 43(1) 
C(5) 1116(3) 8685(2) 869(2) 44(1) 
C(7) -1718(3) 8495(2) 1212(3) 49(1) 
C(13) 3211(4) 9019(2) 2784(3) 56(1) 
C(17) 4289(3) 7434(2) 1032(3) 50(1) 
C(18) 3230(4) 6050(2) 793(3) 61(1) 
C(14) -357(4) 5740(2) 3739(3) 56(1) 
C(9) 171(3) 8963(2) 2770(2) 47(1) 
C(12) 2854(3) 6898(2) 1042(2) 46(1) 
C(6) -593(3) 9086(2) 770(3) 51(1) 
C(16) -1722(4) 6132(3) 1673(3) 79(1) 
________________________________________________________________________________
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Table 3.   Bond lengths [Å] and angles [°] for 1112tk-111-75. 
_____________________________________________________ 
O(3)-C(1)  1.206(3) 
O(1)-C(2)  1.398(3) 
O(1)-C(15)  1.453(3) 
O(2)-C(4)  1.212(3) 
C(4)-C(5)  1.514(4) 
C(4)-C(3)  1.482(4) 
C(3)-C(12)  1.524(4) 
C(3)-C(2)  1.525(4) 
C(2)-C(12)  1.522(3) 
C(2)-C(1)  1.498(4) 
C(1)-C(10)  1.537(4) 
C(8)-C(7)  1.318(4) 
C(8)-C(9)  1.518(4) 
C(11)-C(6)  1.522(4) 
C(11)-C(9)  1.519(4) 
C(15)-C(16)  1.489(5) 
C(15)-C(14)  1.498(4) 
C(10)-C(9)  1.583(4) 
C(10)-C(5)  1.564(4) 
C(10)-C(13)  1.541(4) 
C(5)-C(6)  1.572(4) 
C(7)-C(6)  1.515(4) 
C(17)-C(12)  1.509(4) 
C(18)-C(12)  1.514(4) 
 
C(2)-O(1)-C(15) 116.62(18) 
O(2)-C(4)-C(5) 119.4(2) 
O(2)-C(4)-C(3) 120.5(2) 
C(5)-C(4)-C(3) 120.1(2) 
C(12)-C(3)-C(2) 59.92(16) 
C(12)-C(3)-C(4) 116.8(2) 
C(2)-C(3)-C(4) 121.1(2) 
O(1)-C(2)-C(3) 119.7(2) 
O(1)-C(2)-C(12) 112.6(2) 
C(3)-C(2)-C(12) 60.02(16) 
O(1)-C(2)-C(1) 114.2(2) 
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C(3)-C(2)-C(1) 119.3(2) 
C(12)-C(2)-C(1) 120.3(2) 
O(3)-C(1)-C(2) 120.2(2) 
O(3)-C(1)-C(10) 118.0(2) 
C(2)-C(1)-C(10) 121.7(2) 
C(7)-C(8)-C(9) 107.4(2) 
C(6)-C(11)-C(9) 94.1(2) 
O(1)-C(15)-C(16) 111.9(3) 
O(1)-C(15)-C(14) 105.9(2) 
C(16)-C(15)-C(14) 112.8(2) 
C(9)-C(10)-C(5) 101.1(2) 
C(9)-C(10)-C(13) 109.0(2) 
C(5)-C(10)-C(13) 113.1(2) 
C(9)-C(10)-C(1) 107.8(2) 
C(5)-C(10)-C(1) 116.7(2) 
C(13)-C(10)-C(1) 108.7(2) 
C(4)-C(5)-C(10) 120.4(2) 
C(4)-C(5)-C(6) 109.3(2) 
C(10)-C(5)-C(6) 103.1(2) 
C(8)-C(7)-C(6) 107.4(2) 
C(11)-C(9)-C(10) 101.4(2) 
C(11)-C(9)-C(8) 99.5(2) 
C(10)-C(9)-C(8) 107.2(2) 
C(3)-C(12)-C(2) 60.06(17) 
C(3)-C(12)-C(17) 120.4(2) 
C(2)-C(12)-C(17) 122.3(2) 
C(3)-C(12)-C(18) 116.0(2) 
C(2)-C(12)-C(18) 116.1(2) 
C(17)-C(12)-C(18) 112.6(2) 
C(11)-C(6)-C(7) 100.2(2) 
C(11)-C(6)-C(5) 99.7(2) 
C(7)-C(6)-C(5) 107.2(2) 
_____________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
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Table 4.   Anisotropic displacement parameters (Å2x 103)for 1112tk-111-75.  The anisotropic 
displacement factor exponent takes the form: -22[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
______________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
______________________________________________________________________________ 
O(3) 57(1)  66(1) 42(1)  8(1) 10(1)  1(1) 
O(1) 39(1)  47(1) 60(1)  11(1) 22(1)  3(1) 
O(2) 72(1)  65(1) 41(1)  6(1) 13(1)  5(1) 
C(4) 41(1)  53(2) 37(2)  3(1) 11(1)  1(1) 
C(3) 41(1)  48(1) 42(1)  -4(1) 13(1)  -3(1) 
C(2) 37(1)  43(1) 45(1)  8(1) 14(1)  1(1) 
C(1) 34(1)  53(2) 38(2)  4(1) 12(1)  -2(1) 
C(8) 43(1)  51(2) 53(2)  0(1) 17(1)  5(1) 
C(11) 63(2)  51(2) 56(2)  2(1) 21(1)  4(1) 
C(15) 41(1)  46(1) 68(2)  6(1) 26(1)  0(1) 
C(10) 41(1)  49(1) 40(1)  1(1) 11(1)  -3(1) 
C(5) 47(1)  44(1) 43(1)  5(1) 14(1)  -3(1) 
C(7) 40(1)  53(2) 56(2)  -3(1) 11(1)  6(1) 
C(13) 52(2)  62(2) 55(2)  -4(1) 13(1)  -14(1) 
C(17) 42(1)  63(2) 50(2)  8(1) 18(1)  1(1) 
C(18) 60(2)  59(2) 73(2)  11(2) 34(2)  13(1) 
C(14) 54(2)  62(2) 56(2)  3(1) 24(1)  -9(1) 
C(9) 52(2)  49(2) 41(1)  -4(1) 15(1)  1(1) 
C(12) 45(2)  54(2) 43(1)  8(1) 18(1)  4(1) 
C(6) 56(2)  51(2) 48(2)  8(1) 12(1)  11(1) 
C(16) 47(2)  111(3) 77(2)  32(2) 10(2)  -11(2) 
_________________________________________________________________________
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